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Abstract 
Nanoparticles are utilized in a wide variety of biomedical fields and theranostic 
nanomedicine from imaging and sensing to drug delivery. Multifunctional nanoparticles 
encapsulated with imaging probes/diagnostic agents or therapeutic agents can be delivered in 
vivo via passive or active targeting, making them effective and efficient therapeutic agents. 
However, in order to optimize their efficacy, nanoparticle platforms must be designed in a 
way which limits cytotoxicity and optimizes biocompatibility for safe medical use.  
 
The human immune system is a complex system of networks and cascade reactions which are 
intricate and tightly regulated. It is mainly comprised of two important reaction systems, the 
complement and coagulation cascade. In order to prolong the nanoparticles circulating in the 
bloodstream as well as enhancing sustained release of drugs to targeted tissues, surface 
functionalization ultimately reduces coagulation or complement activation by inhibiting the 
adsorption of blood proteins (stealthing) on the nanoparticles surface, called opsonization.  
 
The most widely used surface functionalization is polyethylene glycol (PEG). The chemical 
conjugation of attaching this organic moiety to the nanoparticle is known as PEGylation. 
PEGylated particles undergo changes in physicochemical properties contributing to the 
overall stability and stealth ability PEG provides to nanoparticles. However, there are many 
drawbacks limiting the usefulness of PEGylation including complement activation or 
degradation.  
 
Therefore, we have proposed and fully characterized alternative polymers, poly(2-methyl-2-
oxazoline) (PMOXA) and poly(2-ethyl-2-oxazoline) (PEtOXA) which are more 
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biocompatible, can escape the mononuclear phagocyte system (MPS), and are easier to 
synthesize than PEG. Furthermore, we proposed two nanoparticle systems in order to 
characterize how biophysicochemical properties like surface functionalization and charge 
alter the way in which particles’ interact with biological systems. We used two nanoparticle 
systems: 1) Inorganic solid silica (SiO2-NPs) as they have become of increasing interest in 
controlled drug release due to their accessibility, versatility, high capacity of processing, and 
physical-chemical properties adapted through synthesis; 2) Gold nanoparticles (Au-NPs) due 
to their vast and unique optical and physical features. Au-NPs are inert, have extreme 
resistance to oxidation, and they are easily able to be functionalized by thiol compounds. 
 
In the second part of my dissertation, I use two alternative animal models in order to probe 
and characterize the interactions nanoparticles have in non-human systems. Prior to human 
clinical trials, drugs were often tested in vitro and in vivo in a murine model, yet failed to be 
approved when proceeding with human trials. In many cases, mice responded quite 
differently than humans to drugs, contributing to the high failure rate of drug development. In 
fact, the majority of drugs never reach the marketplace following clinical trials. Therefore, it 
is imperative to understand the attributes which contribute to this phenomena so as to 
increase therapeutic applications of nanoparticles.  
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Chapter 1: Introduction 
1. Nanoparticle’s use in Bio-applications 
 
Nanotechnology is the study and development of technology dealing with nanometer sized solid 
colloidal particles ranging in size from 10 to 1000 nm.1,2 The driving force behind development 
of nanotechnology is the understanding of biological processes on the nanoscale level. As 
proteins have a typical size around 5 nm and some of the ultrasmall man-made nanoparticles are 
in the range of single digits as well, nanoparticles can be used as probes allowing us to study the 
cellular machinery with little interference. Small nanoparticles also have many other benefits 
over larger particles such as increased surface-to-volume ratio and increased magnetic properties. 
Thus there is great interest in using them in biomedical applications such as targeted drug 
delivery as they not only provide protection to the cargo but also enhance cellular uptake and 
selective delivery, hyperthermia, photoablation therapy, bioimaging, and biosensors.  
1.1 Liposomes 
The first NP platform was the liposome, first described in 1965 by Alec Bangham and colleagues 
as a model of cellular membranes establishing the basis for model membrane systems.3 Enclosed 
phospholipid bilayer structures initially called ‘bangosomes’ consisting of a series of concentric 
bilayers of lipids known as lamellae, which are molecules that have a hydrophilic head group and 
a hydrophobic tail group, alternating with aqueous compartments within which soluble 
substances can be entrapped.4 Phospholipids impulsively form closed structures when they are 
hydrated in aqueous solutions. Therefore, due to their self-assembling nature and thermodynamic 
phase properties, the appropriation by their hydrophobic sections into spherical bilayers are 
entropically focused making liposomes excellent payload carriers. Liposome-entrapped drugs 
with the anti-cancer drug cytosine arabinoside were some of the first used for demonstrations of 
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improved in vivo activity, increasing the survival of mice bearing L1210 leukemia. This form of 
delivery system is known as liposomal encapsulation technology (LET) where liposomes 
encapsulate numerous materials, forming a barrier around their contents. Due to this protection, 
the load is resistant to enzymes in the mouth and stomach, alkaline solutions, digestive juices, 
bile salts, and intestinal flora, generated in the human body, as well as free radicals and thus are 
protected from oxidation and degradation. This protective phospholipid barrier remains 
undamaged until the contents of the liposome are delivered to the exact target and the contents 
can be utilized. 5 The “rigidity” or “fluidity” and the charge of the bilayer are determined by the 
composition of bilayers themselves. Permeable and less stable bilayers can be obtained using 
unsaturated phosphatidylcholine species from natural sources such as egg or soybean 
phosphatidylcholine. However, rigid and impermeable bilayer structures can be obtained using 
saturated phospholipids with long acyl chains such as dipalmitoylphos phatidylcholine. Figure 1 
displays the different kinds of liposomal structures which can be used to deliver lipophilic or 
hydrophilic drugs as well as lipids with negative or positive charges and ligand-targeted 
liposomes for active targeting.6 
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Over the years, development of important technical advances in liposomal research lead to 
remote drug loading, extrusion for homogeneous size, long-circulating (PEGylated) liposomes or 
“second-generation liposomes”, triggered release liposomes, liposomes containing nucleic acid 
polymers, ligand-targeted liposomes, and liposomes containing combinations of drugs.7 The first 
clinical trials of liposomal drugs were to treat patients with primary or metastatic liver cancer 
which was refractory to current therapies using liposomes containing doxorubicin. 
Phosphatidylglycerol, phosphatidylcholine, cholesterol, and DXR were intercalated in the lipid 
bilayer forming a liposome-associated doxorubicin (L-DXR) with a mean size of around 0.3-0.5 
microns.  
 
Although classical liposomes had unique advantages due to their diverse range of compositions, 
abilities to carry and protect many types of biomolecules, as well as their biocompatibility and 
biodegradability, they also had difficulty retaining some types of entrapped molecules in the 
Figure 1: Structure of different liposomes. (a) classical liposome enclosing lipid soluble drugs, (b) 
classical liposome enclosing aqueous soluble drugs, (c) liposomes which have been sterically 
stabilized, and (d) ligand-targeted liposome encapsulating an aqueous soluble drug.  
Taken from: Lila, A. S. A., Ishida, T. & Allen, T. M. in Handbook of Nanobiomedical Research: Fundamentals, Applications and Recent 
Developments 3, 1–53 (2014). 
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liposome interior when exposed to serum proteins.8,9 In order to control the release rate of the 
entrapped cargo, drugs with physical characteristics amenable to retention in liposomes must be 
chosen. Liposomes have high permeability to hydrophobic drugs and have low permeability to 
hydrophilic drugs, similar to biological membranes. Therefore, highly hydrophobic drugs such as 
paclitaxel are very problematic when enclosed inside liposomal carriers. A way in which this was 
avoided was by creating drug loading in response to trans-membrane pH gradients responding to 
internal acidic buffers. Drugs that are weak bases possessing a primary, secondary, or tertiary 
amine, can be loaded in response to pH gradients and drugs such as paclitaxel which are not weak 
bases can be converted to weak base prodrugs thus increasing liposomal retention and 
encapsulation. Drug retention can be further improved by enhancing precipitation via increasing 
intra-liposomal drug concentrations above their solubility limits.  
 
1.2 Surface modification of Liposomes 
Another issue with classical liposomes was the rapid clearance via uptake into cells of the 
mononuclear phagocyte system (MPS), mostly accumulating in the liver and spleen.10 
Although diseases like leishmaniasis, in which the MPS is involved, can benefit from rapid 
liposomal uptake and clearance, and, in general, this response limits their ability to deliver 
drugs to other tissues or cells and can cause toxicity to the MPS organs, because the 
distribution into tissues was highly reduced by MPS capture as well as toxicities to MPS 
organs themselves, an alternative solution needed to be found. First attempts included 
blocking MPS with large pre-doses of empty liposomes before injection with drug loaded 
liposomes. Since the MPS would be blocked, the circulation half-life of classical liposomes 
would increase by evading capture of the MPS organs.11 It was identified the surface 
properties of liposomes led to their premature clearance via absorption of serum proteins, 
opsonines, of the complement system leading ultimately to their rapid clearance. When 
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nanoparticles are introduced into physiological environments such as blood or inside cells, 
proteins, and small molecules which are at very high concentrations, they are absorbed onto 
the surface of the nanoparticle, forming a “protein corona” or a cloud of aggregated 
proteins.12 Opsonins have been previously identified as immunoglobulins, fibronectin, beta 2-
glycoprotein, C-reactive protein (CRP), and beta 2-macroglobulin. The protein corona 
consists of two layers, the hard and soft corona, which are the inner and outer layers of the 
corona, respectively. The hard corona undergoes low molecule exchange rates and high 
affinity to the nanoparticle’s surface whereas the soft corona is composed of weakly bound 
proteins with high exchange rates. The soft corona being dynamic, rapidly exchanges its 
components based upon nearby dynamic protein concentrations and a changing proteome. 
The protein corona composition alters the biological identity of the nanomaterial and thus 
determines the physiological response including agglomeration, cellular uptake, circulation 
lifetime, signaling, kinetics, transport, accumulation, and toxicity. Once the nanomaterial has 
been identified by MPS cells such as neutrophils, monocytes, and macrophages, uptake and 
membrane lysis is initiated and the C5b-9 complexes, also known as the membrane attack 
complex (MAC), produces lytic pores inducing cell lysis or liposomal content release. 
Therefore, research began comparing unmodified phospholipid membranes and biological 
membranes with a surface layer rich in carbohydrates such as natural polysaccharides like 
mannan, amylopectin, and dextran thinking by increasing the surface hydrophilicity of the 
liposomes, the liposome would be “stealth” and avoid attracting proteins onto the surface. 
Such “stealthing” agents are generally enhanced by the removal of hydrogen-bond-donating 
groups from hydrophilic polymers. 
 
Ultimately, classical liposomes were coated with a protective, hydrophilic barrier on the 
liposome surface to sterically stabilized them using inert, biocompatible substances, like 
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ganglioside GM1, phosphatidylinositol, or lipid-conjugated polyethylene glycol (PEG).13–15 
PEG is a linear non-ionic hydrophilic polyether diol which is biocompatibility, soluble in 
aqueous and organic media, nontoxic, has very low immunogenicity, and good excretion 
kinetics. Surface modification of liposomes with PEG can be achieved by physically 
adsorbing the polymer onto the surface of the vesicles, by incorporating the PEG-lipid 
conjugate during liposome preparation, or by covalently attaching reactive groups onto the 
surface of preformed liposomes.16 However, the most widely used method is anchoring the 
PEG polymer in the liposomal membrane via a cross-linked lipid (ie, PEG-
distearoylphosphatidylethanolamine (DSPE)).  
 
PEGylated liposomes strongly reduced MPS uptake and prolonged circulation in the blood 
which subsequently improved distribution in perfused tissues. Moreover, the PEG chains 
improve stability avoiding vesicle aggregation. This is partially due to the molar mass of PEG 
chains and its uniformity “molecular cloud” but also due to its considerable conformational 
flexibility (Figure 2).17 PEG stabilizes liposomes by providing a strong interbilayer repulsion 
that can overcome the attractive Van der Waals forces and thus avoids aggregation by 
increasing the repulsive barrier between two approaching particles. Elastic and osmotic 
restrictions contribute to stabilization. Elastic or volume restriction stems from 
conformational entropy loss or enthalpy gain when the available volume of two surfaces is 
reduced as they come closer together, resulting in particle separation due to an increase in the 
free energy of mixing. Osmotic contribution occurs when polymer concentrations increase as 
the two surfaces come closer together, causing an influx of water which ultimately forces 
particles apart. This mechanism is also applicable to stealthing particles against serum 
proteins of the complement system. As proteins approach the particle’s surface, an osmotic 
repulsive force is created when the polymer coating undergoes a reduction in available 
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conformations due to interpenetration of polymer chains. Therefore, polymer density is 
crucial to stealth as high polymer density suggests that compression is preferred over 
interpenetration, while if the surface density is low, interpenetration is likely to dominate.18  
 
Subsequent clinical trials in humans used PEG-liposomes as carriers of doxorubicin for the 
treatment of Kaposi's sarcoma in HIV patients and for demonstrating the stealthing capability 
of this complex. 19 Yet, antibodies against PEG produced by splenic B cells can develop after 
the first administration of PEGylated liposomes indicating potential immunogenic and 
antigenic effects. PEG can also bioaccumulate and form vacuoles in some organs, can be 
degraded by oxidative reactions, and is non-biodegradable. Also, anti-PEG antibodies have 
been reported indicating PEG has the potential to be immunogenic and antigenic. 
Furthermore, in order to provide effective counter phagocytosis, PEG chains typically need to 
have a molecular weight in excess of 2,000 Da, substantially increasing the overall 
hydrodynamic diameter.20 Therefore, alternatives must be created in order to maintain the 
liposomal effectiveness.  
 
Figure 2: Liposome structure modified with low and high PEG densities for 
targeted delivery of active payloads. 
Taken from: MG, K., V, K. & F, H. History and Possible Uses of Nanomedicine Based on Nanoparticles 
and Nanotechnological Progress. J. Nanomed. Nanotechnol. 6, (2015). 
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Alternative polymers for PEG have been created with the hope of achieving even better control 
over the properties of modified drugs and drug carriers. The qualities of a polymer must be 
soluble, hydrophilic, have a highly flexible main chain, and high biocompatibility. Liposomes 
have been proposed that contain DSPE which are covalently linked to poly(2-methyl-2-
oxazoline) or to poly(2-ethyl-2-oxazoline) and polymers such as polyglycerols, poly[N-(2-
hydroxypropyl)meth-acrylamide)], poly-N-vinylpyrrolidones, polyvinyl alcohol, or L-amino-
acid-based biodegradable polymer-lipid conjugates. Although these alternatives provided longer 
blood circulation time and decreased uptake by MPS, PEG still remains the gold standard in 
steric stabilization of liposomes.  
1.3 Biodegradable polymers with Liposomal coatings  
Ever since the invention of bioabsorbable sutures, the possibility of using biodegradable 
polymers as drug carriers became the forefront of scientific research in pharmacy, chemical 
engineering, biomedicine, and other disciplines. The advantages of biodegradable polymers 
over other carrier systems is they can deliver drugs directly in circulation as well as not 
needing to be removed once the drug is delivered due to their nature of degrading into 
nontoxic materials eliminated from the body via natural metabolic pathways.21 Examples of 
such particles include inorganic mesoporous silica nanoparticles (MSNPs) which have a 
unique mesoporous structure preserving chemical stability, surface functionality, and 
biocompatibility which leads to controlled drug release and targeted delivery.22 A 
biodegradable hollow mesoporous silica nanoparticle (dHMSN) was created with co-
encapsulation of all-trans retinoic acid (ATRA) and doxorubicin (DOX) as well as IL-2 
absorbed on the surface via electronic interaction. In order to improve the stability and 
biocompatibility as well as deliver a synergistic antitumor effect, dHMSNP was further 
coated with a lipid bilayer (dHMLB).23 Another mesoporous silica nanoparticle carrier for 
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pancreatic cancer is a co delivery system for a pancreatic cancer drug, gemcitabine (GEM), 
and an albumin-bound paclitaxel (PTX) nanocarrier (Abraxane). This high drug loading was 
achieved by using a supported lipid bilayer to encapsulate the MSNPs which allowed high 
GEM loading and the ability to copackage PTX with no evidence of local or systemic 
toxicity. Drug co-delivery provided more effective tumor shrinkage than GEM-loaded LB-
MSNP, free GEM, or free GEM plus Abraxane due to the ability of this co delivery system to 
synergistically suppress pancreatic cancer stromal volume and tumor size, and eliminated 
metastatic foci.24 
 
1.4 Inorganic nanoparticles  
Inorganic nanoparticles such as solid silica (SiO2-NPs) and mesoporous silica nanoparticles 
(MSNPs) have become of increasing interest as the mean human adult intake of amorphous 
silica is estimated to be about 2 mg/kg of body weight per day.25 Furthermore, silica is 
utilized for controlled drug release due to their high capacity for processing and physical-
chemical properties adapted through synthesis. However, the loading capacity is double for 
MSNPs than for SiO2-NPs due to the increase surface area via numerous meso-pores ranging 
in size from 2 nm and 50 nm. 26 Figure 3a shows how MSNPs physically or chemically 
absorb active payloads which are released using the “gatekeeper” strategy or control the 
binding affinity by modifying the inner surface of the pores. Whereas in Figure 3b,and c, 
SiO2-NPs encapsulate or conjugate its payloads releasing its cargo via chemical linkers or the 
degradation of silica matrix.27  
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By exploiting versatile silane chemistry, many functional moieties can be attached to the 
nanoparticle’s surface and therefore the desirable surface properties for biomedical 
applications can be tweaked based upon the targeted disease. A wide variety of polymers are 
used to modify the surface of the SiO2-NPs such as cellulose derivatives and polymeric 
matrices based on poly(ethylene oxide) which have low toxicity, are hydrophilic, and are 
stable in biological pH environments. PEG has been utilized frequently as a polymer coating, 
providing better circulation time and targetability. However, alternative polymers such as 
poly(2-methyl-2-oxazoline) (PMOXA) and poly(2-ethyl-2-oxazoline) (PEtOXA) have been 
suggested as protein-repellent or nonfouling polymers which are easier to synthesize and can 
incorporate varying monomers to tailor the nanoparticle for specific applications. Although  
PEGylated oxazoline polymers are highly water soluble, amphiphilic, very flexible and 
hydrated in water, non-toxic, and may be produced with low polydispersity, PMOXA can be 
further tuned in size and structure using a living cationic ring-opening polymerization.28  
  
 
 
Figure 3: (a) Mesoporous silica nanoparticles and (b,c) solid silica drug loading and releasing processes. 
Taken from: Tang, L. & Cheng, J. Nonporous silica nanoparticles for nanomedicine application. Nano Today 8, 290–312 (2013). 
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2. The immune system and stealthing polymers for nanoparticles 
2.1 Innate Immunity and the Complement system  
 
Upon nanoparticle administration, blood is the first physiological environment the particle 
encounters thus dictating its ultimate function. Blood is composed of a cellular component of 
red and white blood cells and platelets suspended in a liquid component, plasma. Plasma can 
be isolated from anti-coagulated whole blood via centrifugation whereas whole blood lacking 
an anti-coagulant undergoes centrifugation and yields the supernatant fluid called the serum. 
Serum lacks fibrinogen, prothrombin, and other clotting proteins but is similar to plasma with 
regard to the concentration and composition of many small molecules including proteins and 
peptides like albumins, globulins, lipoproteins, enzymes, and hormones; nutrients such as 
carbohydrates, lipids, and amino acids; electrolytes; and organic wastes. Serum is responsible 
for transporting dissolved gases, nutrients, hormones and metabolic wastes, as well as 
regulating body temperature, pH and ion composition of interstitial fluids, limiting fluid 
losses at injury sites, the defense against pathogens. One of the major differences between 
plasma and serum is the physiological concentration of small molecules such as 
thromboxanes.29 
The innate immune system utilizes complex mechanisms to defend against pathogens and to 
maintain homeostasis via clearance of cell debris, rapid recall of adaptive responses, and 
facilitating wound healing. Innate immune cells like dendritic cells, macrophages, and 
neutrophils as well as cells from the adaptive immune system such as T cells, express pattern 
recognition receptors (PRRs) which are responsible for detecting pathogen-associated 
molecular patterns (PAMPs). PRRs include Toll-like receptors (TLRs), the nucleotide-
binding oligomerization domain (NODs)-like receptors (NLRs), the retinoic acid-inducible 
gene (RIG)-I-like receptors (RLRs), membrane C-type lectin receptors (CLRs), and DNA 
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receptors. Soluble PRRs such as surfactant proteins (SPs) and mannan-binding lectins 
(MBLs) are also able to recognize PAMPs.30 The deposition of opsonic blood proteins on 
pathogens, called opsonization, clears the pathogens from the body by aiding recognition by 
macrophage receptors, such as fibronectin, immunoglobulins, and some components of the 
complement system which are often the first to respond.31 The complement system is a set of 
unique plasma proteins which are converted to their active form through a cascade of 
zymogen activation where an enzyme is activated by a second enzyme, which itself has been 
activated by proteolytic cleavage.32 The complement system is responsible for the initiation 
of the acute inflammatory response via releasing chemotactic factors and induce 
vasodilatation with increased permeability, mediates antibody-dependent cytolysis, removes 
immune complexes from the circulation, and finally induces phagocytosis by acting as an 
opsonin. There are three distinct pathways: classical, lectin, or the alternative pathway. The 
classical pathway is triggered when C1q, one of the three subunits of the first component of 
complement, binds to IgM or IgG complexed with antigens forming the C1-complex. The 
lectin pathway is triggered by the binding of mannose binding lectins to sugars on the surface 
of the pathogen. The alternative pathway can be spontaneously activated by absorption of 
C3b onto the surface of the pathogen via C3 hydrolysis. The convergence of the three 
complement pathways occurs around the conversion of C3 to C5 convertase activated by C3 
convertase via the binding of C3b ultimately leading to the formation of the membrane attack 
complex (MAC). However, complement can also be activated by acting independently of C3. 
Complement can be activated by an additional bypass pathway acting independently of C3 or 
bypasses the C3 convertase. It is mediated by thrombin acting on the C5 convertase, 
bypassing C3 convertase.33  
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The complement systems exists in a careful state of homeostasis where activation of the 
inactivated proteins are closely monitored by an elaborate system of inhibitors which control 
activation as well as the response of the protein once activated (Figure 4a). In order to 
prevent complement from damaging host tissues, short half-lives of the thioester group of 
C3b and the C3 convertases limit their action to the site of activation. Carboxypeptidase N is 
a fluid phase regulator of all the complement pathways as it cleaves and partly inactivates the 
anaphylactic peptides C3a and C5a. C1 inhibitor (C1INH)  induces the dissociation of the C1 
components and C4bP displaces a component of the C3 thus regulating the classical and 
lectin pathways. Factor H, FHL1, and the activator protein properdin are all fluid phase 
regulators of the alternative pathway. CFHR1, clusterin (Apo J), and vitronectin are soluble 
inhibitors of the terminal pathway and CD59 preventing the assembly of the membrane attack 
complex. High-density lipoprotein (HDL) particles associate with clusterin (Apo J) acting as 
an adhesion protein and as a potent inducer of cell aggregation. Vitronectin is involved in cell 
attachment or spreading by binding to the extracellular matrix. Finally, properdin activates 
C3 convertase in the alternative pathway by directly binding to the labile C3bBb complex 
leading to C3bBbP. In contrast, factor H inhibits the activation of the alternative pathway 
by binding to C3-fragments and Apo E on HDL particles. Apo J complexes with Apo A-1 
inhibiting the cytolytic activity of the C5b-9 complex. C9 polymers are prevented from 
inserting into the cell membrane by Apo A-I and Apo A-II. Complement receptors bound to 
the cell membrane include CR1 (CD35), CR2 (CD21), CD55 (DAF), CD46 (MCP), CD59 
(protectin), and CRIg (vsIG4) (Figure 4b). These receptors have multiple ligands to which 
they bind such as fibrinogen which inhibits the alternative pathway activation by possessing 
binding affinity for factor H. CR1 binds C3b, iC3b, and C4b whereas CR2 binds C3d, C3dg, 
CD46, CD55, CD59, and CRIg. CR3 and CR4 mediate phagocytosis of C3b-opsonized 
particles by binding iC3b, C3dg, and C3d. 
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Although complement activation is best studied in its involvement in innate immunity, it also 
has important functions in adaptive immunity as well. For example, impaired dendritic cell 
differentiation and activation as well as memory B cell and regulatory T cell function are 
associated with C3 deficiency in humans. 34 Furthermore, inflammatory T cell responses and 
tolerance are enhanced by complement signaling via antigen presenting cells.  
 
 
2.1.1 Classical Complement Pathway  
 
During the classical pathway activation, C1q binds to immunoglobulins IgM or IgG 
complexed with antigens forming the C1-complex where one molecule of IgM or at least two 
molecules of IgG are required for efficient activation. In humans, IgG3 and IgG1 are strong 
complement activators, but IgG2 is a poor activator, and IgG4 does not activate complement. 
The charged residues Asp 417, Glu 418, and His 420 in the Cy3 region of IgM have been 
proposed to form the site to which the gClq domain binds, a 33 kDa glycoprotein, one of a 
number of C1q receptors/binding site. C1q (460 kDa) is produced mainly by immature 
dendritic cells, monocytes, and macrophages and is composed of 18 polypeptide chains (6A, 
6B, and 6C) which form six globular target recognition domains (gC1q).35 Two molecules of 
C1r and two molecules of C1s ultimately forms C1qr2s2, a Ca2+dependent tetrameric 
Figure 4: Complement regulators and surface receptors. (a) Complement regulators can be either fluid phase regulators or at the cell 
membrane regulators. (b) Complement receptors on the cell membrane.  
Taken from: Zipfel, P. F. & Skerka, C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729–740 (2009). 
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proenzyme complex by binding to the C1q collagen domain. C1q directly binds to the 
pathogens surface and undergoes a conformational change in the collagen region of Clq 
which in turn activates Clr and Cls which are both serine proteases. C1r2s2 forms via Ca2+ 
dependent interaction with the binding interface comprised of a Ca2+ binding site in the EGF 
domain of each subcomponent.36 Once activated, the tetramer unfolds extending the C1s ends 
outside the C1q cone in order to interact with C4 and C2. C4 is cleaved producing 9 kDa C4a 
and 190 kDa C4b, which binds the zymogen C2 in a Mg2+-dependent manner. C2 is then 
cleaved producing C2a, which contains a von Willebrand factor (vWf) domain and a serine 
protease (SP) domain and attaches to C4b making up the C3-convertase , and C2b, which is 
released into circulation. C3-convertase (C4b2a complex) cleaves C3 into C3a, an 
inflammation mediator, and C3b, an opsonin, which later joins with C4b2a to make C5 
convertase (C4b2a3b complex).37 C5 convertase cleaves C5 into C5a, interacts with C5a 
receptor (C5aR) to attract leukocytes, and C5b, containing binding sites for the next 
components in the pathway, C6, C7, C8, and C9 forming the membrane attack complex 
(MAC or the C5b-9 complex). C3a, C4a, and C5a are small cationic peptides also known as 
anaphylatoxins that bind to specific receptors on basophils and mast cells. C5b contains a 
binding site for C6, which becomes bound while the C5b molecule is associated with its C3b 
tether. The C5b6 complex may be released from C3b, or it may remain anchored until it 
binds a molecule of C7 forming a trimolecular complex, C5b-7, which adopts a hydrophobic 
and lipophilic character and associates with the membrane exposing the binding site for C8 as 
it burrows into the cell membrane.38 As the complex inserts deeper into the membrane, C9 
binds to C8 and undergoes conformational changes which inserts the now C5b-9 complex, or 
the membrane attack complex (MAC) further into the membrane as well as attracting 
between 12 and 18 more C9 molecules in each complex. This forms a hollow cylinder 
destroying the cell membrane thus leading to cell lysis and death.39 The cell which is now 
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permeable to small ions but not to proteins as well as large influxes of Ca2+ ions, poisons the 
cell.  
2.1.2 Lectin Complement Pathway  
 
Lectin pathway activation occurs when sugars on the surface of the pathogen are bound by 
pattern recognition molecules (PRMs) either ficolins (FCNs), 35 kDa FCN1 (M-ficolin), 34 
kDa FCN2 (L-ficolin), and 33 kDa FCN3 (H-ficolin), or certain collectins mannose-binding 
lectin (MBL), collectin (CL)-10, and CL-11 which are non-antibody, non-enzyme 
carbohydrate-binding proteins, as in the selectin adhesion molecules belonging to the 
collectin family produced by the liver.40 MBLs bind d-mannose (Man), N-acetyl-d-
glucosamine (GlcNAc), or l-fucose (Fuc), in both a calcium-dependent manner via membrane 
C-type lectin receptors (CLRs) whereas ficolins bind via a fibrinogen-like (fbg) domain in a 
calcium independent manner.41 Ficolins are also considered to be elastin- and corticosteroid-
binding proteins.41–44 Ficolin-1 and ficolin-3 have only one binding pocket each, while 
ficolin-2 has four binding pockets.45 Ficolin-1 and ficolin-2 possess ligands capable of 
binding to GlcNAc, N-acetyl-d-galactosamine (GalNAc), N-acetylated cysteine as well as an 
artificial ligand, acetylated human albumin. Ficolin 3 binds N-acetylated compounds as well 
as sialic acids. Mannose binds to the carbohydrate-recognition domain in a calcium 
dependent manner via an ASP 206 residue, a calcium ligand, and Glu 193 and Asn 205 
residues, calcium ligands forming H bonds with the 4-OH group of mannose.46 CLRs are 
mostly expressed on myeloid cells, functioning as pattern recognition receptors (PRRs) and 
reacts to ligands from non- self (pathogen-associated molecular patterns, PAMPs), damaged-
self (damage-associated molecular patterns, DAMPs) or altered self (tumor-associated 
molecular patterns, TAMPs).47 CLRs recognize their ligands by a carbohydrate-recognition 
domain (CRD) via two binding motifs: EPN motif which binds to mannose, N- 
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acetylglucosamine, L-fucose, and glucose;  and the QPD motif which recognizes galactose 
and N- acetylgalactosamine.48 These galactose recognizing CRDs bind via a glutamine-
aspartic acid instead of the glutamic acid-asparagine residues which mannose recognizes. 
EPN motif leads to the formation of a complex with protease zymogens called Mannose-
binding lectin Associated Serine Protease MASP1, MASP2, MASP3, MBL-associated 
protein of 19 kDa (MAp19), and MBL-associated protein of 44 kDa (Map44), truncated 
alternative splice products of the MASP2 and MASP1/3 genes.49 MASPs are structurally and 
functionally similar to C1r and C1s where MASP2 cleaves C4 and C2 into C4a, C4b, C2a, 
and C2b forming the C3-convertase (C4b2a complex) as in the classical pathway. Therefore, 
the activation of the lectin pathway via C3 and C5 convertase complexes is impossible 
without MASP2. C3 can be directly activated by MASP1, bypassing C4 and C2, by direct 
cleavage of complex-bound MASP-2 or cleavage of C4b-bound C2. MASP3 does not have 
an identifiable substrate thus far. MASP-1 activates MASP2 as well as factor D, which is a 
component of the alternative pathway which indicates that MASP-1 is an initiator of the 
alternative pathway.50 Collectins bind the same C1q receptor and are thus able to activate the 
classical pathway by directly activating the C1r2C1s2 tetramer in the absence of C1q. 
 
2.1.3 Alternative Complement Pathway  
 
In plasma, during normal physiological conditions, the dominant active complement pathway 
is the alternative, monitoring for pathogen invasion by maintaining a low level of constitutive 
activation by a process known as tick-over. Despite the name, the alternative pathway 
accounts for up to 80–90% of total complement activation. The alternative pathway can be 
spontaneously activated by absorption of C3b onto the surface of the pathogen via C3 
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hydrolysis. C3 is mildly unstable in water, thus causing the internal thioester bond to 
breakdown forming C3(H2O) and binding factor B to form activated C3(H2O)B or fluid-
phase C3 convertase. C3(H2O) can also non covalently bind to the pathogen’s surface and 
bind factor B and D to cleave C3 but on C3(H2O)B convertase cleaves C3 into C3a and C3b 
which following binding to the surface of the pathogen, binds to factor D to form C3bBb, 
stabilized by properdin (P) (Figure 5).51,52 Once bound, properdin (P) can recruit fluid-phase 
C3b, independent of covalent binding, to form the convertase C3bBbP thus directing 
activation in such a way as MBL does in the lectin pathway. Complement factor D cleaves 
complement factor B to Ba and Bb activating the Alternative pathway. A positive feedback 
loop is established, regulated by factor H and I, as the convertase C3bBbP also cleaves C3 
into C3a and C3b, building up more C3b onto the surface of the pathogen. Factor H inhibits 
the alternative pathway by disrupting Bb in the C3 convertase as well as behaving as a 
cofactor for Factor I which cleaves C3b and C4b. C4b-binding protein (C4BP) is involved in 
inhibiting the classical and lectin pathways via binding C3b, decaying C3 convertase, and 
being a cofactor for Factor I. 
 
Furthermore, C3bBbP forms C5-convertase ((C3b)2BbP) by binding additional C3b, and 
converges with the two other pathways where C5 convertase cleaves C5 into C5a, interacts 
with C5a receptor (C5aR) to attract leukocytes, and C5b, interacting with C6, C7, C8, and C9 
forming the membrane attack complex (MAC) or the C5b-9 complex. The MAC complex 
forms transmembrane channels destroying the cell membrane leading to cell lysis and 
death.37 However, on normal cells, C3b is rapidly deactivated to iC3b by factor I via innate 
regulatory mechanisms suppressing complement activation as uncontrolled activation can 
induce tissue damage and the pathogenesis of various conditions like autoimmune diseases, 
sepsis, and transplant rejection are caused by the inappropriate activation of complement.53  
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Figure 5: Schematic diagram of complement C3 protein as well as its cleavage sites and subsequent 
fragments upon C3 activation.  
Taken from: Seifert, P. S., Messner, M., Roth, I. & Bhakdi, S. Analysis of complement C3 activation products in human atherosclerotic lesions. 
Atherosclerosis 91, 155–162 (1991). 
Janssen, B. J. C., Christodoulidou, A., McCarthy, A., Lambris, J. D. & Gros, P. Structure of C3b reveals conformational changes that underlie 
complement activity. Nature 444, 213–216 (2006). 
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2.2 Coagulation Cascade and the Complement system  
 
Many enzymatic cascades control a wide range of biological functions where three protein 
networks play dominant roles including the complement system (discussed above), the 
coagulation cascade, and the fibrinolytic system. These three pathways all consist mainly of 
serine proteinases with trypsin-like activity, together with their activators and inhibitors. The 
complement and the coagulation systems are two distinct protein networks, however, they 
both are involved in the first line of defense against pathogens and the inflammatory response 
as well as having a few points in the cascade which link these two pathways together. 
Hemostasis is continuously active at low levels in the body, terminating bleeding and slightly 
favoring an anticoagulant state, and as in the complement system, the procoagulant factors 
are activated in tightly controlled conditions and regulations. Hemostasis not only supports 
Figure 6: The complement system is divided into 3 pathways: Lectin, Alternative (Mg2+), and 
classical (Ca2+). Whichever pathway is taken, it leads to C3 convertase and cell lysis via an 
amplification loop.  
Taken from: Oikonomopoulou, K., Ricklin, D., Ward, P. A. & Lambris, J. D. Interactions between coagulation and complement—
their role in inflammation. Semin. Immunopathol. 34, 151–165 (2012). 
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blood clotting (coagulations), but also is involved in fibrinolysis, the dissolution of blood 
clots, and is activated by either an intrinsic or extrinsic cascade (Figure 6). Following tissue 
damage, the functions of blood cells, the vascular system, several soluble plasma proteins, 
aggregation of platelets, and low molecular weight components are all involved in the 
regulation of hemostasis. For example, effective hemostatic responses depend greatly on the 
regulation of mediators such as the activated and aggregated platelets which provide a 
negatively charged surface in areas in which the clotting cascade is initiated.54  
 
Upon tissue damage, platelets are activated via adhesion to the extracellular matrix by 
collagen binding to either platelet GP Ia/IIa and GP VI receptors or by binding to platelet 
glycoprotein (GP) Ib-IX-V receptor complex via a bridge produced by Factor XV or the von 
Willebrand factor. Platelet adhesion can be inhibited by high density lipoprotein (HDL) and 
Apo A-1 which prevents von Willebrand factor (vWF) self-association and prevents 
circulating vWF binding to adherent vWF fibers, respectively.55 Thrombin also activates 
platelets through protease-activated receptors (PAR) on the platelet surface via G protein-
coupled receptors (GPCR). Platelet degranulation releases thromboxane A2 (TXA2) which 
triggers platelet activation through GPCR leading to an increase in cytosolic calcium 
concentrations.56 Coagulation is initiated and TXA2 being unstable, quickly hydrolyzes into 
the stable and inactive thromboxane B2 (TXB2). TXA2 is a prostanoid, an oxygenated lipid, 
produced by the metabolism of arachidonic acid (AA) released from membrane 
phospholipids by phospholipase A2 (PLA2) through the cyclooxygenase (COX) pathway. 
Phospholipase A2 catalytically hydrolyses the Sn2 ester bond of phospholipids releasing a 
free polyunsaturated omega-6 fatty acid, AA, and a lysophospholipid. COX-1 and COX-2 
convert AA to prostaglandin (PG) intermediate PGH2 which is then converted to five primary 
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bioactive prostanoids PGD2, PGE2, PGF2a, PGI2, and thromboxane A2 (TXA2). Stimulated 
platelets also activate further platelets creating a feedback loop promoting clot formation.29,57  
 
During the extrinsic pathway, tissue factor (TF) tightly binds the serine protease FVIIa 
circulating in the blood forming the TF-FVIIa complex which in turn increases the catalytic 
activity of FVIIa by roughly 30,000-fold.58 TF-FVIIa complex activates the downstream 
serine protease factor X (FX) and factor IX (FIX), thus initiating the coagulation cascade and 
where the extrinsic and intrinsic pathways of the coagulation system converge.59 FX can also 
be activated by IXa (FIXa) forming a complex with its cofactor protein, factor VIIIa 
(FVIIIa). Activated FX or FXa binds FVa forming prothrombinase which converts 
prothrombin to thrombin (FIIa) allowing thrombin to activate platelets, FV, factor VIII 
(FVIII), and factor XI as well as cleavage of fibrinogen to fibrin.60  
 
During the intrinsic pathway, the negative charges of the aggregated platelets initiates plasma 
FXII, an 80 kDa glycoprotein, to be converted to the protease FXIIa in a plasma kallikrein-
high molecular weight kininogen (HMWK)-dependent fashion (contact system). This 
contact-activation complex, formed by prekallikrein, FXI, HMWK, and FXII, brings all the 
factors into reactive proximity thus triggering the reaction cascade. HMWK is a 120 kDa 
nonenzymatic cofactor of FXII which circulates in complex with prekallikrein, an 80 kDa 
protein. FXII cleaves prekallikrein into two subunits, a 46 kDa heavy chain and one 36 or 33 
kDa light chain. Activated kallikrein can now activate FXII, plasminogen, and factor IX. 
Either FXIIa catalyzes the activation of FXI, 160 kDa glycoprotein, to FXIa or FXI can also 
be activated by thrombin or FXIa, leading to the activation of FIX and subsequent thrombin 
generation. At this step, the extrinsic and intrinsic pathways of the coagulation system 
converge with the activation of factor X (FX).61 
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Coagulation is resolved by fibrinolysis, which leads to the degradation of fibrin, the product 
of the coagulation cascade. Plasminogen, the zymogen of the serine proteinase plasmin which 
can be found on HDL, is activated by tissue plasminogen activator (tPA) and urokinase 
plasminogen activator (uPA) which generates active plasmin on the fibrin surface and soluble 
plasmin, respectively. HDL is both an activator and inhibitor of the fibrinolysis pathway. 
Kallikrein is also found on HDL which suggests HDL activates plasmin by promoting the 
interaction of plasminogen and kallikrein but HDL also binds alpha- 2-antiplasmin and alpha-
2-macroglobulin.  
 
 
The coagulation, complement, and fibrinolysis pathways are linked in intricate and tightly 
regulated ways having some shared activators and inhibitors (Figure 7). It has been 
established that the rapid activation of the coagulation cascade following trauma is 
accompanied by a very early onset of an uncontrolled, progressive inflammatory response 
which can end in lethal repercussions, indicating coagulation components can activate 
Figure 7: The coagulation cascade depicting the Intrinsic and Extrinsic pathways as 
well as the part of the cascade in which they both have in common. 
Taken from: Oikonomopoulou, K., Ricklin, D., Ward, P. A. & Lambris, J. D. Interactions between coagulation and 
complement—their role in inflammation. Semin. Immunopathol. 34, 151–165 (2012). 
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components of the complement cascade. C3a and C5a, the activated form of C3 and C5 
respectively, of the complement cascade, can be formed via kallikrein activation of factor B 
in the coagulation cascade. Activated platelets can phosphorylate C3 by releasing a 
serine/threonine protein kinase leading to a phosphorylated C3b which is not susceptible to 
deactivation to iC3b. This causes an increase in C3b deposition and CR1 receptor binding 
inducing the alternative complement pathway.  
Thrombin activation can proteolytically generate C5a triggering the complement pathway 
and inducing the expression of the decay accelerating factor (DAF) in a PAR1-dependent 
manner, reducing C3 deposition thus inhibiting the complement pathway. Both C3 and C5 
can be activated by FIXa, FXa, FXIa, thrombin, and plasmin as well as being inactivated by 
thrombin-activatable fibrinolysis inhibitor (TAFI) generated by a thrombomodulin–thrombin 
complex. TAFI also can inhibit the plasmin-mediated fibrinolysis, inhibiting fibrin 
degradation. Chondroitin sulfate on platelet surface can also contribute to binding of C1q 
(which itself can also be activated by XIIa), as well as the complement regulators C1 
inhibitor (C1INH), C4b-binding protein (C4BP), and factor H. C3 and C4 activation can 
occur with the interaction of fibrinogen/fibrin with recognition molecules that trigger 
initiation of the lectin pathway.  
Complement cascade components can activate components of the coagulation pathway 
(Figure 8). Thrombin activation can occur via MASP2, which itself along with C1r/s and C3b 
can be inhibited by C1-esterase. Kallikrein and XIIa are also inhibited by C1-esterase. While 
the membrane attack complex (MAC) or the C5b-9 complex associates with the cell 
membrane, changes in the membrane- associated components are triggered which in turn 
affects platelet activation and thus the coagulation pathway. Platelet activation and 
aggregation is further induced by activated C3 whereas tissue factor (TF) activity is induced 
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by activated C5, triggering the extrinsic coagulation pathway. Furthermore, a C5a receptor 
(C5aR)-TF has been found demonstrating obvious cross-talk between the two pathways.59  
 
Fibrinolysis, which leads to the degradation of fibrin, the product of the coagulation cascade, 
generates the fibrinolytic proteinase plasmin via C5 activation of the complement system 
leading to upregulation in the coagulation cascade component plasminogen activator inhibitor 
1 (PAI-1). PAI-1 can inhibit the enzymatic activity of the serine protease tissue plasminogen 
activator (tPA). However, plasmin can also activate C3 and C5.  
 
  
 
 
 
 
Figure 8: Intercommunication between the coagulation, complement, and 
fibrinolysis cascades.  
Taken from: Oikonomopoulou, K., Ricklin, D., Ward, P. A. & Lambris, J. D. Interactions between coagulation and 
complement—their role in inflammation. Semin. Immunopathol. 34, 151–165 (2012). 
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2.3 Hepatic lipid pathway and complement activation interplay 
Lipoprotein metabolism functions as a fuel transport system where insoluble hydrophobic fat 
becomes soluble in the form of lipoproteins for delivery to peripheral tissues. Very-low-
density lipoprotein (VLDL) are produced hepatically, functioning as triglyceride (TG) 
transporters. Lipoproteins include chylomicrons (CM), VLDL, intermediate-density 
lipoproteins (IDL), low-density lipoprotein (LDL), and high-density lipoproteins (HDL) 
organized by their core lipid density composition. Further structural characteristics include 
surface phospholipids, cholesterol, and apolipoproteins which function either as structural 
(apolipoproteins B and AI), or exchange between different lipoprotein particles 
(apolipoproteins AII, C, and E).62 Apolipoproteins are multifunctional, important in both 
lipoprotein metabolism via receptor-binding regulation and controls enzyme activity. 
Apolipoprotein A-I (Apo AI) is a 29 kDa protein and is a major component of high-density 
lipoprotein (HDL) cholesterol (70-80%) as well as Apo AII, a 17 kDa protein, which makes 
up about 20% of HDL. Both Apo AI and AII are involved in lecithin cholesterol 
acyltransferase (LCAT). Apo AI interacts with lipid transfer proteins and specific receptors 
and Apo AII regulates lipoprotein lipase (LPL) activity as well as regulating the reactivity of 
HDL towards lipid transfer proteins, enzymes, and receptors. Apo AIV is a 44 kDa protein 
which activates Apo CII lipoprotein lipase and lipoprotein modifiers such as LCAT, but to a 
lesser degree than Apo AI. Apo AIV also interacts with Apo CII, and Apo E mediates the 
binding, internalization, and catabolism of lipoprotein particles as well as being a ligand for 
the LDL (Apo B/E) receptor and for the specific Apo E receptor. Apo E also binds LDL 
receptors with a higher affinity than Apo B-100. Apo B-100 functions as a recognition signal 
for low-density lipoprotein (LDL) as it contains the LDL receptor binding domain.  
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Components of the lipid metabolism and complement pathway have been shown to crosstalk. 
Apo E interacts via domains 5–7 with Complement factor H (FH) reducing alternative 
pathway activation and iC3b formation. FH induces platelet aggregation, thrombin 
production, and an associated platelet procoagulant response by forming a complex with 
heparin via electrostatic interactions as well as binding glycosaminoglycans. Complement 
factor H is released from platelet α-granules upon platelet activation and platelet FcγIIa 
receptors cross link with subsequent immune complexes composed of FH-heparin complex 
and IgG molecules. However, FH also functions as a complement inhibitor of the alternative 
pathway as it inactivates C3b via factor I and increases C5 and C3 convertase 
dissociation.62,63 Furthermore, Apo A1 is involved in the MAC complex assembly. Both Apo 
A1 and Apo AII have specific binding sites on the surface of C9 which can disrupt the 
formation of the C5b-9 complex which inserts into the cell membrane. Apo AI also disrupts 
the formation of the C5b-9 complex by forming together with clusterin, a high density 
lipoprotein complex as well as hydrophobically associating with C3. Therefore, Apo AI and 
AII can be associated with complement down regulation.64 
 
 2.4 Mononuclear phagocyte system 
 
Once inside the bloodstream, the mononuclear phagocytic system (MPS) targets and clears 
nanoparticles via cells such as monocytes circulating in the blood, macrophages, and 
dendritic cells (DCs) which are derived from hematopoietic bone marrow stem cells and are 
present in tissues like the liver, spleen, lung (alveolar macrophages), and bone marrow. 
Dendritic cells are also found in lymphoid and nonlymphoid tissues and are responsible for 
activating T cells in an antigen-dependent manner. Current literature indicates that unlike 
previously accepted, tissue-specific macrophages are in fact first derived during 
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embryogenesis instead of bone marrow-derived monocytes accumulating in the tissues and 
replenishing their populations by self-renewal. Being a part of the innate immune system, 
macrophages phagocytose dead and damaged cells and organisms and release cytokines 
which may activate other cells such as lymphocytes and eosinophils. Concerning the acquired 
immune system, macrophages are responsible for removing opsonized cells and particles as 
well as antigen processing, presentation, and T lymphocyte priming.65 Macrophages have 
several responsibilities in the upkeep of normal homeostasis such as removing dead and 
dying cells during normal tissue cell turnover or are recruited during an inflammatory 
response where they differentiate from circulating blood monocytes. Macrophages have four 
different stages in their life cycle: differentiation, priming, activation, and resolution. The 
first stage occurs when monocytes differentiate from bipotential stem cell (CFU-GEMM) via 
stimulation by growth-stimulating cytokines such as interleukin 3 (IL-3), stem cell factor 
(SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), retinoic acid, 
lipoproteins, and macrophage colony-stimulating factor (M-CSF), and factor increasing 
monocytopoiesis (FIM). Because the capillaries in the lung are only 6.5 μm, circulating 
monocytes are roughly 7-8 μm whereas monocyte derived macrophages are 15-20 μm.66 
Macrophage priming is accomplished by the different cytokine milieus during 
their continuous recruitment into tissues which ultimately impacts their innate immune 
response. Two categories of macrophages exists, M1 with classical activation or M2 
macrophages with an alternative activation. M1 macrophages are characterized by 
inflammatory cytokine secretion and produce nitric oxide (NO), by metabolizing arginine, 
induced by intracellular pathogens, lipoproteins, bacterial cell wall components, and 
cytokines such as interferon gamma (IFN-Ɣ) and tumor necrosis factor alpha (TNF-α). M2 
macrophages produce trophic polyamines and are subdivided based on their stimuli M2a, 
M2b, M2c, and M2d. M2 macrophages are induced by parasites, fungal cells, apoptotic cells, 
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immune complexes, complements, and MCSF. 67 More specifically, M2a is activated in 
response to IL- 4 and IL-13, the M2b to immune complexes and bacterial lipopolysaccharide 
(LPS), the M2c to glucocorticoids and TGF-β, and the M2d to IL-6 and adenosines. M2 
macrophages not only clear apoptotic cells, mitigate inflammatory responses, and encourage 
wound healing but they also produce extracellular matrix (ECM) components, angiogenic 
and chemotactic factors, and IL-10.   
Monocytes are differentiated from bipotential stem cell (CFU-GEMM) and express cell 
surface markers CD14 (LPS co-receptor), CD16 (FcƔRIII), CD64 (FcƔRI), and the 
chemokine receptors CD192 (CCR2) and CX3CR1 (fractalkine receptor).68 Similar to 
macrophages, monocytes are also subdivided into three categories of classical monocytes 
(CD14++CD16−) which are responsible for about 80–90% of peripheral blood monocyte 
population, non-classical monocytes (CD14+CD16++), and intermediate monocytes 
(CD14++CD16+) which are found primarily in the circulation, bone marrow, and spleen.69 
Monocytes can be further distinguished based upon their differential expression of surface 
markers as well as the pathogenic stimuli each subset responds to where classical and 
intermediate monocytes preferentially express CD11b and CD62L and respond to bacteria-
associated signals whereas CD11c and CX3CR1 are expressed on the non-classical 
monocytes and respond to virus-associated signals.66,70  SIRPα, an inhibitory receptor that 
suppresses phagocytosis, DC differentiation and maturation, and cytokine production, is 
preferentially expressed on non-classical monocytes. Circulating monocytes represent 5-10% 
of leukocyte populations circulating in blood.  
 
Classical monocytes are responsible for phagocytic and microbial activity with low pro-
inflammatory cytokine production. They express high levels of chemokine receptor 2 
(CCR2), chemokine receptor (CXCR) 1, 2 and 4, and CD62L (L selectin). CX3CR1 
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(fractalkine receptor) and CCR5 (the receptor for the following chemokines: CCL3, CCL4, 
CCL8, and CCL3) are expressed at low levels. Classical monocytes also produce the 
cytokines and chemokines upon lipopolysaccharide (LPS) stimulation including IL-10, IL-6, 
IL-8, TNF-α, IL-1𝛽, and CCL2. They also express CD64, the opsonin receptor FcƔRI, but 
not CD16 (FcƔRIII) as well as expressing integrins CD11a/CD18 and CD11b/CD18 but not 
CD11c/CD18. Non-classical monocytes are responsible for anti-inflammatory and 
constitutively produces IL-1RA. They express high levels of CX3CR1 but not CCR2 and 
CD62L and when stimulated with LPS, they produce high levels of TNF-α and IL-1𝛽. In 
addition to their low phagocytic capacity, non-classical monocytes express CD16 (FcƔRIII) 
but little of CD64 (FcƔRI). Intermediate monocytes are responsible for Pro-inflammatory 
function and actively produces TNF-α (in response to LPS), IL-1𝛽, and IL-6. They express 
high levels of CCR1, CCR2, and CXCR2 similar to classical monocytes, as well as CX3CR1, 
similar to non-classical, and they uniquely express CCR5. Intermediate monocytes further 
express both opsonin receptors CD64 (FcƔRI) and CD16 (FcƔRIII), CD36 scavenger 
receptor, and high integrin expression of CD11a/CD18, CD11b/ CD18, and CD11c/CD18.71 
 
2.5 Mechanism for Nanoparticle uptake by MPS  
 
Just like nanoparticles are engineered to function in a specific manner, they too can be 
engineered to avoid opsonization by the MPS thus increasing their efficacy and prolonging 
their circulation time. The molecular features on nanoparticles such as surface charge, corona 
molecules, size, and shape of the nanomaterials impact immune activation highly. 
Opsonization or the recruitment of serum proteins bound to the surface of the particles, leads 
to the formation of a biomolecular corona on the particle. The surface functionalities which 
are determined by the size and shape of the nanoparticle, interacts with biological systems 
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with their uptake highly dependent on the cell type, therefore utilizing different uptake routes 
or targeting different organelles.72 These interactions are dependent on thermodynamic 
exchanges between the nanoparticle surface and the biological surface, colloidal forces, as 
well as dynamic biophysiochemical interplays. Therefore, the protein corona is not just a 
function of the specific material of the nanoparticle or the surface modification, but also of 
time. Once formed, the corona will change the distribution, macrophage and reticular 
endothelial system uptake, blood coagulation, and complement activation, however, the 
composition of the corona is dynamic, changing overtime in relation to their association 
strengths and rate constants.73  
 
The issue of the formation of a protein corona is twofold. Firstly, opsonization of the particle 
occurs via complement protein absorption and activation eventually clears the pathogens 
from the body by aiding recognition by macrophage receptors, such as fibronectin, 
immunoglobulins, and complement proteins themselves as discussed above. Therefore, the 
particle’s function and identity are impaired and altered than the intended chemical design. 
Secondly, phagocytosis of nanoparticles happens when opsonization of particles by iC3b and 
immunoglobulin G (IgG) occur which is mediated by either the CR or FCɣR receptors. MPS 
phagocytosis ultimately leads to the accumulation of nanoparticles in the tissues of the MPS 
which causes inflammation, release of toxic byproducts by biodegradation, and uncontrolled 
and unpredictable localization. 
 
However, it is not just the composition of the corona which dictates the nanoparticle’s 
ultimate biological function, but also the structure of the proteins adsorbed on the 
nanoparticle. Protein absorption on the particle’s surface can cause denaturation, changing 
the structure of the protein. Examples of this phenomena can be seen by lysozyme and 
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chymotrypsin losing their secondary structure and activity following adsorption by 10 nm 
gold nanoparticles as well as cytochrome c upon binding to sulfonated polystyrene and 
magnetic nanoparticles. Loss of secondary structure can also be caused by the surface charge 
of a particle not just its material. BSA binds to anionic particles but conserves its structure 
and ability to bind to native albumin receptors. However, when BSA binds to cationic 
nanoparticles, the subsequent denaturation of the protein structure causes the BSA to bind to 
scavenger receptors.74  
 
Particles larger than 100 nm are sequestered by Kupffer cells, macrophages lining hepatic 
sinusoids in the liver, together with marginal zone and red pulp macrophages in the spleen 
via phagocytosis, eliminating particles through the hepatobiliary system. Hepatocytes 
endocytose and enzymatically break down particles usually between 10-20 nm and depending 
on their composition, expelling them into the bile through biliary excretion whereas Kupffer 
cells of the MPS remove particles through intracellular degradation. Particles less than 5 nm 
are subjected to renal filtration by passing through the pores of the glomerulus in the kidneys 
thus rapidly cleared from the circulatory system. The glomerular capillary wall is composed 
of three layers where glomerular filtrate flows through the fenestrate, across the glomerular 
basement membrane, and through the filtration slits.75 Nanoparticles of around 50 nm 
undergo the most efficient uptake through the receptor-mediated endocytosis in contrast to 
particles smaller and larger than 50 nm as there is, respectively, insufficient free energy to 
efficiently wrap the nanoparticle with cell membrane lipids or wrapping the nanoparticles 
takes too long as more time is needed to diffuse the receptors of the cell membrane around 
the nanoparticle.20 However, in general smaller particles of the same composition absorb less 
complement proteins than larger particles and thus the blood concentration decreases with 
increasing size. A likely explanation of why particles around 50 nm induce more 
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immunogenic and cytotoxic responses is likely due to an inherent, conserved immunogenic 
signal stemming from the nano-size range bearing great similarity to viral particles. Other 
physical properties which are affected by particle size such as zeta potential and available 
surface area also contribute to the ultimate fate and clearance of the particle. Particles with a 
negative surface charge and hydroxylation of the surfaces are found to increase activation of 
the complement and therefore a more rapid clearance. Even the shape of the surface is known 
to activate complement in different ways, for example spheres and short filomicelles are 
more rapidly taken up by cells than longer filaments example under fluid flow conditions, 
because longer filaments are extended by the flow.76 This indicates the internalization of 
nonspherical particles occurs via different mechanisms of endocytosis.  
 
Surface charge of a particle can directly affect the fate of the nanoparticle. Renal filtration 
can be dictated by interactions between charged molecules and fixed charges within the 
glomerular capillary wall. Particles within the 6-8 nm range who are unable to undergo 
normal filtration due to their size, depending on their surface charge, may still undergo renal 
filtration.75 Opsonization of a particle occurs predominantly by hydrophobic and ionic 
interactions, although the process can be more complex given the heterogeneous surface. 
Complement activation is increased as hydroxylation of the surface on more negatively 
charged particles increases. This indicates that complement activation is party caused by C3b 
covalently binding to hydroxyl groups. Thus hemolysis and complement activation increases 
with more negatively charged particles. Inflammatory signaling and phagocytic uptake are 
mediated through receptors such as class B SRs, SR-B1, and CD36, preferentially expressed 
on macrophages, which bind anionic lipids and lipoproteins, in particular, phosphatidylserine 
and phosphatidylinositol liposomes. Furthermore, both anionic and cationic nanoparticles are 
internalized via CD64 on macrophages. Conversely, cationic liposomes favorably interact 
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with DCs and had significantly slower uptake of phosphatidylserine liposomes.31 Therefore, a 
particle with a more hydrophilic polymeric coating will be less likely to induce protein 
corona-mediated complement activation.  
 
3. Stealthing polymers for nanosystems 
 
Once introduced to biological fluids following internalization by cells, nanoparticles are 
typically localized inside highly acidic endosomes and/or lysosomes, being exposed to and 
ultimately stabilized by negatively charged groups. This leads to agglomeration due to the 
loss of charge, and the reduced pH enhances nanoparticle corrosion inducing toxic ion 
release. Furthermore, during internalization by cells and in the subcellular compartments, the 
polymers coating hydrophobic nanoparticles can be dissociated from the surface as well as 
the nanoparticle’s protein corona enzymatically degrading, altering the surface chemistry of 
the particle.77,78 Therefore surface modification and ultimately stealth properties of 
nanoparticles are designed to 1) increase the circulation lifetime and to prevent or reduce 
nonspecific interactions with the MPS, 2) targeting and therapeutic molecules can be 
conjugated to the nanoparticle, 3) prevent aggregation, 4) protect the payload from 
detrimental effects during transport, 5) release effective quantities and facilitate elimination 
of the payload following administration, and 6) reduce cytotoxicity.  
 
Nanoparticles are coated with polymers in order to grant stealth behavior from opsonins, 
which is achieved by osmotic pressure (crowding of polymer chains in any fixed space), 
elastic restoring forces, Van der Waals attraction, ionic forces, and hydrophobic/hydrophilic 
forces. Higher osmotic contribution or higher elastic contribution is associated with a longer 
equilibrium layer thickness or a shorter equilibrium layer thickness, respectively.79 As the 
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surface density of the polymer increases and the chain length increases, the greater the 
repulsion force and thus the better at resisting protein interactions. For example, PEG which 
is the most widely studied stealth polymer to date, has a hydrophilic and flexible nature 
which lends it its “brush” conformation. The polymer chains exert steric repulsive force as 
the chains extend from the particle surface and interact with one another at high polymer 
densities. This conformation causes absorbed opsonins to compress the chains leading the 
polymers to condense lending to a higher energy conformation. Therefore, the attractive 
forces between opsonins and nanoparticles are counterbalanced by the subsequent repulsive 
forces caused by polymer-protein interaction.  
 
Not only can modifying the surface of the nanoparticle reduce the likelihood of absorbing 
complement proteins and activating phagocytosis, but chemically engineering nanoparticles 
enhances desirable surface properties for biomedical applications based upon the targeted 
disease. 
 
3.1 Targeted drug delivery  
 
Targeted drug delivery is composed of a wide range of approaches with the ultimate goal to 
enhance a drug delivery system (DDS) with better specificity, increased circulation lifetime, 
and decrease toxicity. This is achieved via a few methods involving passive targeting, active 
targeting, contact-facilitated drug delivery, or biological barrier delivery.  
 
Passive targeting, utilized extensively in tumor therapeutics, is realized by conjugating a 
therapeutic agent to a nanoparticle which then passively reaches the target organ via blood 
circulation thus depending highly on circulation time. Many tumors and vascularized solid 
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tumors display an enhanced permeability and retention (EPR) effect where leaky vasculature 
and absent or impaired lymphatic drainage can be exploited by roughly 20-500 nm drug-
loaded nanoparticles or high molecular weight molecules (polymers) to accumulate within 
the tumor site (Figure 9).  
 
On the other hand, active targeting involves tissue or cell-specific ligands conjugated to the 
therapeutic particle which interacts with its complementary membrane-bound receptor. 
However, active targeting begins with passive accumulation of the DDS therefore an active 
carrier must also be biocompatible, stable in circulation, long circulating, and appropriate 
diameter permitting efficient extravasation and accumulation in tumors as passive DDS are 
required to be for effective treatments.80,81 In order to achieve controlled, localized delivery 
of a particle’s payload, stimulus-responsive nanoparticles can be further designed to release 
their content in response to a trigger such as pH, ultrasound, UV light, temperature, 
biological microenvironment (protease). 82 
 
Contact-facilitated drug delivery involves transferring lipid-prodrugs following particle 
docking to a cell surface receptor and releasing the lipid surfactant components into the outer 
Figure 9: Schematic representation of enhanced permeability and retention (EPR) effect where leaky 
vasculature and absent or impaired lymphatic drainage can be exploited.  
Taken from: Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as 
Potential Alternatives. Angew. Chemie Int. Ed. 49, 6288–6308 (2010). 
 43 
leaflet of the target cell membrane. The drug would then be distributed throughout the 
intracellular membranes following translation from the outer lipid leaflet into the inner lipid 
leaflet.83 These types of enhanced lipid-lipid exchanges can exhibit prolonged release kinetics 
and long persistence at the target site.  
 
Another type of sustained delivery of therapeutic agents involves crossing biological barriers 
such as the blood brain barrier (BBB) which controls the exchange of hydrophilic 
compounds, small proteins, and charged molecules between the plasma and the CNS. Drugs 
which cannot cross this barrier are extremely limited but when conjugated to a nanoparticle, 
they become more lipid-soluble, providing greater CNS penetration, slower drug release in 
the brain, and decreasing peripheral toxicity. Drugs can be directed across the BBB via 
passive diffusion or receptor-mediated endocytosis as well as active site-directed delivery 
where high-affinity ligands for these transporters are placed on the surface of the NPs.84 
 
3.2 Silica nanoparticles 
 
Silica is the second most abundant material on earth after oxygen, frequently found bonded in 
the form of silicon dioxide (SiO2) also known as silica, occurring naturally as crystalline 
quartz sand, rocks, and clays which are then used as industrial silica products like silica gel, 
precipitated silica, silica sol (colloidal silica), and fumed silica.85 Crystalline silica is known 
to cause silicosis, a progressive fibrotic lung disease, when inhaled, via the production of 
ROS leading to DNA damage or oxidative membrane damage, which in turn spurred the use 
of amorphous silica instead. Amorphous silica occurs naturally in the form of diatomaceous 
earth, opal, and silica glass or as human-made products like additives to cosmetics, drugs, 
printer toners, varnishes, and food. Amorphous silica may present some short-range order but 
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lacks long-range order in three dimensions and does not exhibit a sharp x-ray diffraction 
pattern. Whereas crystalline silica exhibits long-range order in all dimensions and produces a 
sharp x-ray diffraction pattern.86 Inorganic nanoparticles such as solid silica (SiO2-NPs) and 
mesoporous silica nanoparticles (MSNPs) have become of increasing interest as the mean 
human adult intake of amorphous silica is estimated to be about 2 mg/kg of body weight per 
day.25 Furthermore, they are utilized in controlled drug release due to their accessibility, 
versatility, high capacity of processing, and physical-chemical properties adapted through 
synthesis. The structure of silica is rigid, inert, and stable as it does not swell or change 
porosity with solvent or pH variation. Silica contains negatively charged isolated, vicinal and 
geminal silanol groups, silicon-bonded hydroxyl groups, giving rise to a strongly negative 
zeta potential at physiological pH. Vicinal silanol groups, one hydroxyl group per tetrahedron 
less than three nm apart from one another, interacts strongly with water molecules whereas 
germinal silanol groups, two hydroxyl groups per tetrahedron, interact with water molecules 
with less affinity. As the number of silanol groups increases, the hydrophilicity increases as 
well as its ability to form H bonds with water molecules. Amorphous silica has a 
concentration of 4-5 hydroxyl groups on the surface per square nanometer.86   
 
Synthesis of silica nanoparticles occurs via the Stober protocol, in reverse microemulsions, or 
in aqueous micellar solutions. 87 The Stober method is a sol-gel approach of synthesizing 
silica involving silicon alkoxides such as tetraethylorthosilicate (TEOS) combined in a 
mixture of water, alcohol, and ammonia and agitated to form monodisperse particles ranging 
in size from 50 nm–2 μm. The size of the silica nanoparticles is controlled by the 
concentration of the solvents and silicate additives such that as the amount of TEOS 
increases, the particle size decreases forming uniform particles (Figure 10).88 The reaction 
includes hydrolysis and condensation reactions: 
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Hydrolysis: Si(OR)4(aq) + 2H2O(l) → Si(OH) 4(aq)+ 4R-OH(l)  
Condensation: (HO)3 Si-OH(aq)  + HO-Si(OH) 3 (aq)  → (HO) 3Si-O-Si(OH) 3(sol)+ H2O(l)  
where R represents either a methyl (CH3) or ethyl (CH2CH3) moiety in the case of TEOS. 
The “sol” phase of the reaction is the formation of small colloidal particles from the initial 
condensation of two hydrolyzed organosilane molecules. The “gel” phase is the formation of 
discrete, solid particles following a continued condensation of particles.  
 
Reverse microemulsion synthesizes silica spheres around 30-60 nm with better average 
monodispersity than using the Stober protocol. TEOS is added to a reverse water-in-oil 
microemulsion, resulting in the hydrolysis of the alkoxide, via the diffusion of the alkoxide 
into the water droplets, as well as the formation of oxy-hydroxy-silicate species and 
alcohol.89 Aqueous micellar solution synthesis involves micellar aggregates encapsulating 
polymerized lipophilic organosilane derivatives in the hydrophobic core.  
Controlled polymerization of organosilane derivatives produces amorphous silica materials 
(ORMOSIL) where the Si atom is covalently bonded to an organic moiety. ORMOSIL 
conserves stability and physical features and properties as with inorganic SiO2-NPs but they 
have a larger chemical versatility because of the organic substitutions and are biologically 
inert, biocompatible, and are chemically and mechanically resistant. Therefore, they present 
an interesting alternative to the already established and more common organic delivery 
systems such as liposomes, micelles, dendrimers, and polymeric particles. It also produces 
electrostatic repulsion between the negative charges of the deprotonated silanol groups which 
stabilizes the particle but unfortunately also causes particle aggregation and precipitation 
when exposed to biological fluids such as human serum which is a high ionic strength media. 
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Furthermore, complement can be activated by opsonization via the adsorption of proteins on 
the surface by exploiting both hydrogen bonding and electrostatic interactions.87 Even 
surface silanol groups are directly involved in hemolysis and in alveolar epithelial cell 
toxicity. Therefore, surface passivation is a necessity in order to avoid capture of the MPS 
using such strategies as coating particles with hydrophilic and neutral species like 
poly(ethylene) glycol (PEG).   
 
 
 
 
Figure 10: Popular methods to synthesize silica nanoparticles.  
Taken from: Liberman, A., Mendez, N., Trogler, W. C. & Kummel, A. C. Synthesis and surface 
functionalization of silica nanoparticles for nanomedicine. Surf. Sci. Rep. 69, 132–158 (2014). 
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3.3 Gold nanoparticles 
Gold nanoparticles (Au-NPs) or colloidal gold have been of great interest throughout history 
from being used as a coloring pigment back in the middle ages to today in the biomedical 
field, due to their vast and unique optical and physical features. Au-NPs are inert, have 
extreme resistance to oxidation, have a large surface-to-volume ratio, high X-ray absorption 
coefficient, excellent biocompatibility, low toxicity, and they are easily able to be 
functionalized by thiol compounds. Current applications of gold nanoparticles include 
organic photovoltaics, sensory probes, therapeutic agents, drug delivery, electronic 
conductors, and catalysis. Gold nanoparticles can be directly conjugated with drug molecules 
via ionic or covalent bonding, or by physical absorption thus changing its surface chemistry. 
Optical and electronic properties can be altered by changing the size, shape, or aggregation 
state.90 Ranging from 1-100 nm, gold nanoparticles in solution exhibit size-dependent range 
of colors with red indicative of smaller particles and blue/purple for larger or aggregated 
particles. Size dependent changes to the physical and chemical properties of the nanoparticle 
can possibly occur due to the number of surface atoms. For example, take an iron 1cm cube 
where 10-5 % are surface atoms, but taking just 10 nm of that cube results in 10% surface 
atoms while 1 nm results in every atom being a surface atom. Even slight changes in size 
from a couple of nanometers can trigger size dependent alterations in the particle’s 
properties. 91 
 
Gold nanoparticle are particularly unique due to their optical properties which are used 
extensively in diagnostics. Gold nanoparticles will undergo a change in their 
physicochemical properties upon molecular binding to itself. Such changes include surface 
plasmon resonance, conductivity, and redox behavior, which all lead to detectable signals. 
Surface plasmon resonance (SPR) is the phenomena when plasmons, oscillations of the free 
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electrons, occurs in response to oscillating electromagnetic field of the incident light (Figure 
11).92 This causes a coordinated dipole oscillation of electron charge formed around the 
particle’s ionic lattice in resonance with the frequency of visible light. The SPR is when the 
amplitude of such oscillations at a specific frequency reaches maximum.93 Plasmon 
oscillation in small nanoparticles undergo non-propagating excitations called localized 
surface plasmons (LSPs) distributed over the whole particle volume but SPR is absent in 
particles less than 2 nm or for bulk material. When the photons are confined to a small 
particle, radiative and nonradiative properties of the nanoparticles are enhanced by the SPR 
thus making Au-NPs highly useful for biological and medical applications. SPR reflectivity 
measurements can be used to detect molecular adsorption, such as polymers, DNA, or 
proteins via detecting the changes in the surface plasmon waves due to the alteration of the 
local index of refraction by the absorbed molecules. SPR can be modified based on the size 
and shape of the particle thus allowing for greater tuning and control. For example, <10 nm 
Au-NPs conjugated with short-chain thiolated ligands causes the native SPR to be dampened. 
Furthermore, nanospheres with the size of 2–50 nm show only one plasmon band at ~520 nm, 
while for cylindrical Au-NPs, two SPR bands appear.94 Furthermore, quenching of 
fluorophores occurs by either the surface plasmon band overlapping with the emission 
spectrum of excited fluorophores known as fluorescence resonance energy transfer (FRET) or 
by the photoinduced electron transfer (PET) where Au-NPs act as electron acceptors.  
 
As synthetic protocols became more robust and controllable, various shapes of Au-NPs can 
be achieved including nanorods, nanoshells, nanocages, and nanospheres.95 Nanospheres of 
gold ranging between 5 to 100 nm are produced in various ways, some of the most common 
being the reduction of chloroauric acid HAuCl4 and sodium citrate into boiling water.
96 
Reducing particle size leads to different physical and optical properties due to the effect on 
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the energy level spacing as the system becomes more confined. The bandgap energy 
increases with size reductions and the onset of the bandgap transition is shifted to higher 
frequencies.91 A red-shifted SPR is seen for aggregated particles due to interparticle plasmon 
coupling and the broadening of the surface plasmon band.  
 
 
Because of the versatility and physicochemical properties of gold nanoparticles, new 
opportunities for therapeutic treatments have been of increasing focus. At first, when the 
nanoparticles are introduced into circulatory system, the plasma proteins are the first to form 
the corona dominated by albumin, the most abundant protein in serum (55%) along with 
apolipoproteins, fibrinogen, and immunoglobulins. However, similar to silica nanoparticles, 
when exposed to plasma or serum, unwanted side effects occur from protein interactions with 
the particle’s corona triggering immunogenicity, cytotoxicity, platelet aggregation, or altering 
blood coagulation pathways.97 Gold particles themselves can trigger coagulation as the van 
der Waals forces between two metal nanoparticles leads towards coagulation or they can 
trigger coagulation via interactions with plasma proteins based on their surface charge where 
anionic surfaces initiate coagulation due to the fact that the intrinsic coagulation pathway is 
activated by anionic physiological surfaces, extracellular matrix, or aggregated platelets.  
 
Figure 11: Schematic representation of Surface plasmon resonance (SPR). This phenomena occurs when plasmons, 
oscillations of the free electrons, occurs in response to oscillating electromagnetic field of the incident light.  
Taken from: Yeh, Y.-C., Creran, B. & Rotello, V. M. Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale 4, 1871–1880 (2012). 
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Nanoparticle modification and surface passivation via alterations of the surface of the gold 
nanoparticle is a necessity in order to avoid triggering coagulation as well as increasing 
positive surface attributes and efficacy using such strategies as direct conjugation with 
antibiotics or other drug molecules via ionic or covalent bonding, or by physical absorption. 
Ionic bonding is weaker than covalent bonding but allows for efficient release of drug 
payloads once it has reached the target zone whereas covalent bonding offers high stability. 
Instead, functional ligands can be utilized to alter the surface charge of the particle by 
exploiting non-covalent binding. Agglomeration can also be avoided depending on the 
synthesis of the modification. Polyelectrolytes such as poly(sodium-4-stryrenesulfonate; 
PSS), poly(diallydimethyl ammonium chloride; PDADMAC), and poly(allylamine 
hydrochloride; PAH) have already been employed for this purpose. Stabilization can occur 
via electrostatic stabilization, where negatively charged ions are attracted to the Au-NPs 
forming a second layer with positive counterions, or by steric stabilization where polymers 
made of long alkyl chains bind to the surface thus physically preventing two particles from 
getting too close to one another.90 However, altering the surface charge, the size, or the 
surface with polymers will ultimately change how the particle interacts with plasma proteins. 
For example, sulphonated chitosan 13 nm and pyrimidine 10 nm Au-NPs inhibited 
coagulation and platelet aggregation whereas 220 nm carboxylated polystyrene NPs show an 
increased thrombogenicity. Therefore, since Au-NPs synthesis greatly affects biodistribution, 
it is crucial to evaluate and modify Au-NPs synthesis to promote favorable in vivo blood 
circulation times and biodistribution of the NP.  
3.4 PEG Coatings 
 
PEG is a linear non-ionic hydrophilic polyether diol which is biocompatible, soluble in 
aqueous and organic media, nontoxic, and has very low immunogenicity and good excretion 
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kinetics. PEGylation is the surface modification and polymer conjunction of a molecule by 
the linking of one or more 5-60 kDa polyethylene glycol (PEG) chains resulting in changes in 
physicochemical properties such as increased size, hydrophilicity, and molecular weight as 
well as changes in surface charge, solubility, stability, and steric hindrance of intermolecular 
interaction (Figure 12). Aggregation of PEG is also prevented by steric stabilization 
following the formation of a sterically hindering cloud, thereby producing nanoparticle 
platforms with increased stability during storage and applications.98 This cloud of PEG 
polymers depends on the molar mass of the PEG polymers, the surface density, and the way 
the PEG is attached such as brush-like or mushroom-like conformations. An increased size 
and molecular weight can influence and decrease renal glomerular filtration favoring a 
hepatobiliary route, as well as the hydrodynamic volume which is dependent on the 
architecture of the polymer. These alterations ultimately leads to an enhanced 
pharmacokinetic and immunological profiles, extended circulation time, increases their 
bioavailability, modifies their biodistribution profiles, and altered tissue localization and 
cellular uptake.99  
Surface modification of silica is easily achievable using a condensation reaction. 
Alkoxysilanes bind silanol groups on the surface by forming one to three Si–O–Si links 
which can coordinate with two to three water molecules per oxy-ethylene (-OCH2CH3) unit. 
This results in a loss of the overall positive protein charge, loss of the protein glycosilic 
functions involved in the galactose-receptor-mediated uptake, loss of protein pairing with 
haptoglobin, and a high hydrodynamic volume. These PEGylated alterations contribute to 
prolonging the body’s exposure to proteins. PEGylated ORMOSIL can be achieved by the 
polymerization of lipophylic organosilane derivatives in the hydrophobic core of detergent 
micelles.100 On one end of the PEG polymer, functional groups can bind the N-terminal 
amine, lysine, cysteine, and other amino acids.101 For protein modification, the thiol group of 
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cysteine is an excellent anchoring site due to the infrequency in amino acid sequence and that 
disulfide bonds require two cysteine residues allowing for only one, if present, to be used for 
selective PEGylation. Stealth properties are provided by a reduction in their zeta potential as 
the thiol groups are masked. However, the most widely used synthesis method is PEGylation 
of the α- amino of the N terminus where differences in pKa between the 𝜀-amino group of 
Lys and the α-amino of the N terminus are exploited to site selectively bind PEG molecules 
to the N terminus.99 Amino group modification was among the first proposed methods due to 
the fact that amine groups are the most represented groups in proteins. Conjugation strategies 
include alkylation (forming a secondary amine group) or acylation which either maintains the 
positive charge of the starting amino group or loses its charge, respectively.102  
 
Although PEG is the gold standard for polymer stealthing, there are many drawbacks that 
limits the usefulness of PEGylation. Firstly, complement can be activated by PEG, inducing 
specific and non-specific interactions with blood proteins leading to opsonization. This can 
ultimately lead to hypersensitivity reactions (HSR) which can lead to anaphylactic shock. 
Secondly, due to its polyether and hydrophilic behavior, PEG is prone to oxidative 
degradation resulting in the molecular weight deterioration and cleavage of the polymer 
chain.103 This process leads to a loss in coating functionality thus reducing its hydrophilicity, 
charge masking ability, and resistance to non-specific adsorption. PEG is also known to 
autocatalytically degrade in bulk (solid state), surface-bound state, and in dilute solutions.104 
Thirdly, antibodies against PEG produced by splenic B cells can develop after the first 
administration of PEGylated liposomes indicating potential immunogenic and antigenic 
effects. Fourthly, PEG can also bioaccumulate and form vacuoles in some organs. PEG is 
non-biodegradable, and anti-PEG antibodies have been reported indicating that PEG has the 
potential to be immunogenic and antigenic.105 Furthermore, in order to provide effective 
 53 
counter phagocytosis, PEG chains typically need to have a molecular weight in excess of 
2,000 Da, substantially increasing the overall hydrodynamic diameter.20 Finally, PEG is 
synthesized via an exothermic, living anionic ring-opening polymerization of ethylene oxide, 
which is highly toxic, explosive, and gaseous at room temperature.106 Therefore, in 
combination with the limitations of PEG as a stealthing agent, alternative polymers have been 
proposed which are more biocompatible, can escape the MPS, and are easier to synthesize.  
 
 
3.5 Poly(2-oxazoline) polymers  
Alternative polymers for PEG have been created with the hope of achieving even better 
control over the properties of modified drugs and drug carriers. The qualities of a polymer 
must be soluble, hydrophilic, have a highly flexible main chain, and high biocompatibility. 
Poly(2-oxazoline) (POZ) has been proposed as an alternative polymer for PEG given that 
they are easier to synthesize and can incorporate varying monomers to tailor the nanoparticle 
for specific applications.  
Figure 12: PEG polymer-protein conjugate. The protein is shielded by PEG polymer chains preventing binding 
and degradation by steric hindrance as well as increasing solubility via PEG hydrophilicity. Furthermore, the 
particle’s size decreases renal glomerular filtration of the PEGylated protein.  
Taken from: Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451–1458 (2005). 
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Oxazolines are hydrophilic, tertiary polyamides with the amide group in the side chain, as 
well as being structural isomers of polypeptides. 107 Three isomers of oxazolines exist 
depending on the location of the double bond, 2-, 3-, and 4-oxazoline, where 2-oxazoline is 
by far the most studied. They can be further substituted on the 2, 4, or 5 position of the 2-
oxazoline ring, however substitution on the 4th or 5th position is more difficult to polymerize 
due to steric crowding. POZs have structural similarities to PEG and polypeptides due to 
having (C-C-N) backbone repeat units and amide side chains. POZ has higher chemical 
stability due its N-vicinal C–H bond causing a lower polarization compared to PEG which 
has an O-vicinal C–H bond. Although PEGylated polymers are highly water soluble, 
amphiphilic, very flexible and hydrated in water, non-toxic, and may be produced with low 
polydispersity, POZ can be further tuned in size and structure using a living cationic ring-
opening polymerization (CROP) as well as facile surface functionalization and fluorescent 
labeling via click chemistry thus overcoming PEGs low drug loading capacity.28 CROP 
utilizes a thermodynamically favorable isomerization of the imino ether group to the amide 
which results in a stable polyamide, due to ring strain, and narrow average molecular weight 
distributions.108 POZ is highly biocompatible and behaves as an entropic spring in a crowded 
environment giving rise to its antifouling and stealth effect to particles.  
 
Several monomers can be synthesized namely poly(2-methyl-2-oxazoline) (PMOXA) and 
poly(2-ethyl-2-oxazoline) (PEtOXA). In a one pot synthesis, sequential monomers may be 
added giving rise to a well-defined block copolymer, allowing for complex multifunctional 
architectures together with tunable physicochemical properties.109 PEtOXA is slightly more 
lipophilic and has a smaller intra-chain flexibility than PMOXA and PEG, and is also 
significantly less viscous than PEG. PEtOXA is also stable against hydrolysis in acidic 
conditions and/or in the presence of enzymes but most importantly, hydrolysis does not lead 
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to molecular weight deterioration or cleavage of the polymer chain.110 Furthermore, since the 
2-ethyl-2-oxazoline repeating unit is significantly spatially larger than ethylene glycol giving 
rise to steric hindrance, PEtOXA will bind less to the nanoparticle surface compared to PEG, 
ultimately giving rise to a smaller coated particle.111    
 
4. Interspecies comparison 
Nanomedicine, like most scientific fields, employ the mouse model, Mus musculus, as an 
experimental tool to probe human biology and disease whether it be in vitro or in vivo. The 
mouse has many features which make it an attractive scientific model such as their 
phylogenetic relatedness, physiological similarity, and genetic homologies to humans as well 
as their ease of breeding and producing many inbred strains with fast generation turnover. 
However, in many cases, experimental interventions in mice are responded to quite 
differently than in humans thus contributing to the high failure rate of drug development 
where the majority of drugs never reach the marketplace following clinical trials. Therefore, 
it is imperative to understand the attributes which contribute to this phenomena so as to 
increase therapeutic applications of nanoparticles.  
 
There are many similarities between humans and different species concerning the immune 
system. Pigs (Sus scrofa) share anatomical and physiologic characteristics with humans. 
Studies done to compare the orthology preservation of familial gene expansion deriving from 
family member expansion analysis revealed that in total, humans and pigs share 42 genes that 
are not found in mice; mice and humans share 14 genes that are not found in pigs; and mice 
and pigs share 7 genes that are not found in humans.112 Human and porcine macrophages 
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produce pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-8, and IL-12 via the 
production of indoleamine 2,3-dioxygenase (IDO) upon LPS activation instead of NO 
synthase as with murine macrophage cells. Mouse and human complement proteins C2, C3, 
C4, and factor B have a very high degree of similarity113 9 out of 12 Toll-like receptors in 
mice and 9 out of 10 human TLRs are conserved between species.30 Roughly 80% for TLR1, 
3, and 10; 85% for TLR7; and 73% for TLR8 are homologous between porcine and humans 
as well as sharing typical functional TLR domains. Porcine NOD 1 and 2 have an 83.8% and 
81.6% amino acid sequence conserved with human NOD2, respectively.114 Mouse C3 has 
79% identity to human C3 at the nucleotide level and 77% identity at the amino acid level.115  
 
Although there are quite a number of similarities between mice and humans, there are quite a 
number of limiting factors which make the mouse model not always appropriate for 
nanomedicine. Firstly, the most obvious difference between the two species is size where 
mice are about 2,500 times smaller than humans. Size is correlated with metabolic rates and 
the variations between mice and humans can manifest in anatomic, physiologic, and 
biochemical differences. Higher metabolic rates in small mammals can be attributed to 
thermoregulation and heat-loss where not only is capillary and mitochondrial density 
increased in tissues, but metabolically active tissues, such as liver and kidney are found in 
higher amounts. Mouse cells also have a higher content of fatty acid composition of their 
membrane phospholipids such as readily oxidizable polyunsaturated fatty acid 
docosahexaenoic (DHA), an omega-3 (n-3) with 22 carbons and 6 double bonds, thus also 
contributing to higher rates of oxidative damage.116 DHA is highly active and flexible due to 
the low potential barriers of rotation around the carbon-carbon single bonds between the 
double bonds, despite no rotation around the cis double bonds.117  
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Secondly, serum and plasma protein compositions differ between species where human (HS), 
mouse (MS), pig (PS), and fetal calf serum (FCS) are the most commonly utilized 
experimentally. The protein hard-corona formed in FCS is uniquely different from that 
formed in human plasma (HP) where coagulation and complement components, 
immunoglobulins (IgG), and lipoproteins are defective in FCS compared to HP.118  
Albumin, which is the most abundant protein in blood, is the predominant component of the 
corona. Human serum albumin (HSA) and bovine serum albumin (BSA) differ in amino acid 
composition and charge, BSA: -17 and HSA: -15, which can affect protein absorption based 
on conformational changes. The interspecies homology between BSA and HSA is largely 
restricted to the Fab portion of bovine IgG, however bovine IgGs are unable to bind murine 
Fc-receptors which do recognize human IgG.119 Complement and coagulation factor proteins 
are species specific with many proteins only present in human serum and not in bovine. 
Apolipoprotein B-100 in not present in FCS which is responsible for binding and 
internalization of low-density lipoproteins (LDL) and Alpha 1-antitrypsin inhibitor. 
Complement component C3c, C4a, and C4b which are all involved in complement activation 
as well as coagulation factor II (thrombin) which cleaves fibrinogen to fibrin.120 
 
Thirdly, different composition and properties of cellular components results in different 
strategies in immune responses. In C57BL/6 mice, there is a 10–25% neutrophils, 75–90% 
lymphocytes, and about 2% monocytes and for CD-1 mice there is 15–20% neutrophils and 
50–70% lymphocytes whereas for humans have 50–70% neutrophils and 20–40% 
lymphocytes. Furthermore, the size and phagocytic capability of the cells are distinct where 
human pulmonary alveolar macrophages (PAMs) are larger and are able to sequester foreign 
particles with regard to size as compared to mice.121 The expression of inducible NO-
synthase and arginase is enhanced in activated murine macrophages which is barely found in 
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human macrophages. Mast cells in mice release serotonin whereas human mast cells release 
histamine. Complement receptor 1 (CR1, CD35), which bind C3 and C4, are present on 
erythrocytes, macrophages, neutrophils, B cells, follicular dendritic cells, and some T cells 
whereas complement receptor 2 (CR2, CD21), regulates B cells activation as well as binding 
CD59, is present on B cells, follicular dendritic cells, and some T cells.122 Human CD59 
highly inhibited lysis by human and pig complement with an AA conservation level of 48% 
whereas with mouse complement, it was only moderately effective and shared only 34%. 
Furthermore, human CD59 inhibits human complement to a higher degree than pig 
complement and pig CD59 inhibits pig complement to a higher degree than human 
complement.123 Human platelets lack CR1 whereas human blood monocytes express CR1.124 
However, mouse CR1 is not present on the membrane of erythrocytes, macrophages, 
neutrophils, B cells, follicular dendritic cells, and some T cells therefore indicating an 
alternative to CR1 for an immune adherence receptor which is a single receptor able to bind 
C3 but seen separately by human CR1 and CR2.113 Furthermore, mouse Kupffer cells do not 
express CR3. Natural killer cells (NK) are responsible for lytic activity and production of 
cytokines such as IFN-γ. The CD3 T-cell receptor and CD4, CD5, and CD6 T-cell co-
receptors are lacking in porcine NK cells but they do express CD2, CD8α, CD16, CD45RC, 
and perforin.114  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Chapter 2: Results and Discussion 
Section 1: Silica  
Physiochemical characterization of SiO2-NPs  
With the express purpose of gaining a more in-depth and thorough insight into the role played 
by polymers who coat vinyl-triethoxysilane-derived organically modified silica nanoparticles 
(ORMOSIL) influencing serum protein corona and cell interactions, we first prepared coated 
and non-coated amorphous silica materials (ORMOSIL) particles. The following protocols 
are also outlined in the Methods section for additional information. Using the Stober 
protocol, in collaboration with Professor Fabrizio Mancin of the Department of Chemistry at 
the University of Padova, the particles were labeled with (10 mM in DMSO) Rhodamine B 
triethoxysilane with loadings in the 0.1-0.3% w/w range (Figure 13). All NP types presented 
comparable UV−visible spectra (Figure 52 in the appendix section) and NMR data of both 
PEG and PEMOXA- coated NPs showed all signals belonging to nanoparticle-grafted 
species, where a diffusion filter removed free molecules (Figure 53 in the appendix section). 
Transmission electron microscopy analysis (TEM) and dynamic light scattering analysis 
(DLS) of uncoated ORMOSIL particles showed a diameter of 115 nm with the most negative 
zeta potential of all the SiO2-NPs, -6. Not only did all the coated particles retain similar 
diameters, 100 nm, but also similar ζ-potentials, -4, and number of polymer chains (n), 44. 
This indicated although the addition of coatings changes the surface of the uncoated NPs, it 
does not change other physiochemical properties such as charge, size, grafting-density and so 
on. Thermogravimetric analysis (TGA) revealed another major difference between the coated 
particles which are their polymer footprints. Polymer footprints divulges the average space 
occupied by one polymer chain on the NPs’ surface. Using the data obtained by TGA, the 
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footprints ie the grafting densities, of PEG coated ORMOSIL was calculated to be ~ 3 nm2, 
whereas PMOXA coated ORMOSIL has a footprint of ~ 2.4 nm2,  and PEtOXA coated 
ORMOSIL has a footprint of ~ 4.6 nm2. Therefore, particles of the same diameter but having 
different footprints will have a different amount of polymer chains which are able to occupy 
the surface of the nanoparticle. PEtOXA (2-ethyl-2-oxazoline) repeating unit is significantly 
spatially larger than PEG (ethylene glycol), hence a smaller number of polymer chains will 
reach the particle’s surface and be able to bind compared to PEG. This is an important 
characteristic of a nanoparticle given the intricate balance at minimizing the free energy of 
the system by balancing low area per molecule which induces steric clashes among ligand 
chains and too high an area per molecule which exposes the nanoparticle to water. 
Furthermore, this optimal coverage must also impart colloidal stability thus preventing 
particle aggregation which is vital to biomedical applications of nanoparticles.  
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Nanoparticle 
# 
polymer 
chains 
(n) 
MW 
(Da) 
Diameter 
(nm) 
ζ-potential 
(mV) 
Footprint 
(nm2) 
m 
ORMOSIL - - 115 ± 23 -6 - - 
PEG-ORMOSIL 44 2000 100 ± 10 -4 3.0  10,000 
PMOXA-ORMOSIL 44 3800 100 ± 6 -4 2.4 13,000 
PEtOXA-ORMOSIL 44 - 100  -4 4.6 - 
Table 2: 
Physiochemical 
properties of 
ORMOSIL 
nanoparticles 
either Naked or 
coated by PEG, 
PMOXA, or 
PEtOXA.Nanoparticle 
n 
MW 
(Da) 
Diameter 
(nm) 
ζ-potential 
(mV) 
Footprint 
(nm2) 
m 
ORMOSIL - - 115 -6 - - 
Table 1: Physiochemical properties of ORMOSIL nanoparticles either 
uncoated NPs or coated by PEG, PMOXA, or PEtOXA.  
 
B 
 
C 
 
A 
 
D 
Figure 13: TEM analysis of silica ORMOSIL nanoparticles coated with either (A) Uncoated (B) PEG (C) PMOXA (D) 
PEtOXA. TEM analysis, performed using FeiTecnai 12, 100 keV, yielded 100 nm diameter particles in good agreement 
with the DLS size (samples prepared by spreading a droplet of the nanoparticles diluted in PBS buffer (~ 1 mg/mL) 
onto standard carbon-coated copper grids (200 mesh). Image J software was used for dimensional analysis). 
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Characterization of SiO2-NPs’ capture by human monocytes and macrophages in serum 
from varying species 
 
In order to probe the impact of serum from multiple species on coated nanoparticle cellular 
association with phagocytes, flow cytometry was performed with primary human monocytes 
isolated from healthy blood donors and macrophages differentiated from monocytes. Figure 
14A demonstrates the effect on cellular uptake by human monocytes when 70% (v/v) human 
serum (HS), pig serum (PS) and mouse serum (MS), is incubated with 800 g/mL uncoated, 
PEGylated, PMOXA-coated, and PEtOXA-coated NPs first in the absence of cells for 20 min 
at 37 °C and then incubated with cells after a 10-fold dilution in protein-free culture medium 
for 3 hours at 37 °C. Uncoated and PEGylated particles had a reduced phagocytic effect, 
whereas PMOXA-coated NPs had the highest cellular capture by human monocytes with 77 
times more cellular association than uncoated and 49 times more than PEGylated NPs. 
PEtOXA-coated NPs, while still inducing phagocytosis by 22 times and 15 times over 
uncoated and PEGylated, respectively, have a reduced cellular association by 70% compared 
with PMOXA-coated NPs. In mouse serum, all nanoparticles display a universal lack of 
cellular association with human monocytes. This may indicate either a stealth effect by the 
coating or a molecular mismatching between non-orthologous cells and serum. Interestingly, 
the same trend is seen in pig serum as with human serum where the coated particles are 
captured more than PEGylated or uncoated particles. Similarly to HS, PEGylated NPs were 
captured 41% more than uncoated NPs in PS. Furthermore, in PS PEtOXA-coated NPs, while 
still inducing phagocytosis by 7 times and 4 times over uncoated and PEGylated NPs, 
respectively, had a reduced cellular association by 80% compared with PMOXA-coated NPs.  
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In human macrophages with human serum (Figure 14B), the trends seen with monocytes is 
only in part reproduced. In fact, the macrophages’ capture of PMOXA-coated NPs was 17 
times more intense than that of  PEG-coated NPs, which was captured 1.3 times more than 
uncoated NPs. However, the most interesting effect was seen by PEtOXA-coated NPs, which 
induced cellular association of NPs with macrophages 28% more compared to PMOXA-
coated NPs. This observation was not expected given the fact that uncoated, PEGylated, and 
PMOXA-coated NPs associate with monocytes and macrophages in a similar fashion. 
Similarly, in mouse serum there was an increase capture of PEtOXA-coated NPs two times 
over PMOXA-coated NPs, which has a similar capture to uncoated and PEGylated NPs. 
Another interesting observation concerns pig serum where PMOXA-coated NPs cellular 
association is highly reduced, just 2.4 times more than PEG which is roughly 14 times less 
than with human monocytes. Furthermore, PEtOXA- coated NPs capture in PS is 58% more 
than PMOXA-coated NPs which is 30% more than in HS.  
 
These results taken together suggest circulating monocytes and human macrophages showed 
preferential tendency to capture PMOXA-coated and PEtOXA-coated NPs, compared with 
uncoated and PEGylated NPs.  
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Figure 14: The effect of serum proteins from multiple species on SiO2-NPs cellular association. Following a 20 min incubation 
at 37 °C in 70% serum, 80 μg/ml SiO2-NPs were incubated for 3 hours at 37 °C with human (A) monocytes and (B) 
macrophages for 3 hours. The cells were subsequently analyzed by flow cytofluorimetry to measure nanoparticle- 
associated fluorescence. Data are mean ± standard error of the mean (n = 3). Values above the bars indicate cell association 
expressed as the mean Fluorescence Intensity 
A 
B 
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Moreover, these studies demonstrate the differences of nanoparticle uptake by human 
phagocytic cells in the presence of serum from varying species. In contrast to our 
unpublished previous studies performed with PEGylated NPs in FCS (Figure 15), this 
polymer did not provide stealth properties in HS but it also didn’t increase the uptake of the 
nanoparticles either.  
 
PEtOXA-coated particles have different behaviors in macrophages versus monocytes yet the 
trend is the same in both human and pig serum indicating the cell interacts independently of 
protein differences in species’ serum composition. The lack of cell interaction in both human 
monocytes and macrophages with MS could be attributed to different cellular receptors’ 
characteristics, which could lead to molecular mismatching. In this case, although MS might 
act the same as HS, opsonic receptors on human cells might be unable to interact with 
proteins from MS. Furthermore, the fact that particles behave similarly in PS as they do in 
HS indicates that pig serum opsonic proteins likely interact similarly with human cell 
receptors as with equivalent human serum opsonins. Additionally, data may also suggest that 
the protein composition of the pig serum-derived corona is similar to that of human serum-
derived. This is fascinating due to the possible experimental implications for testing particles 
as drug delivery carriers in preclinical models. Data suggests pigs and pig serum better 
predict the behavior of NPs in the human context, therefore being a more effective alternative 
model for in vitro testing, compared to FCS or MS which produced trends not reproducible in 
humans.  
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Characterization of the cellular affinity and uptake of SiO2-NPs in orthologous species 
and cells. 
 
In order to investigate why human phagocytes do not favor coated particles in the presence of 
mouse serum unlike in human serum and whether that is due to a molecular mismatch 
between non-orthologous serum and cells, we decided to probe the nanoparticles in mouse 
serum with orthologous mouse macrophage RAW cell line as well as bone marrow derived 
mouse macrophages (BMM). Figure 16 demonstrates the effect of serum proteins from 
multiple species on SiO2-NPs cellular association in RAW and BMM cells. Following a 20 
min incubation at 37 °C in 70% serum (v/v) and a 10 fold dilution in culture medium, 80 
μg/mL SiO2-NPs were incubated for 3 hours at 37 °C with (A) RAW 264.7 mouse 
macrophage cell line with MS and (B) primary mouse macrophages with MS for 3 hours. The 
cells were subsequently analyzed by flow cytofluorimetry to measure nanoparticle- 
Figure 15: The effect of serum proteins from fetal calf serum (FCS) on PEG and PMOXA 
SiO2-NPs cellular association. 
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associated fluorescence. In addition, we also probed the possible complement involvement in 
particle capture by mouse cells with human and pig serum.  
 
The data showed uncoated NPs were captured more by RAW and BMM cells in MS 
compared to PEGylated and PMOXA-coated particles. This supports the idea the lack of 
capture seen by MS in human cells is due to molecular mismatching between non-
orthologous serum and cells. In addition, all NPs in HS and PS showed little cellular capture 
in mouse cells as compared to capture by human cells, further supporting the idea that NP 
capture is dependent on the serum protein and cell interactions which are species specific.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 16: The effect of serum proteins from multiple species on SiO2-NPs cellular association with orthologous macrophages. Following a 20 
min incubation at 37 °C in 70% serum, 80 μg/ml SiO2-NPs were incubated for 3 hours at 37 °C with human (A) RAW 264.7 mouse macrophage 
cell line with MS and (B) primary mouse macrophages with MS for 3 hours. The cells were subsequently analyzed by flow cytofluorimetry to 
measure nanoparticle- associated fluorescence. Data are mean ± standard error of the mean (n = 3). Values above the bars indicate cell 
association expressed as the mean Fluorescence Intensity.  
A B 
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Localization of SiO2-NPs in primary human macrophages 
 
Localization of SiO2-NPs in primary human macrophage cells was visualized using 
fluorescence microscopy after 3 hour incubation. Cells were incubated with 75 nM 
Lysotracker DND-26 (Invitrogen, CA, USA), a green fluorescent dye that stains acidic 
compartments in live cells (green, λexc 504 nm and λem 511 nm). Co-localization of 
nanoparticles with Lysotracker and rhodamine indicates endocytosis by cells and 
accumulation in acidic endolysosomal/phagosomal vesicles via cell internalization. Cells 
were incubated for 3 hours at 37 °C in HS, PS, and MS, in the presence of nanoparticles 
diluted in culture medium, and then inspected. In HS (Figure 17A), the uncoated particles 
showed little cell internalization indicated by the stark decrease in fluorescent cytoplasmic 
signal as well as little co-localization evidence of reduced accumulation in acidic 
endolysosomal/phagosomal vesicles. However, PMOXA-coated particles demonstrated an 
increased cell internalization as compared to uncoated, clearly seen by the striking increase in 
fluorescent signal as well as high co-localization. Furthermore, PEtOXA-coated NPs 
demonstrated an even greater cell internalization and co-localization. Similarly, in PS 
conditions, Figure 17B, uncoated nanoparticles showed little cell internalization and co-
localization, similar to the HS conditions, whereas PMOXA-coated and PEtOXA-coated NPs 
showed an equally similar increase in fluorescent and Lysotracker signals. The trends 
between coated and non-coated particles are consistent for both human and pig serum where 
coated particles were captured by phagocytic cells and uncoated particles were stealth.  
At variance, in MS (Figure 17C), uncoated particles showed the greatest cell internalization 
and co-localization, whereas the coated particles showed decreased cell internalization, which 
 69 
is in contrast to NP capture in human and pig serum. Thus, coated particles are in fact not 
stealth but were recognized by the immune system in MS.  
These results further support previous flow cytometry data where PMOXA-coated and 
PEtOXA-coated NPs induce cellular phagocytosis in HS and PS whereas uncoated NPs 
increase cellular capture in MS.  
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PEtOXA 
SiO2-NPs LysoTracker 
Human Serum 
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A 
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PEtOXA 
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C 
Figure 17: Effect of human macrophage capture on the transport of SiO2-NPs in HS, PS, MS to acidic endolysosomes. Confocal images of human 
macrophages treated at 37 °C for 3 hr with 80 μg/ml SiO2-NPs in (A) HS (B) PS (C) MS in RPMI medium (indicated to the left of the boxes), stained with 
LysoTracker green. Merge fields indicate SiO2-NPs/acidic compartments co-localization 
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Next, we decided to look at whether we could distinguish between the classical and 
alternative complement pathways in order to discern a possible mechanism by which the 
coated and non-coated particles use to activate the immune response. Due to the fact that the 
classical complement cascade is calcium dependent and the alternative complement cascade 
is magnesium dependent, we used 10 mM EDTA and 10 mM EGTA supplemented with 2.5 
mM magnesium in order to probe this effect. EGTA has a lower affinity for magnesium than 
EDTA, making it more selective for calcium ions where EDTA chelates both calcium and 
magnesium. When supplemented with additional magnesium, EGTA can selectively inhibit 
the classical pathway, allowing for the alternative pathway to remain active, whereas EDTA 
inhibits both pathways. In addition, in order to determine which situation is responsible for 
the low cellular capture by coated particles, we decided to probe the nanoparticles in mouse 
serum with orthologous mouse macrophage RAW cell line. As we have already demonstrated 
particles behave similarly in pig serum as they do in human serum with human cells, we 
wanted to further probe complement involvement by deactivating the complement system via 
calcium chelation with human cells and pig serum, and mouse serum and mouse cells (Figure 
18).  
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In congruence with previous confocal images with human macrophages, when uncoated, 
PEGylated, and PMOXA-coated particles are incubated with mouse serum and incubated 
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Figure 18: The effect of serum proteins from multiple species on SiO2-NPs cellular association with orthologous 
macrophages with calcium chelating agents. Following a 20 min incubation at 37 °C in 70% serum, 80 μg/ml SiO2-
NPs were incubated for 3 hours at 37 °C with human (A) RAW 264.7 mouse macrophage cell line with MS and (B) 
human macrophages with PS for 3 hours. The cells were subsequently analyzed by flow cytofluorimetry to 
measure nanoparticle- associated fluorescence. Data are mean ± standard error of the mean (n = 3). Values 
above the bars indicate cell association expressed as the mean Fluorescence Intensity.  
B 
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with RAW mouse macrophage cell line, uncoated NPs had a higher uptake compared to the 
coated particles. With the chelation of calcium, uncoated NPs were captured 6 times less 
compared to normal calcium supplemented serum. PEGylated and PMOXA-coated NPs 
showed no change in nanoparticle uptake in EGTA conditions, which when taken together 
with previous findings and the fact that the particles behaved as seen in FCS, indicate that the 
coated particles are stealth, there is a lack of cellular recognition and internalization in 
orthologous non-human cells and serum, and this phenomena is calcium dependent. 
 
We wanted to demonstrate this effect of calcium chelation on the transport of SiO2-NPs in PS 
and MS to acidic endolysosomes in human macrophages. Figure 19 demonstrates the 
comparison between non-coated particles, PEGylated, and PEtOXA-coated NPs in mouse 
and pig serum with human macrophage cells. We used PEtOXA-coated NPs due to the fact 
that it had the highest cytoplasmic signal and co-localization compared to the other PMOXA-
coated particles. Furthermore, we wanted to compare PEtOXA-coated NPs to an already 
established polymer coating for stealthing particles, PEG. Finally, because interspecies 
comparison is of great interest to us, we wanted to compare pig serum (PS) and mouse serum 
(MS) in order to compare the effect of cell internalization and to probe the efficacy of coated 
nanoparticles’ surface. Non-coated particles and PEtOXA-coated particles incubated with PS 
(Figure 19A) supported previous finding in Figure 17B where uncoated NPs had a low 
cytoplasmic signal and co-localization whereas PEtOXA-coated NPs had high cytoplasmic 
signal and co-localization. In addition, PEG, which has been shown to be captured by 
macrophages previously in this lab, was seen to induce phagocytosis, however, less than that 
of PEtOXA-coated NPs. The three particles were analyzed in PS supplemented with 10mM 
EGTA and 2.5mM Mg2+ (Figure 19B). Images indicate PEtOXA had a reduced cell 
internalization given the reduced cytoplasmic signal but PEGylated NPs in fact had an 
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increase in fluorescence and co-localization. Furthermore, when comparing MS, (Figure 19C) 
images indicate a reverse trend as seen with PS and even HS. Uncoated particles had an 
increase fluorescence comparable to that in the PEtOXA-coated NPs and PS conditions, and 
both PEGylated and PEtOXA-coated particles evaded phagocytosis by human macrophages. 
Furthermore, similar to PS, when 10 mM EGTA and 2.5 mM Mg2+ (Figure 19D) were 
supplemented to MS, there was a slight decrease in signal in the uncoated NPs conditions, 
although there was no remarkable reduced signal either with PEGylated or PEtOXA-coated 
NPs. 
These results further indicate that PEtOXA-coated particles induce cellular capture by human 
macrophages in PS and this trend is calcium dependent. Furthermore, cellular capture by 
mouse cells in MS is increased by uncoated particles and is also calcium dependent. These 
observations may suggest a likely role for complement activation in NP recognition by 
human phagocytic cells with pig serum, as well as mouse phagocytic cells and mouse serum.  
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Characterization of the SiO2-NPs corona composition by gel electrophoresis and LC 
MS/MS.  
Given the observed difference between the four ORMOSIL nanoparticles in affecting SiO2-
NPs’ cellular uptake as well as differences between serum species, it is reasonable to 
conclude given past studies118,125 the difference lies in the protein corona composition 
Figure 19: Effect of calcium chelation on the transport of SiO2-NPs in PS and MS to acidic endolysosomes in human 
macrophages. Confocal images of human macrophages treated at 37 °C for 3 hr with 80 μg/ml SiO2-NPs in (A) PS (B) 
PS+EGTA (C) MS (D) MS +EGTA in RPMI medium (indicated to the left of the boxes), stained with LysoTracker green. Merge 
fields indicate SiO2-NPs/acidic compartments co-localization. 
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between particles, altering the ability of phagocytes to interact with them. Therefore, we 
analyzed the protein corona formed on uncoated, PEGylated, PMOXA-coated, and PEtOXA-
coated nanoparticles incubated for 20 min at 37 °C in 70% (v/v) human, mouse, and pig 
serum in order to elucidate the protein differences. Following NP recovery and thorough 
ultracentrifugation washings, gel electrophoresis under non-reducing conditions was 
performed, where the proteins were revealed by silver nitrate staining and further analyzed by 
densitometry. We first began to characterize the protein corona in 70% (v/v) human serum, 
where the major electrophoretic bands with uncoated SiO2-NPs are shown in Figure 20 
corresponds to p220, p60, p50, p20, p35, p33, and p8. However, in the mock NP free 
samples, there are bands belonging to certain proteins such as p60, p50, and p20 indicating 
that these proteins could be remnants from serum. The p60 also demonstrates an inverse 
correlation to particle amount, seemingly getting more intense as the uncoated ORMOSIL 
concentration decreases. In human serum, p50 and p60 are at the same intensity in the mock 
as in the samples with NPs (Figure 20A). It is apparent that the major bands of p35 and p33 
proteins vary in intensity directly proportional to the concentration of nanoparticles, 
decreases as the particle amount decreases. In addition, p20 seems to be slightly 
concentration dependent, only slightly reducing its relative intensity even at 25 g/mL versus 
800 g/mL.  
In contrast, the pattern of the main proteins strongly associated with PEGylated NPs (Figure 
20B) varies considerably with much of the predominant bands being concentration 
dependent. Below 100 g/mL, p20, p35, p40, p80, p100, and p120 proteins almost entirely 
disappear yet p80, p65, p60, and p10 are not only more intense at higher concentrations such 
as 800, 400, and 200 g/mL but are located within the context of a more complex set of 
bands than uncoated. This is supported by our previous results from confocal imaging, 
cellular uptake assay with FACS, as well as LC MS/MS. Furthermore, coated PMOXA-
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coated SiO2-NPs (Figure 20C) showed a similar band pattern and intensity with p20, p33, and 
p35 yet with a further increase in band intensity. They are also concentration dependent, 
decidedly visible at higher concentrations, tapering off to a fraction of the amount at low 
particle amounts. Furthermore, p60 and p65 which were very prominent in PEG conditions, 
but was highly reduced with PMOXA even at the highest tested concentrations. The most 
striking difference between PMOXA-coated and PEGylated NPs is the band between 45 kDa 
and 30 kDa.  
 
 
 
 
 
 
Figure 20: SDS-PAGE analysis of the pattern of HS with clot activator and HS without clot activator proteins adsorbed on SiO2-
NPs. (A) Uncoated (B) PEG (C) PMOXA (D) PEtOXA SiO2-NPs were incubated at the indicated concentrations for 20 minutes at 
37 °C in 70% HS, washed and analyzed by SDS-PAGE (12%). Equal sample volumes were loaded onto an SDS-PAGE and stained 
by silver nitrate, where a semi-quantitative estimation of the relative amount of the main protein bands found (arrows), 
labeled by their rough apparent molecular weight in kDa (pxx), were determined by densitometry and represented in 
histograms. On the left-hand side of each image, the values indicate the MW in kDa of the molecular weight standard 
polypeptides used in the gel. 
A 
B 
C D 
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Although the band pattern once again changes for PEtOXA-coated nanoparticles (Figure 
20D), where p65 increased intensity compared to PMOXA-coated NPs and p35, p33, and p20 
have decreased band intensities, the patterns are more complex compared to uncoated NPs 
which is in line with the other coated particles. From the gel, it seems the band between 45 
kDa and 30 kDa is in higher amount in PMOXA-coated and PEtOXA-coated, compared to 
PEG and uncoated NPs.  
These results indicate that the corona composition is not only concentration dependent but is 
quite different between particles. Thus, NP capture and cellular affinity is most likely due to 
the proteins identified here.  
 
Because we observed differences between the four ORMOSIL nanoparticles in affecting 
SiO2-NPs’ cellular uptake as well as differences among serum species, we decided to next 
characterize the protein corona in 70% (v/v) pig serum (Figure 21). Furthermore, all the 
bands were quantified using densitometry methods and are displayed in Figure 22. The major 
differences between particles incubated in pig serum than in human serum are mainly for 
p120, p100, and a significant amount of the high molecular weight proteins which are absent 
in uncoated and PEGylated nanoparticles. In addition, the bands corresponding to p80 are 
much more intense in all four NPs compared to HS conditions. p18 is present in PS but is not 
found in HS, and at concentrations of 50 g/mL and 25 g/mL, the band signal is equivalent 
to the background mock serum condition (without particles) (Figure 21A). The bands at p15 
and p18 are found in only pig serum conditions as well as p30, which is seen in small traces 
in human serum. The bands at p33 and p35 are highly reduced in pig serum as well as p60 
and p65, which are interestingly dose dependent in PS but not in HS. This phenomena is also 
found to be the case for p20 which decreases with decreasing particle dosage but is relatively 
stable in HS. Certain bands in the mock NP free samples correspond to certain proteins such 
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as p60, p50, and p20 indicating the proteins could be remnants from serum. However, p15 is 
found in PS and not in HS. According to densitometry quantitative measurements, p100, p50, 
p40, p35, p33, p30, p20, p18, P15, and p10 in conditions of 50 g/mL and 25 g/mL have 
equivalent signal seen in the nanoparticle-free mock, serum-only control samples.  
 
As for coated nanoparticles, the protein corona pattern is relatively the same for PEGylated 
NPs (Figure 21B) as was for uncoated however, bands corresponding to p80 and p10 are 
highly more intense and p35 and p33 are slightly more intense. p15 was reduced in 
PEGylated NPs by 80%, with only traces of protein, equivalent to the mock samples, 
indicating it might be a remnant from PS. The doublet at p50 and p20 was also reduced by 
11% and 35%, respectively. p18 increased by 16% in PEGylated NPs compared to uncoated 
NPs.  
However, PMOXA-coated and PEtOXA-coated NPs (Figure 21 C and D, respectfully) have a 
much more complicated corona formation in PS. All major protein bands are evident where 
P120 as well as the other high molecular weight proteins that were absent on uncoated and 
PEGylated NPs are now present and more intense. The most striking difference between 
PMOXA-coated and PEtOXA-coated NPs is the band between 30 kDa and 45 kDa which is 
not present in PEGylated NPs or uncoated NPs. The band at p12 which was also absent in 
uncoated and PEGylated NPs is also present in PMOXA-coated NPs but is once again 
reduced in PEtOXA-coated NPs by 50%. Compared to PEGylated, PMOXA-coated NPs 
proteins increased by: p10 (25%), p12 (100%), p18 (55%), p20 (50%), p30 (24%), p33 
(12%), p35 (57%), p40 (52%), p50 doublet, p60, and p80 (69%). This patter predominates in 
the corona pattern for both PMOXA-coated and PEtOXA-coated NPs. Below 400 g/mL, 
p33 bands disappear for PMOXA-coated NPs whereas it is still present at 100 g/mL for 
PEtOXA-coated NPs. The major differences between PMOXA -coated and PEtOXA-coated 
 80 
NPs are as follows: p100 and p120 appears as well as p15 (53%) and p18 (23%) increases in 
intensity for PEtOXA as well as the doublet at p50 (56%) but also appears to become a 
singlet at 400 g/mL. The band at p20 deceases by 17% in intensity compared to PMOXA-
coated NPs and p12 and p30 almost entirely disappears. It is obvious to conclude from these 
gels that the protein corona becomes more complex and elaborate for the two oxazoline 
coated particles than for uncoated NPs and even PEGylated particles which is in line with 
densitometric analysis data.  
These results indicate the corona composition is not only concentration dependent but is quite 
different between particles and between species. Thus, the differences in NP capture and 
cellular affinity between species is most likely due to the proteins identified here.  
 81 
 
 
 
Figure 21: SDS-PAGE analysis of the pattern of PS proteins adsorbed on SiO2-NPs. (A) Uncoated (B) PEG (C) PMOXA (D) 
PEtOXA SiO2-NPs were incubated at the indicated concentrations for 20 minutes at 37 °C in 70% PS, washed and analyzed 
by SDS-PAGE (12%). Equal sample volumes were loaded onto an SDS-PAGE and stained by silver nitrate. On the left-hand 
side of each image, the values indicate the MW in kDa of the molecular weight standard polypeptides used in the gel.   
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Figure 22: Densitometric analysis to examine the corona protein levels absorbed onto ORMOSIL SiO2-NPs.  Following silver 
staining, a semi-quantitative estimation of the relative amount of the main protein bands found (arrows), labeled by their 
rough apparent molecular weight in kDa (pxx), were determined by densitometry. 
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Given the fact PEtOXA-coated NPs showed unusual cellular behavior as shown in Figure 14 
and the complex corona composition elucidated by gel electrophoresis Figure 20 and Figure 
21, we decided to perform semi-quantitative estimations by label-free methods after liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis for determining the 
polypeptide composition of proteins bound to PEtOXA-coated NPs in the presence of HS, 
MS, and PS (Table 2 and Figure 23). The main corona components included the expected 
common circulating blood proteins, coagulation and complement factors, and protease 
inhibitors. Proteins bound to PEtOXA-coated NPs in human serum included Albumin, 
Apolipoprotein A1, Apolipoprotein E, Clusterin, and Complement C3. In pig serum, the most 
abundant polypeptides were found bound to the surface of PEtOXA-coated NPs included 
Complement C3, Prothrombin, Albumin, Ficolin 1, Ficolin 2, Apolipoprotein A1, 
Apolipoprotein E. For mouse serum, the major polypeptide components include 
Antithrombin-III, Prothrombin, and Apolipoprotein E. The major differences between the 
human and the pig serum is the lack of Clusterin in PS and the lack of Ficolin 1 and 2 in HS. 
Clusterin, also known as Apolipoprotein J, is a 75- to 80-kDa heterodimeric glycoprotein 
consisting of an α-chain and a β-chain, linked by five disulphide bridges. It has been shown 
in past studies126,127 that clusterin, a dysopsonic protein, provides stealth effects against 
phagocytes by inhibiting complement, preventing protein aggregation, and by inducing 
apoptosis of inflammatory cells. This phenomena could explain why there was a reduction in 
band intensities with PEtOXA-coated NPs in HS as seen in Figure 20 and why PEtOXA-
coated NPs had a reduced capture by human macrophages in HS compared to PS (Figure 14). 
However, clusterin also mediates and accelerates sC5b-9 formation as well as complexing 
with HDL and ApoA1. Our data shows even when complement is inhibited, clusterin 
deposition is still present in the corona composition, thus indicating direct HDL binding to 
the surface of the particle is required or clusterin complexed with Apo A1 is transferred from 
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HDL to the surface. However, despite the complement inhibitory effects and the ability to 
remove opsonization molecules, clusterin does not seem to inhibit complement activation in 
human serum by PEtOXA-coated NPs.  
 
The other major difference between the two sera is the presence of Ficolin 1 and 2 in PS. 
Ficolins are involved in the lectin complement pathway by binding via a fibrinogen-like (fbg) 
domain.41 ficolin-1 and ficolin-3 have only one binding pocket each, while ficolin-2 has four 
binding pockets.45 Ficolin plasma levels in pig (30 pg/ml) are relatively higher than in mouse 
(1-2 pg/ml) or human (4.13 pg/ml) and are comprised of two ficolin 12-mers connected face-
to-face by their fbg domains.128 It has been shown that repeated freeze-thaw cycles of plasma 
and serum can reduce complement and ficolin concentrations by repeated clotting, 
degradation of ficolin, or salting-out during freezing.129 Therefore, experiments were 
performed with either fresh or once-frozen samples thus ensuring the activation and presence 
of ficolin proteins. Therefore, the lack of ficolin in human serum with PEtOXA-coated NPs is 
directly related to complement activation, or lack thereof by ficolin association, instead of 
inactivated serum samples ensuring accurate quantitative ficolin amounts. Ficolin may be 
directly involved in complement activation via the lectin pathway by PMOXA-coated and 
PEtOXA-coated nanoparticle which is species specific to pigs.  
Both pig and mouse serum show specificity for prothrombin which when activated by FXa 
bound to FVa forming prothrombinase, converts into thrombin (FIIa) allowing thrombin to 
activate platelets, FV, factor VIII (FVIII), and factor XI as well as cleavage of fibrinogen to 
fibrin. Thrombin activation can proteolytically generate C5a activating the complement 
pathway as well as inducing the expression of the decay accelerating factor (DAF) in a PAR1-
dependent manner which reduces C3 deposition thus inhibiting the complement pathway. 
Therefore, the roles in pig and mouse serum might be quite varying, either inhibiting or 
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initiating complement. However, taken together with the fact that both human and pig serum 
showed complement C3 fragments either native C3 or covalently bound C3 with molecular 
weight greater than native C3, thus indicating complement activation, we can suggest that, 
possibly, prothrombin plays some role in complement activation in pigs. However, given the 
lack of Complement C3 protein in mouse as well as the presence of another major 
polypeptide components for antithrombin III, which is an inhibitor by neutralizing the 
enzymatic activity of thrombin, it was imperative to look further into C3 specificity among 
the three species. 
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Bands Species Accession # Protein name Mass (Da) Score Peptides Sequence 
coverage 
% 
EMPAI 
1 pig P01025 Complement C3 188,229 130 15 (7) 4 0.16 
2 pig P01025 Complement C3 188,229 159 8 (1) 0 0.02 
3 pig Q19AZ8 Prothrombin 71,447 216 5 (4) 8 0.24 
4 pig P08835 Albumin 71643 194 9 (2) 4 0.12 
 pig P01025 Complement C3 188,229 128 7 (7) 4 0.19 
5 pig Q29041 Ficolin 2 35,173 302 7 (6) 18 0.97 
 pig Q29042 Ficolin 1 35,680 270 5 (4) 12 0.56 
 pig P01025 Complement C3 188,229 266 7 (5) 3 0.11 
6 pig Q29041 Ficolin 2 35,173 316 6 (6) 18 1.11 
 pig P18650 Apolipoprotein E 36,634 186 7 (2) 5 0.27 
 pig Q29042 Ficolin 1 35,680 245 4 (4) 12 0.64 
7 pig P18650 Apolipoprotein E 36,634 206 6 (2) 7 0.24 
8 pig P18648 Apolipoprotein A1 30,307 282 10 (1) 3 0.16 
9 mouse P32261 Antithrombin-III 52,484 449 11 (5) 4 0.44 
 mouse P19221 Prothrombin 71,649 237 5 (4) 5 0.24 
10 mouse P08226 Apolipoprotein E 35,901 562 12 (8) 28 1.39 
11 human P01024 Complement C3 188,569 476 14 (7) 4 0.16 
12 human P01024 Complement C3 188,569 525 17 (7) 4 0.17 
13 human P02768 Albumin 71,317 377 13 (7) 12 0.46 
 human P01024 Complement C3 188,569 1,431 35 (28) 20 0.77 
14 human P10909 Clusterin 53,031 62 2 (1) 2 0.08 
 human P01024 Complement C3 188,569 337 10 (5) 3 0.12 
15 human P02649 Apolipoprotein E 36,246 61 2 (1) 2 0.1 
 human P10909 Clusterin 53,031 174 5 (3) 9 0.22 
16 human P02649 Apolipoprotein E 36,246 52 5 (0) n.d. n.d. 
17 human P02647 Apolipoprotein A1 30,759 270 11 (3) 14 n.d. 
 
Table 
4Bands 
Species Accession # Protein name Mass (Da) Score Peptides Sequence 
coverage 
% 
EMPI 
1 pig P01025 Complement C3 188,229 130 15 (7) 4 0.16 
2 pig P01025 Complement C3 188,229 159 8 (1) 0 0.02 
3 pig Q19AZ8 Prothrombin 71,447 216 5 (4) 8 0.24 
4 pig P08835 Albumin 71643 194 9 (2) 4 0.12 
 pig P01025 Complement C3 188,229 128 7 (7) 4 0.19 
5 pig Q29041 Ficolin 2 35,173 302 7 (6) 18 0.97 
 pig Q29042 Ficolin 1 35,680 270 5 (4) 12 0.56 
 pig P01025 Complement C3 188,229 266 7 (5) 3 0.11 
6 pig Q29041 Ficolin 2 35,173 316 6 (6) 18 1.11 
 pig P18650 Apolipoprotein E 36,634 186 7 (2) 5 0.27 
 pig Q29042 Ficolin 1 35,680 245 4 (4) 12 0.64 
7 pig P18650 Apolipoprotein E 36,634 206 6 (2) 7 0.24 
8 pig P18648 Apolipoprotein A1 30,307 282 10 (1) 3 0.16 
9 mouse P32261 Antithrombin-III 52,484 449 11 (5) 4 0.44 
 mouse P19221 Prothrombin 71,649 237 5 (4) 5 0.24 
10 mouse P08226 Apolipoprotein E 35,901 562 12 (8) 28 1.39 
11 human P01024 Complement C3 188,569 476 14 (7) 4 0.16 
12 human P01024 Complement C3 188,569 525 17 (7) 4 0.17 
Table 2: Serum proteins from different species bound to PEtOXA-coated amorphous silica nanoparticle 
surface identified by tandem mass spectrometry analysis. 
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One of the more interesting aspects of the MS/MS results is the fact that the readout analyzed 
multiples peptides corresponding to different molecular weights as Complement C3 (180 
kDa). C3 is composed of two chains, α and β, connected by a disulphide bond, which is 
reduced in the presence of β-mercaptoethanol. Upon C3 activation, cleavage forms C3b and 
C3a which is released into solution. C3b contains an exposed thioester bond in the C3dg 
region which allows C3b to covalently bind to foreign cells via hydroxyl (-OH) and amine (-
NH2) groups on the cell’s surface. C3b is further inactivated by Factor H and I to form C3f 
and iC3b, which is further degraded into C3c, C3d, and C3g. Peptide mapping was performed 
with human serum and pig serum (Figure 24) in order to identify which C3 fragments were 
present by mapping the identified peptide sequences onto the full C3 protein sequence. The 
three peptide fragments identified corresponds to the molecular weight 180->200 kDa, 70 
kDa, and 38 kDa in both human and pig C3. Mapping these peptides onto the C3 sequence 
revealed the peptide corresponding to 70 kDa mapped as C3β which is about 80 kDa and is in 
line with reduced C3. The peptide at 180->200 kDa mapped to the region C3b containing 
C3dg bounded to the particles. The native fragment is about 80 kDa, but since it’s covalently 
Figure 23: Serum proteins from different species bound to PEtOXA amorphous silica nanoparticle surface identified 
by tandem mass spectrometry analysis. Major complement proteins and lipoproteins in HS, MS, and PS are 
identified and shown with their band identified by silver staining following gel electrophoresis.  
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bound to the particle, the molecular weight will be much higher, therefore this is the reason 
why this fragment is seen at such a higher than expected MW. This fact is interesting because 
it indicates that C3 is in fact activated pointing to complement activation by the 
nanoparticles. Furthermore, the final peptide associated with 38 kDa, was mapped to C3c α’ 
fragment 1 at the corresponding 39 kDa which occurs upon C3b inactivation. Thus not only 
is C3 activated in human and pig serum by PEtOXA coated nanoparticles, but it is also 
inactivated thus indicating opsonization by C3 leading to complement activation and 
phagocytosis.  
It is known that C3 and C4 are homologous and share the same receptor, CR1, which is not 
only involved in complement activation, but also involved in inhibiting the classical and 
alternative pathway C3/C5 convertases as well as being a cofactor for the cleavage of C3b 
and C4b by factor I.130 Therefore, we performed peptide mapping with C4a as it was done 
with C3. In congruence with the C3 findings, C4 was activated, bound to the particle, and 
then inactivated further supporting the idea of complement activation.  
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Figure 24: Peptide mapping of key conserved residues and motifs found in the amino acid sequence of human 
and pig C3 and human C4A. On the left hand side, the molecular weight of the peptide found in the SDS PAGE 
gel is indicated while on the right hand side, the predicted fragments of the protein of interest. The dark blue 
highlighted portion represents the amino acids which form the amide bond to the target particles.  
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Polypeptide abundance in complement activation in human, mouse, and pig serum with 
SiO2-NPs.  
To obtain a more in-depth examination of the proteins involved in complement activation 
upon particle introduction into serum, shotgun proteomics analysis was performed via 
analyzing peptides released through proteolytic digestion of intact proteins. As it is possible 
to observe in Figure 25, the logarithmic distribution displays the molar amount (iBAQ) for 
each protein which is the summed intensity for each protein divided by the number of 
theoretically observable peptides in serum. The theoretically observable peptides are 
considered to be all tryptic peptides between 6 and 30 amino acids long. The peptides listed 
are in descending abundance corresponding to uncoated SiO2-NPs after the elimination of 
proteins with peptide number <4 and elimination of contaminants (keratins, dermicidins, and 
hornerin).  
 
The greatest difference between uncoated particles and coated ones concerned properdin, 
platelet F4, C3, and C4b. Polypeptide molar abundances relative to uncoated for Properdin 
are 5.99E+07 for PEtOXA-coated NPs and 1.56E+07 for PMOXA-coated NPs compared to 
5.56E+06. Furthermore, the molar abundances of C3 and C4b respectively for uncoated are 
1.81E+07 and 1.08E+06, for PEGylated NPs 1.47E+07 and 6.87E+05, for PMOXA-coated 
NPs 2.81E+07 and 9.70E+05, and for PEtOXA-coated NPs 9.64E+07 and 1.91E+07. 
Properdin is a major player in enhancing the Alternative pathway by stabilizing C3 and C5 
convertases by binding C3b and to Bb which prevents their spontaneous or induced 
activation. Complement C4b is a 193 kDa glycoprotein comprised of modified C4 α-chain 
(α') and intact β- and γ-chains which binds to target cell surfaces by a covalent ester bond. 
Inflammatory cell CR1 complement receptor can be bound by C4b bounded to the surface, 
leading to opsonic and immune adherence activities. Although non-enzymatic, C4b is an 
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essential component of the classical complement pathway. Properdin also aids in the uptake 
of immune complexes which can directly activate the Alternative pathway. C9 which is 
increased in PEtOXA-coated NPs, is part of the MAC complex which is the terminal 
component of all three complement pathways. Therefore, increased amounts of the 
complement factors may suggest a major role that the Alternative and classical pathway play 
in complement activation by PMOXA-coated and PEtOXA-coated NPs in human serum. 
However, as we have demonstrated that C3 is activated and then inactivated upon 
nanoparticle introduction, therefore it would make sense that factors involved in complement 
inhibition would be present at higher levels in the coated particles as well. The polypeptide 
abundance of Complement factor H (FH) bound to PEtOXA-coated NPs is 5.23E+06 and 
4.60E+05 for PMOXA-coated NPs compared to 1.24E+05 for uncoated. As factor H is both a 
coagulation initiator and a complement inhibitor, FH plays a crucial role in the intricate 
balance and regulation of the two pathways as well as suggesting C3 is involved in 
nanoparticle uptake.  
 
The most striking difference in pig serum (Figure 25B) is the high abundance of ficolin 1 and 
especially ficolin 2 for PMOXA-coated and PEtOXA-coated NPs compared to PEGylated 
NPs and uncoated particles. This is in congruence with previous in gel digestion data where 
Ficolin 1 and 2 (Table 2) was found bound to PEtOXA-coated NPs only in pig serum and not 
in human or mouse as well as gel electrophoresis where ficolin was also only found in pig 
serum and not in mouse or human serum (Figure 23). These findings may further support the 
role of lectin pathway in complement activation in pig serum with coated particles.  
However, in mouse serum (Figure 25C), Complement C3 peptide abundance is much lower 
than in human serum, 1.30E+07 for PMOXA-coated NPs which is 2 times lower than in 
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human serum, 8.91E+06 for uncoated NPs, 5.08E+06 PEtOXA-coated NPs which is almost 
19 times lower than in human serum, and 4.11E+06 for PEGylated.  
 
The most abundant polypeptides found in human serum (Figure 26A) are associated with the 
apolipoproteins: Apo AI, AII, AIV, CII, CIII, E; Clusterin; Complement C3, truncated C1, 
and C4b; and properdin. Complement proteins C3, truncated C1, C4b, FH, and C9 were all in 
much higher abundance for PMOXA-coated and PEtOXA-coated particles than for uncoated 
and PEGylated NPs. Apo CIII was more abundant with uncoated particles compared to 
coated ones which is congruent with the fact that Apo CIII (8.8 kDa) inhibits the activity of 
lipoprotein lipase and disturbs lipids as well as interfering with the binding of Apo E to 
hepatic receptors. Therefore, reduced amount of Apo CIII indicates an increase in amount of 
Apo E for coated particles. Apolipoprotein E, which is 1.40E+08 for PEtOXA-coated NPs is 
about one and a half times less abundant than PEtOXA-coated NPs in human serum at 
1.92E+08. Apo AIV, Coagulation factor V, C3, properdin, and clusterin are in higher 
abundance for coated PMOXA-coated NPs than uncoated NPs whereas Apo AIV, 
prothrombin, Coagulation factor V, and antithrombin III are higher for PEtOXA-coated NPs 
compared to uncoated. Apo AIV is the only protein higher in abundance for PEGylated NPs. 
The reduced protein amount of complement activation associated proteins in mouse serum 
compared to human as well as the reduced relative abundance between the four particles 
indicate that complement, while still possibly activated, does not have the same specificity to 
the same degree in mouse serum to the particles as does human serum. Furthermore, because 
uncoated NPs has a greater abundance of complement activating proteins such as 
prothrombin, Apo AI, AII, CII, and clusterin which are all proteins which can be associated 
with complement downregulation.  
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Figure 25: Polypeptide abundance of SiO2-NPs in human, mouse, and pig serum. The iBAQ score on the 
left of the graph corresponds to the sum of all the peptides intensities divided by the number of 
observable peptides of a protein. The peptides listed are in descending abundance corresponding to 
serum with Uncoated SiO2-NPs after the elimination of proteins with peptide number <4 and elimination 
of contaminants (keratins, dermicidins, and hornerin). 
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Figure 26: Apolipoprotein polypeptide abundance of SiO2-NPs in human, mouse, 
and pig serum. The iBAQ score on the left of the graph corresponds to the sum of 
all the peptides intensities divided by the number of observable peptides of a 
protein. The peptides listed are in descending abundance corresponding to serum 
with Uncoated SiO2-NPs after the elimination of proteins with peptide number <4 
and elimination of contaminants (keratins, dermicidins, and hornerin). 
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Due to the fact that the classical complement cascade is calcium dependent and the 
alternative complement cascade is magnesium dependent, we decided to look at whether we 
could distinguish between the two pathways in order to discern a possible mechanism by 
which the coated and non-coated particles use to activate the immune response. In order to 
probe this effect, we wanted to discern the protein abundance of the corona for the particles 
in the presence of calcium chelating agents. The addition of EDTA prevents complement 
activation and C3b opsonization of the NPs for the classical and lectin pathways. It has 
already been established that ficolins bind MASPs via a fibrinogen-like (fbg) domain in a 
calcium independent manner and C1q interacts with C1r2C1s2 via Ca
2+ binding domains. For 
most of the proteins identified in uncoated NPs (Figure 27A) incubated in human serum, their 
abundance does not seem to be affected by the addition of calcium chelating agents. 
However, complement C3 in much higher abundance in PEtOXA-coated but it also showed a 
significant decrease upon calcium chelation. C9, C4b, Apo B, and FH saw a substantial 
reduction in protein abundance as well (Figure 31). As discussed previously, C1r2s2 forms via 
Ca2+ dependent interaction with the binding interface comprised of a Ca2+ binding site in the 
EGF domain of each subcomponent.36 Once activated, the tetramer unfolds extending the C1s 
ends outside the C1q cone in order to interact with C4 and C2. C4 is cleaved producing 9 kDa 
C4a and 190 kDa C4b, which binds the zymogen C2 in a Mg2+-dependent manner. Therefore, 
both C3 and C4b polypeptide content in the protein corona would be reduced if there is a lack 
of calcium as well as C9 which is part of the MAC formation. In contrast to complement 
proteins, in all nanoparticles, clusterin, lipoproteins, and other predominantly deposited 
species are all slightly affected on divalent cation chelation.  
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The removal of calcium and subsequent reduction in proteins which are calcium dependent in 
the protein corona not only affects the composition of the corona directly but also indirectly. 
Because the corona is highly dynamic and constantly changing given the environment and 
surroundings, the lack of certain proteins may allow for the physical opportunity of other 
proteins to bind which might not have the steric space to do so in the presence of other, more 
abundant proteins. 
The protein abundance pattern for PEGylated NPs (Figure 27B) was more complicated than 
uncoated NPs where not only was C4b and C3 reduced with the addition of calcium 
chelation; but slightly more than with uncoated particles. Furthermore, Apolipoprotein A1, 
AII, AIV, Apo E, Apo CII, and Complement component C9 were also reduced.  
Not only was the abundance in normal human serum for complement component C9 higher 
for PMOXA-coated NPs (Figure 27C), but in HS with EDTA, the amount of protein was 
significantly reduced. Additionally, Apo D was also slightly reduced without the presence of 
calcium. 
For PEtOXA-coated NPs (Figure 27D), it is interesting to note the fact that properdin 
abundance was undetectable in EDTA conditions and C3 and C4b was highly reduced. Apo 
A1, AII, AIV, E, CII, and C9 decreased upon EDTA administration.  
Unlike in human serum, mouse serum presented quite a different polypeptide pattern. Figure 
28 and Figure 32 demonstrates how mouse complement proteins were highly reduced in the 
protein corona in all particles compared to HS and PS. However, complement proteins were 
the most prevalent in the mouse serum derived corona of uncoated nanoparticles compared to 
coated particles. This indicates, in contrast to the effect induced in human and pig serum, 
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complement activation is inhibited by coatings in mouse serum compared to uncoated 
particles in agreement with previous phagocyte capture experiments.  
On the other hand, pig serum revealed a protein pattern quite similar to that found in humans 
(Figure 29). High abundance of complement proteins such as C3, clusterin, C1s, and FB can 
be found primarily in the coated PMOXA and PEtOXA particles and less so in the uncoated 
NPs which is in congruence with the human serum (Figure 33). However, the main difference 
as seen with the in gel digestion, is the absence of properdin, C4b, and C9 with the presence 
of Ficolin (Figure 30). Not only is Ficolin 2 the highest abundant protein in the corona for 
both PMOXA-coated and PEtOXA-coated NPs, but it is specific for only pig serum and is 
not found in human nor mouse serum.  
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Figure 27: Polypeptide abundance of SiO2-NPs in human serum with chelating agents (EDTA). The iBAQ score on the 
left of the graph corresponds to the sum of all the peptides intensities divided by the number of observable peptides 
of a protein. The peptides listed are in descending abundance corresponding to serum with SiO2-NPs without EDTA 
after the elimination of proteins with peptide number <4 and elimination of contaminants (keratins, dermicidins, and 
hornerin). 
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Figure 28: Polypeptide abundance of SiO2-NPs in mouse serum with chelating 
agents (EDTA). The iBAQ score on the left of the graph corresponds to the sum of 
all the peptides intensities divided by the number of observable peptides of a 
protein. The peptides listed are in descending abundance corresponding to serum 
with SiO2-NPs without EDTA after the elimination of proteins with peptide number 
<4 and elimination of contaminants (keratins, dermicidins, and hornerin). 
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Figure 29: Polypeptide abundance of SiO2-NPs in pig serum with chelating agents (EDTA). The iBAQ score on 
the left of the graph corresponds to the sum of all the peptides intensities divided by the number of observable 
peptides of a protein. The peptides listed are in descending abundance corresponding to serum with SiO2-NPs 
without EDTA after the elimination of proteins with peptide number <4 and elimination of contaminants 
(keratins, dermicidins, and hornerin). 
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Figure 30: Specific polypeptide abundance of Ficolin 2 with SiO2-NPs in pig serum with chelating agents 
(EDTA). The iBAQ score on the left of the graph corresponds to the sum of all the 
peptides intensities divided by the number of observable peptides of a protein. The peptides listed are in 
descending abundance corresponding to serum with SiO2-NPs without EDTA after the elimination of 
proteins with peptide number <4 and elimination of contaminants (keratins, dermicidins, and hornerin). 
 102 
 
Figure 31: Specific polypeptide abundance of certain complement proteins and clusterin with SiO2-
NPs in human serum with chelating agents (EDTA). The panels on the left represent the change in 
abundance between the human serum and serum supplemented with EDTA. On the right, panels 
indicate the difference between particles with HS and particles with HS+EDTA (𝚫). The iBAQ score on 
the left of the graph corresponds to the sum of all the peptides intensities divided by the number of 
observable peptides of a protein. The peptides listed are in descending abundance corresponding to 
serum with SiO2-NPs without EDTA after the elimination of proteins with peptide number <4 and 
elimination of contaminants (keratins, dermicidins, and hornerin). 
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Figure 32: Specific polypeptide abundance of certain complement proteins with SiO2-NPs in mouse 
serum with chelating agents (EDTA). The panels on the left represent the change in abundance 
between the mouse serum and serum supplemented with EDTA. On the right, panels indicate the 
absolute value when normalized against EDTA. The iBAQ score on the left of the graph corresponds to 
the sum of all the peptides intensities divided by the number of observable peptides of a protein. The 
peptides listed are in descending abundance corresponding to serum with SiO2-NPs without EDTA 
after the elimination of proteins with peptide number <4 and elimination of contaminants (keratins, 
dermicidins, and hornerin). 
Figure 33: Specific polypeptide abundance of certain complement proteins with SiO2-NPs in pig serum 
with chelating agents (EDTA). The panels on the left represent the change in abundance between the pig 
serum and serum supplemented with EDTA. On the right, panels indicate the absolute value when 
normalized against EDTA. The iBAQ score on the left of the graph corresponds to the sum of all the 
peptides intensities divided by the number of observable peptides of a protein. The peptides listed are in 
descending abundance corresponding to serum with SiO2-NPs without EDTA after the elimination of 
proteins with peptide number <4 and elimination of contaminants (keratins, dermicidins, and hornerin). 
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Complement activation via cleavage of C3 
Given that C3 is the most versatile molecule of the complement cascade and the common link 
between all three cascades, studying the functional properties of the C3 molecule would allow us to 
better understand the human complement system with the different ORMOSIL particles, but also how 
different animal models, which are necessary in scientific works, interact with C3 and thus the 
complement cascade. C3a, a 9 kDa anaphylatoxin, and C3b is generated upon complement 
activation and subsequent cleavage of C3. The convergence of the three complement 
pathways occurs around the conversion of C3 to C5 convertase activated by C3 convertase by 
the binding of C3b which ultimately leads to the formation of the membrane attack complex 
(MAC). Therefore, in order to determine whether complement is activated by PMOXA-
coated NPs and PEtOXA-coated ORMOSIL nanoparticles, the C3 cleavage product C3a 
which is released into solution, was detected by Western blot. Therefore, we analyzed the 
protein corona formed on the nanoparticles after being incubated for 20 min at 37 °C in 
human, mouse, and pig serum. The supernatant was collected as C3a is released into solution 
upon cleavage in addition to recovering the NPs following ultracentrifugation and washings  
to be used as a negative control as those samples would not contain any C3a. Gel 
electrophoresis under non-reducing conditions was performed, and after transfer to 0.45 μm 
nitrocellulose the blotted bands were immunodetected with a specific rabbit anti-human C3a 
Mab and subsequently visualized with peroxidase labeled goat anti-rabbit IgG antibodies and 
further analyzed by densitometry. Based on the Western blot analysis and densitometry 
quantifications (Figure 34), C3a amounts released following particle and human serum 
incubation for 20 min at 37 °C shows a significant increase in free C3a in the media 
following PMOXA-coated NPs (37%) and PEtOXA-coated NPs (36%) particle incubation 
compared to positive control samples. In fact, C3a levels are two times higher in pig serum 
than in human serum where free C3a is increased for PMOXA-coated NPs by 72% and 
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PEtOXA-coated NPs by 69% in pig serum compared to the positive control. Western blot 
further revealed C3a is activated roughly the same by PEtOXA-coated and PMOXA-coated 
NPs when using the same amount of particles. However, in mouse the C3a signal was well 
below the detectable amount to do any analysis, although shotgun and in gel digestion further 
support the lack of C3a activation.  
 
Figure 34: Specific polypeptide abundance of complement C3 protein with SiO2-NPs in human, mouse, and pig serum with 
chelating agents (EDTA). The panels on the left represent the change in abundance between the human, mouse, and pig 
serum and serum supplemented with EDTA. On the right, panels indicate the absolute value when normalized against EDTA. 
The iBAQ score on the left of the graph corresponds to the sum of all the peptides intensities divided by the number of 
observable peptides of a protein. The peptides listed are in descending abundance corresponding to serum with SiO2-NPs 
without EDTA after the elimination of proteins with peptide number <4 and elimination of contaminants (keratins, 
dermicidins, and hornerin). 
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These results obtained from Western blots against C3a, an indicator of C3 activation and 
therefore complement activation, support the hypothesis that in human serum, PMOXA-
coated and PEtOXA-coated ORMOSIL nanoparticles greatly activate complement via 
opsonization of complement system proteins. In MS, there was no C3 activation, suggesting 
that the addition of nanoparticles does not activate the complement system (Figure 35).  
 
Figure 35: Western Blot analysis of complement activation via C3 cleavage into C3a (9kDa) by PMOXA and PEtOXA coated SiO2-NPs. 
(A) 800 ug/mL of SiO2-NPs were incubated for 20 minutes at 37 °C in 70% HS, MS, or PS. Equal samples volumes of either 
supernatants and washed pellets were analyzed by SDS-PAGE (12%). After transfer to 0.45 μm nitrocellulose the blotted bands 
were immunodetected with a specific rabbit anti-human C3a Mab and subsequently visualized with peroxidase labeled goat anti-
rabbit IgG antibodies. (B) A semi-quantitative estimation of the amount of the indicated proteins associated with NPs were 
obtained by densitometry of the corresponding SDS-PAGE bands. Data were normalized against the positive control (PC) where the 
percentage of the PC was plotted. 
PMOXA PEtOXA No NPs PC 
HS 
MS 
PS 
A 
B 
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It is well known that C1q and C2 mouse complement proteins involved in the classical 
pathway can malfunction and improper storage and handling of serum can cause protein 
degradation and complement deactivation. For that reason, in order to control complement 
activity, sera were treated with Zymosan to be used as a positive control since it is a well-
known activator of the complement system. Therefore, we can conclude the sera used in 
these studies are in fact functional with an intact complement system and thus the results 
produced represent an actual difference between mouse and human complement activation. 
In addition, as the C3a antibody is polyclonal, we can exclude recognition issues and can 
reason the lack of C3a is due to no C3 cleavage indicating a lack of opsonization of PMOXA-
coated and PEtOXA-coated NPs in MS with complement proteins. This is in congruence with 
confocal microscopy data performed with the same batches of sera in the Western Blot 
experiments, where there was no phagocytic cellular uptake by macrophages in mouse serum 
supporting the absence of immune activation.  
Similarly to human serum, pig serum showed an increase in C3a, which is in line with the 
confocal microscopy and flow cytometry data, which quantifies NP-cell association, 
demonstrating how PMOXA-coated and PEtOXA-coated NPs activates cellular uptake, at 
times even higher than in human serum. This observation can be explained by complement 
activation via either of the three pathways or partially by a pathway independent of C3. This 
can transpire where complement is activated by an additional bypass pathway that acts 
independently of C3 such as activation by thrombin which acts as a C5 convertase to generate 
C5a and mediate pathology, bypassing C3 convertase, or by Fcɣ receptors (FcɣRs) which 
recognize immunoglobulin G (IgG) thus releasing either activating or inhibitory intracellular 
signals via the interaction of the Fc portion of antibody molecules. In fact, mass spectrometry 
data (Table 2) of PEtOXA-coated NPs with PS showing a presence of prothrombin, the 
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precursor to thrombin, suggests complement activation by pig serum could be a combination 
of both a C3 and C3a independent pathway activation.  
We further looked into the abundance of C3 in all three species compared to samples with 
EDTA. Figure 34 demonstrates the amount of C3 present in the protein corona upon 
nanoparticle incubation with serum. It is apparent that C3 is much more prolific in PMOXA-
coated and PEtOXA-coated NPs in both human and pig serum, yet for mouse serum, there is 
a high, uniform decrease in C3 content. Therefore, complement is not activated by MS in 
either particles, and PMOXA-coated and PEtOXA-coated NPs in PS activates complement 
which is supported by other analytical methods but does not always go through C3 
complement mediated activation.  
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Activation of the lectin complement pathway by SiO2-NPs 
Given the proteomic findings concerning the involvement of ficolins in nanoparticle 
recognition in pig serum, we wanted to probe ficolin further to determine the possible 
underlying mechanism. It is known the acid-amide side chain arrangement is essential for the 
specificity of sugar binding of membrane C-type lectin receptors (CLRs). Mannose 
recognizes glutamic acid-asparagine residues whereas galactose recognizes glutamine-
aspartic acid residues, indicating in a mannose-binding lectin activation, galactose does not 
compete and therefore will not affect the activation of the lectin pathway. Given this, 
galactose was proposed as an internal control to probe activation of the lectin complement 
pathway. Furthermore, given CLRs recognize their ligands by a carbohydrate-recognition 
domain (CRD) via binding to mannose and/or N- Acetylglucosamine among others discussed 
previously, we decided to use mannose and N- Acetylglucosamine sugars to compete with 
MBLs in lectin pathway activation mediated by ficolin. In order to further probe the role of 
the lectin pathway of complement activation by the nanoparticles’ surface to prevent uptake 
by primary human macrophages, we performed competition assays with 25 mM or 50 mM 
sugar inhibitors incubated with particles and pig serum. We also compared human serum as 
well which was found not to contain ficolin like pig serum did, therefore human would be 
used as a further control (Figure 38). In fact, data from the competition assay seems to 
support the major role of ficolins in the lectin pathway of complement activation by 
PMOXA-coated and PEtOXA-coated NPs. In the case of PMOXA-coated NPs (Figure 37C), 
25 mM mannose reduced ficolin binding by 26.5% and 25 mM N- Acetylglucosamine 
reduced ficolin binding by 17%. However, the biggest effect was seen using 50 mM N-
Acetylglucosamine as it marginally reduced ficolin deposition (Figure 37C) by 65.5%. 
Ficolin was not deposited on uncoated SiO2-NPs (Figure 37A) and showed no inhibition by 
any of the monosaccharides. PEGylated NPs had almost no ficolin deposition too (Figure 
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37B) as well as having no inhibition by monosaccharides. PEtOXA-coated nanoparticles also 
showed no sensitivity to monosaccharides inhibitors with 25 mM mannose and 50 mM N-
Acetylglucosamine marginally reduced ficolin deposition (Figure 37D). Therefore, 25 mM 
sugars had no effect on NP binding and only 50 mM N-Acetylglucosamine showed marginal 
effects with PMOXA-coated NPs. Furthermore, gels (Figure 38) with human serum showed 
no ficolin binding and no reduction upon sugar supplementation thereby confirming previous 
results. As the sugars were only introduced to the cells for a 3 hr incubation, the cells’ 
phagocytic activity was not impaired with high sugar concentrations as it was found to be if 
cells were cultured in high sugar environments.131 These results support the idea that ficolin 
and therefore the lectin pathway is involved in complement activation.  
 
 
 
 
 
 
 
Figure 36: Densitometric analysis to examine the corona protein levels absorbed onto (A) PMOXA and (B) PEtOXA ORMOSIL 
SiO2-NPs.  Following silver staining, a semi-quantitative estimation of the relative amount of the ficolin bands found, were 
determined by densitometry. 
A 
 
B 
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Figure 37: SDS-PAGE analysis of monosaccharide inhibition of the complement lectin pathway activation by SiO2-NPs. 25 
mM or 50 mM sugar inhibitors N-Acetylglucosamine, Mannose, or Galactose were incubated with 800 g/mL of (A) 
Uncoated (B) PEG (C) PMOXA (D) PEtOXA SiO2-NPs were incubated for 20 minutes at 37 °C in 70% PS, washed and analyzed 
by SDS-PAGE (12%). Equal sample volumes were loaded onto an SDS-PAGE and stained by silver nitrate. On the left-hand 
side of each image, the values indicate the MW in kDa of the molecular weight standard polypeptides used in the gel. 
Figure 38: SDS-PAGE analysis of the pattern of HS proteins adsorbed on SiO2-NPs in the presence of sugar inhibitors. 25 mM or 50 mM sugar inhibitors N-
Acetylglucosamine, Mannose, or Galactose were incubated with 800 g/mL of (A) PMOXA or  (B) PEtOXA for 20 minutes at 37 °C in 70% HS, washed and 
analyzed by SDS-PAGE (12%). Equal sample volumes were loaded onto an SDS-PAGE and stained by silver nitrate. On the left-hand side of each image, the 
values indicate the MW in kDa of the molecular weight standard polypeptides used in the gel. 
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We also performed confocal microscopy (Figure 39) with human macrophages incubated for 
3 hours at 37 °C in pig serum (PS), in the presence of 800 ug/mL nanoparticles diluted 10X 
in culture medium either supplemented with 25 mM sugar inhibitors or without (mock 
control sample), and then inspected. Figure 39A illustrates uncoated nanoparticle’s evident 
low cytoplasmic signal which supports previous confocal experiments (Figure 17 and Figure 
19). However, with the addition of 25 mM sugar inhibitors, neither N- Acetylglucosamine 
nor mannose reduced the fluorescent signal of uncoated nanoparticles, being equal to that of 
the internal control of galactose and of uncoated in un-supplemented PS conditions. 
PEGylated nanoparticles demonstrated an increase in cell capture in un-supplemented PS 
conditions compared to uncoated, but similarly there was no effect with the addition of sugars 
(Figure 39B). However, conversely PMOXA--coated NPs (Figure 39C) displayed similar 
cytoplasmic signal as uncoated NPs, which is in contrast to previous findings. Furthermore, 
there was no effect with the addition of 25 mM sugars. PEtOXA-coated NPs, which 
demonstrated high ficolin binding by SDS-PAGE analysis of the protein corona composition 
in PS, now showed reduced fluorescence with 25 mM N-Acetylglucosamine condition in 
contrast to the internal control of galactose and PEtOXA-coated NPs in normal PS (Figure 
39D). The fact 25mM sugar inhibitors were used and were seen to be ineffective at 
competing with ficolin binding, can indicate a higher concentration of sugars are required to 
see an affect as in SDS PAGE. However, cells were not viable with 50 mM sugars due to 
undesirable osmotic changes. Therefore, any cellular experiments such as functional studies 
with cells or confocal were unfeasible as they required a low sugar concentration which was 
below the threshold to see an effect.   
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Figure 39: Effect of sugar inhibitors on the transport of SiO2-NPs in PS to acidic endolysosomes in human macrophages. 
Confocal images of human macrophages treated at 37 °C for 3 hr with 80 μg/ml (A) Uncoated (B) PEG (C) PMOXA (D) 
PEtOXA SiO2-NPs in RPMI medium with 25 mM sugars N-Acetylglucosamine, Mannose, or Galactose were incubated 
(indicated to the left of the boxes), stained with LysoTracker green. 
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Flow cytometry was performed with primary human monocytes isolated from healthy blood 
donors and macrophages differentiated from monocytes in order to probe the impact of serum 
from multiple species on coated nanoparticle cellular association with serum proteins. Given 
the presence of ficolin was only observed in PMOXA-coated and PEtOXA-coated NPs from 
the inhibition assay, we decided to specifically look at the association between these 
polymers and lectin complement activation with human phagocytes. In congruence with the 
inhibition assay and confocal images, 25 mM N-Acetylglucosamine supplemented PS was 
seen to be only slightly effective at preventing cellular uptake of PMOXA-coated and 
PEtOXA-coated NPs (Figure 40), where the effect is marginal and not significant. Until this 
point, 25 mM sugars were tested which was also used to probe the corona composition as 
well as Ficolin in pig serum. Effective protocols to study the effect of sugars with cells 
should be designed in order to probe the effect of higher sugar concentrations on competition 
with ficolin with particle phagocytosis. For example, particles can be incubated with sugars 
to form the corona with ficolin binding competition, however cells do not need to be 
supplemented with sugars as the inhibition of ficolin will have already occurred in the initial 
incubation. Therefore, high concentrations of sugars can be used without affecting cell 
viability.  
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Due to the fact that 25 mM sugars showed no influence on ficolin binding and 50 mM 
showed limited effect, we decided to probe ficolin binding using 100 mM sugar inhibitors 
against PMOXA-coated NPs as they showed to have the greatest sensitivity to ficolins. SDS-
PAGE analysis accompanied by Western Blot against ficolin revealed an intense reduction in 
ficolin by 54% via Silver staining analysis and 60% using Western Blotting when 100 mM of 
N-Acetylglucosamine was incubated in pig serum with PMOXA-coated NPs (Figure 41 and 
Figure 42). On one hand, it appears ficolin has a stronger binding specificity towards 
PEtOXA-coated NPs rather than PMOXA-coated NPs, therefore there would be less 
Figure 40: The effect of sugar inhibitors on SiO2-NPs cellular association with serum proteins from multiple species in human 
monocyte and macrophage cells. Following a 20 min incubation at 37 °C in 70% serum and 25 mM sugars N-
Acetylglucosamine, Mannose, or galactose with 80 μg/ml SiO2-NPs were incubated for 3 hours at 37 °C with human 
monocyte and macrophage cells. The cells were subsequently analyzed by flow cytofluorimetry to measure nanoparticle- 
associated fluorescence. Data are mean ± standard error of the mean (n = 3). Values above the bars indicate cell association 
expressed as the mean Fluorescence Intensity. 
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competition from the sugars. On the other hand, ficolin binding might occur through another 
binding site which does not favor N-Acetylglucosamine and therefore no competition would 
arise either, or the interaction between PEtOXA-coated NPs with ficolin is non-specific. 
Therefore, we wanted to know if ficolin binding is actually involved in complement 
activation.   
 
 
Figure 41: SDS-PAGE analysis of the pattern of PS proteins adsorbed on PMOXA SiO2-NPs in the presence of 100 mM sugar 
inhibitors. 100 mM sugar inhibitors N-Acetylglucosamine, Mannose, or Galactose were incubated with 800 g/mL of  
PMOXA for 20 minutes at 37 °C in 70% PS, washed and analyzed by SDS-PAGE (12%). Equal sample volumes were loaded 
onto an SDS-PAGE and stained by silver nitrate (Below). Western Blot analysis was performed against ficolin 2 (Above). 
After  transfer to 0.45 μm nitrocellulose the blotted bands were immunodetected with a specific Rabbit anti-human Ficolin 2 
Mab and subsequently visualized with peroxidase labeled goat anti-rabbit IgG antibodies. 
A B 
Figure 42: Densitometric analysis to examine the corona ficolin levels absorbed onto PMOXA-coated ORMOSIL SiO2-NPs 
analyzed by (A) WB and (B) silver staining. Following silver staining, a semi-quantitative estimation of the relative amount of 
the ficolin bands found, were determined by densitometry. 
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In order to discern the effect of ficolin binding on C3 activation, we performed a series of 
SDS-PAGE analyses both in the presence of 100 mM N-Acetylglucosamine as well as in 0 
°C and 37 °C with PMOXA-coated and PEtOXA-coated NPs (Figure 43). It is known that 
protein binding kinetics, protein interactions, and binding potentials are all greatly 
temperature dependent as well as enzymatic activity which will influence C3 cleavage and 
subsequent activation thus the reason for temperature comparison in this experiment. For 
both nanoparticles, there is a lack of C3b as well as a reduction in ficolin at 0 °C. Ficolin 
binding is inhibited by 100 mM N-Acetylglucosamine at 37 °C with PMOXA-coated NPs but 
not PEtOXA-coated NPs. However, complement activation via C3b presence is not inhibited 
for both PMOXA-coated and PEtOXA-coated NPs thereby indicating that although there is 
such a huge presence of ficolin in PS for both coated particles, ficolin does not play a role in 
complement activation and subsequent particle clearance via phagocytosis.  
 
 
 
 
Figure 43: SDS-PAGE analysis of the pattern of PS proteins adsorbed on PMOXA-coated  and PEtOXA-coated SiO2-NPs in the 
presence of 100 mM sugar inhibitors and different temperatures. 100 mM sugar inhibitors N-Acetylglucosamine, Mannose, 
or Galactose were incubated with 800 g/mL of  PMOXA -coated or PEtOXA- coated NPs for 20 minutes at either 0 °C or 37 
°C in 70% PS, washed and analyzed by SDS-PAGE (12%). Equal sample volumes were loaded onto an SDS-PAGE and stained 
by silver nitrate 
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Subsequently, we asked ourselves given that ficolin is in fact binding to our particles, given 
that N-Acetylglucosamine is able to compete with ficolin binding, and finally given that this 
binding has no effect on C3 activation, can we determine which binding site ficolin is using 
to bind the nanoparticles and can we determine a substrate that would compete with ficolin 
binding and disrupt C3. Furthermore, could ficolin enhance phagocyte capture of 
PMOXA/PEtOXA-coated NPs via complement opsonization, as it is the case for bacteria 
clearance? To answer these questions, we decided on using the competitor sucrose octasulfate 
(SOS), given that SOS can bind heparin similarly to ficolins, which are able to bind 
acetylated ligands, demonstrated by the carbohydrate N-Acetylglucosamine, but they are also 
capable of binding DNA, ligands shared with mouse ficolin-B, and with immobilized 
heparin, a highly sulfated molecule as well. Furthermore, it has been found SOS competes 
with ficolin binding, therefore we hypothesized SOS could compete with ficolin for binding 
to our coated particles.132 It has also been shown that SOS competes less efficiently for 
ficolin 2 binding to acetylated BSA than to heparin which indicates that acetylated ligands 
are displaced less easily.133 Therefore, we hypothesized that SOS and N-Acetylglucosamine 
might be binding ficolin in different binding sites. Using SOS as a binding competitor at 
varying concentrations, we probed its efficiency at preventing ficolin binding to PMOXA-
coated and PEtOXA-coated NPs. Interestingly, SDS-PAGE analysis revealed that SOS does 
not decrease ficolin binding (Figure 44) at either 3 concentration titrations of SOS. However, 
surprisingly, C3b was reduced with 20 mM SOS incubated with PMOXA-coated NPs and as 
low as 5 mM with PEtOXA-coated NPs. Given that there are 4 binding sites on ficolin, S1-4 
where it was identified that S3 binds sulfate and phosphate groups, and S1 was found to bind 
acetyl groups, we can conclude from our results that N- Acetylglucosamine is favored to bind 
at S1, and SOS, which is sulfated, preferably binds S3. Therefore, this indicates that our NPs 
bind to ficolin via S1 and therefore SOS, which binds at S3, would not affect binding. 
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However, the fact that C3b is reduced upon SOS introductions indicates that SOS-bound 
ficolin reduces complement, indicating the binding site S3 is potentially involved in 
nanoparticle recognition and immune responses. Possible other binding sites might play a 
role in complement activation as well as other protein-protein interactions that can arise upon 
changing polymers’ surfaces. Although we cannot speculate for sure which mode of action 
ficolin is involved in complement activation, we can conclude binding to particles does not 
occur via the S1 binding site and that ficolin binding through this site does not affect 
complement activation. Furthermore, binding is particle specific where even slight variations 
in polymer chains contribute to significant alterations in biological function. It has been well 
documented that nanoparticle surface camouflaging with polymers such as PEG or 
polyoxazolines can provide stealthing effects to impede macrophage recognition, thus 
increasing the particle’s longevity in the blood. However, studies have also shown that these 
polymers may catalyze complement depending on surface polymer configuration. Therefore, 
altering the polymer’s architecture on the particle’s surface from a flat to mushroom- brush 
configuration, was seen to switch complement from the classical, C1q-dependent pathway to 
a lectin pathway in human serum.134 Binding sites are dependent on the particle’s repetitive 
recognition patterns on the surface which can be altered by changes in surface density, 
possibly creating new binding sites which may affect complement activation. Previously, it 
was shown that PEG chains share structural similarities with d-mannose/ N-
Acetylglucosamine in the terminal regions, thus indicating when in mushroom-brush 
configuration, PEG is able to form dynamic “pathogen-mimicking” clusters which allows for 
lectin pathway activation via MBL, ficolin, or CL11 docking. Yet, not only was it shown that 
the surface of the particle dictates which complement pathway is activated, it was also shown 
that lectin pathway activation can be modified through binding of different lectin pathway 
initiating molecules such as favoring MBL over Ficolin 2 or visa versa.135 In addition, it was 
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also shown that although ficolin 3 does not recognize substrates in vivo, it is the most 
abundant ficolin in human serum and the most potent activator of the lectin pathway in 
vitro.40 Therefore, not only is the surface of the particle important at dictating lectin 
activation but also the initiating molecules themselves play an important role in determining 
complement initiation. For these reasons, our results are in line with previous literature to the 
extent that ficolin binds preferentially to the surface of PEtOXA-coated NPs and to a lesser 
extent to PMOXA-coated NPs, where the different bindings can be attributed to variations in 
polymer chains. PMOXA-coated NPs are acylated proteins, similar to N-Acetylglucosamine, 
whereas PEtOXA-coated NPs are propanoyl proteins thus possibly binding alternative 
binding sites. However, our results diverge from previous literature where we found that 
although ficolin docking is inhibited in PMOXA-coated NPs, C3b is not, indicating 
complement activation is independent of ficolin binding. Perhaps this high level of ficolin is 
just an artifact of the serum itself as pig serum is found to have ficolin levels more than 10X 
higher than in humans or mice. This could explain the intense ficolin docking to our particles 
via weaker binding interactions, yet, does not affect C3 cleavage and complement activation. 
Furthermore, as ficolin is known to bind like C1q does, directly acting as an opsonin for 
apoptotic cells clearance, ficolin might also bind the coated particles in such a way, or 
perhaps direct binding of C1q is responsible for particle clearance in pig serum as with 
human serum or could complex with ficolin in order to mediate binding. Further experiments 
are required to fully investigate the role of ficolin in particle binding and capture however the 
importance of our results lies in the fact there are distinct differences between PMOXA-
coated and PEtOXA-coated nanoparticle uptake as well as the way in which they interact and 
activate potential complement pathways. This distinction is not only physio-chemical specific 
to the polymer, but to also the species in which the polymer is tested in.  
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Figure 44: SDS-PAGE analysis of the pattern of PS proteins adsorbed on PMOXA-coated  and PEtOXA-coated  SiO2-NPs in 
the presence of different concentrations of sucrose octasulfate (SOS) inhibitors. 1.5 mM, 5 mM, or 20 mM SOS inhibitors 
were incubated with 800 g/mL of  PMOXA-coated  and PEtOXA-coated  SiO2-NPs for 20 minutes at 37 °C in 70% PS, 
washed and analyzed by SDS-PAGE (12%). Equal sample volumes were loaded onto an SDS-PAGE and stained by silver 
nitrate. Complement C3b is marked by blue arrows. 
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Conclusions: 
 
Nanoparticles are undoubtedly an important tool, utilized in a wide variety of biomedical 
fields and theranostic nanomedicine from imaging and sensing to drug delivery. However, in 
order to optimize their efficacy, nanoparticle platforms must be designed in a way which 
limits cytotoxicity and optimizes biocompatibility for safe medical use. We have 
demonstrated coating ORMOSIL nanoparticles with PMOXA and PEtOXA polymers, which 
provides “stealthing” effects in murine conditions, effectively activates the complement 
system in human and pig environments. We have shown the extent of C3, C4b, C9, and 
properdin deposition on PEtOXA-coated NPs and to a lesser extent PMOXA-coated NPs in 
human serum, which correlates to the extent of phagocytosis by human macrophages. In 
addition, C3 deposition in pig serum with PMOXA-coated and PEtOXA-coated NPs along 
with functional studies, exhibit similar activation as in human conditions although mouse 
serum does not seem to activate complement given the lack of C3 activation supported by 
proteomic and functional studies. We suggest in order to probe the compatibility of the 
nanomaterial with the human immune system preclinically, it is highly beneficial to do so 
with human materials, instead of depending on non-human species such as murine models. 
Given that Poly(2-oxazoline) (POZ) has been proposed as an alternative polymer for PEG as 
they are easier to synthesize and can incorporate varying monomers to tailor the nanoparticle 
for specific applications, future perspective should focus on further modification of POZs in 
order to evade recognition by components of the human innate immune system.  
 
 
 
 123 
Section 2: Gold 
Physiochemical characterization of Au-NPs  
Because of the versatility and physicochemical properties of gold nanoparticles, new 
opportunities for therapeutic treatments have been of increasing focus. At first, when the 
nanoparticles are introduced into circulatory system, the plasma proteins are the first to form 
the corona, dominated by albumin, the most abundant protein in serum (55%) along with 
apolipoproteins, fibrinogen, and immunoglobulins. However, similar to silica nanoparticles, 
when exposed to plasma or serum, unwanted side effects occur from protein interactions with 
the particle’s corona triggering immunogenicity, cytotoxicity, platelet aggregation, or altering 
blood coagulation pathways.97 Gold particles themselves can trigger coagulation as the van 
der Waals forces between two metal nanoparticles leads towards coagulation or they can 
trigger coagulation via interactions with plasma proteins based on their surface charge. For 
example, anionic surfaces initiate coagulation due to the fact that the intrinsic coagulation 
pathway is activated by anionic physiological surfaces, extracellular matrix, or aggregated 
platelets. Our initial characterization of four gold nanoparticles can be seen in Figure 45 
where gold nanoparticles, roughly 10 nm in diameter, were conjugated with different thiols 
thus giving rise to four, separately charged particles: positive (cationic), negative (anionic), 
neutral, and zwitterionic. Nanoparticles were analyzed by NMR in situ, their core 
characterized by TEM analysis, and the organic monolayer was studied by thermogravimetric 
analysis (data not shown). In contrast with ORMOSIL particles where the surface 
characteristics remained similar except for the polymer, gold nanoparticles were designed so 
their chemical-physical features would be altered and therefore allow us to probe the effects 
of charge, thiol density…etc on our system.  
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We have previously demonstrated the importance of corona composition on the ultimate fate 
of nanosystems as well as predicting the way in which the immune systems responds to 
particle administration. Furthermore, although the complement and the coagulation systems 
are two distinct protein networks, they both are involved in the first line of defense against 
pathogens and the inflammatory response as well as having a few points in the cascade which 
link these two pathways together. Therefore, we analyzed the protein corona formed on the 
Figure 45: Chemical structures of the thiols constituting mixed-monolayer gold 
nanoparticles.   
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10 nm cationic, anionic, neutral, and zwitterionic nanoparticles incubated for 10 min at 37 °C 
in human plasma supplemented with 15 mM calcium chloride to activate the coagulation 
system in order to elucidate the protein differences in a pro-coagulant environment. 
Interestingly, to date, the coagulation cascade has never been probed previously using 
conditions which mimic those seen in the human system, for example, with full calcium, 
required for coagulation to occur as human plasma is supplemented with citrate or heparin in 
order to be obtained. Thus, although quite experimentally difficult as margins of error must 
be in the seconds, we decided to probe coagulation activation by the four gold nanoparticle in 
human plasma resembling the solution which the nanoparticle will first encounter upon 
administration in the human body.  
 
Following NP recovery and thorough ultracentrifugation washings, gel electrophoresis under 
non-reducing conditions was performed, where the proteins were revealed by silver nitrate 
staining and further analyzed by MS spectrometry after in-gel digestions of major 
electrophoretic bands obtained in the SDS-PAGE. The major electrophoretic bands are quite 
distinct between the four gold particles as with SiO2-NPs, however the amount of proteins are 
much reduced (Figure 46). This is likely because the gold nanoparticles are 10 times smaller 
in diameter and smaller NPs experience greater changes in hydrodynamic diameter with the 
formation of the protein corona as well as clot strength decreasing with particle size. 
Furthermore, it was demonstrated in vitro that neutrally charged particles have a much lower 
opsonization rate than charged particles and the kinetics of the corona formation depends 
greatly on physical-chemical properties of the particle, such as size and surface ligands.136 
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Band 
# 
Protein MW (kDa) 
1 Prothrombin 68.7 
2 Apolipoprotein H 38 
3 C4b 190 
4 Prothrombin 68.7 
5 Hyaluronan-binding protein 62 
6 Prothrombin 68.7 
7 Prothrombin 68.7 
8 Apolipoprotein A 28.3 
 
Table 3: Serum proteins from different species bound to 
PEtOXA amorphous silica nanoparticle surface identified by 
tandem mass spectrometry analysis. 
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Figure 46: SDS-PAGE analysis of the pattern of proteins adsorbed onto anionic, cationic, neutral, and zwitterionic Au-NPs. 200 g/mL gold nanoparticles 
were incubated for 10 minutes at 37 °C in 70% citrated human plasma supplemented with 15 mM CaCl2, washed and analyzed by SDS-PAGE (12%) in 
reducing conditions. Equal sample volumes were loaded onto an SDS-PAGE and stained by (A) silver nitrate and (B) Coomassie to undergo in gel 
digestion for LC MS/MS. Red brackets indicate bands which disappeared in no Ca2+ conditions and green brackets indicate bands which appeared in no 
calcium conditions but were absent in full calcium plasma. The main protein bands found (arrows), are labeled by their rough apparent molecular 
weight in kDa (pxx). 
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 The purple color which is smeared throughout the upper lane for anionic particles is due to 
high molecular weight complexes of aggregated particles which under normal circumstances 
would not leave the loading lane, but is forced to travel down its lane due to its negative 
charge, leaving parts of the complex behind as it does so. Normal gold nanoparticles are a 
deep red color but as they become more aggregated, they turn more purple/blue. The major 
electrophoretic bands common between all four particles are p220, p110, p100, p70, p50, 
p42, and p30. However, there are differences in intensities as seen for p42 which is more 
prominent for anionic nanoparticles than for the others. This is also the case for p110 and 
p100 which is more intense for cationic NPs. The bands at p35 for anionic and p60 for 
cationic are the two distinct bands which are unique to those particles. Furthermore, p35 
disappears when calcium is absent, indicated by the red box, but as the band is not able to be 
stained using Coomassie, mass analysis was not able to be performed on this band. Although 
p60 is specific for cationic, it however is not calcium dependent and is present even when 
calcium is chelated. Interestingly, the band corresponding to p100 which is quite faint with 
anionic NPs, appears much more intense without calcium.  
 
In order to determine the polypeptide composition of proteins bound to the particles and 
therefore specific interactions of specific coatings, we decided to perform semi-quantitative 
estimations by label-free methods after liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis (Table 3). The main corona components included the expected 
common circulating blood proteins, coagulation and complement factors, such as 
prothrombin, C4b, and Apo A. Proteins bound to anionic NPs which were detectable with 
Coomassie staining included Apo H (38 kDa) at p42 whereas p60 for cationic was identified 
as Hyaluronan-binding protein (62 kDa), which is also known as Factor VII Activating 
Protease (FSAP).  
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FSAP is a single chain zymogen which undergoes autoactivation to be converted to a two 
chain form connected by a disulfide bond and is proteolytically active, consisting of a 46 kDa 
heavy chain and a 29 kDa light chain. The heavy chain is further cleaved in the N-terminal 
section around 18 kDa. FSAP activates the coagulation Factor VII, thus instigating 
coagulation independently of tissue factor as well as being able to cleave fibrinogen and 
high-molecular-weight kininogen.137 Given the specificity of FSAP to cationic particles, we 
decided to perform a dose dependent gel to determine the binding specificity of FSAP to the 
gold Au-NPs (Figure 47). In non-reducing conditions, as expected, there is only one band 
corresponding to FSAP single chain at 60 kDa visible only for concentrations above 200 
ug/mL. However, in reducing conditions, first fragments corresponding to the heavy chain of 
FSAP can be seen at 45 kDa at 50 ug/mL as well as second and third fragments at 29 kDa 
and 18 kDa at 100 ug/mL and 25 ug/mL respectively. This indicates FSAP is activated in 
plasma containing cationic particles. We wanted to validate the SDS PAGE findings using 
western blot against FSAP which continued to support the fact in reducing conditions, FSAP 
is activated, however the fragments can only be seen at 50 ug/mL or higher (Figure 48).  
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Figure 48: SDS-PAGE analysis of the pattern of FSAP proteins adsorbed on cationic Au-NPs. Cationic 
gold nanoparticles were incubated at the indicated concentrations for 15 minutes at 37 °C in 70% 
citrated human plasma supplemented with 15 mM CaCl2, washed and analyzed by SDS-PAGE (12%) in 
reducing and non-reducing conditions. Equal sample volumes were loaded onto an SDS-PAGE and 
stained by silver nitrate. 
Figure 47: Western Blot analysis of FSAP activation by varying concentration of cationic Au-NPs. Different concentrations of 
Au-NPs were incubated for 10 minutes at 37 °C in 70%. Equal samples volumes of washed pellets were analyzed by SDS-
PAGE (12%). After transfer to 0.45 μm nitrocellulose the blotted bands were immunodetected with a specific rabbit 
polyclonal anti FSAP Ab and subsequently visualized with peroxidase labeled goat anti-rabbit IgG antibodies. 
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Because coagulation is very much time dependent138, we decided to characterize the protein 
corona formation in 70% human plasma supplemented with 15 mM calcium chloride 
incubated with 200 g/mL cationic particles at varying time points. Comparing samples with 
particles in reducing and non-reducing conditions to control samples without particles 
incubated for the same time periods, we found even at time zero, FSAP is present as well as 
activated FSAP fragments, which are not present in non-reducing conditions (Figure 49 and 
Figure 50). This can be explained by autoactivation of FSAP which is promoted by 
endogenous Glycosaminoglycans (GAGs), such as heparin.139 FSAP is also known to release 
nucleosomes from secondary necrotic cells via a plasmin-like protease which is induced by 
human plasma.140 Nucleosomes are roughly 10 kDa in size where only histones and 
nucleosomes can activate FSAP in plasma. H1 and H3 are able to be degraded by FSAP. 141 
Furthermore, as histones are highly positively charged where highly negative plasma proteins 
including heparin, pentraxin 3, C-reactive protein, and inter- α inhibitor protein are all able to 
bind to and neutralize them, we propose FSAP is binding to our 10 nm cationic particles 
mistaking them for nucleosomes. As we can see in Figure 49, Densitometric analysis of all 
activated fragments of FSAP deposition on the cationic Au-NPs shows that intensity of FSAP 
fragments increases with incubation time which is consistent with previous studies.  
Figure 49: Densitometric quantification (arbitrary units) of SDS PAGE analysis of FSAP’, FSAP”, and FSAP”” binding to 
engineered NPs (200 g/mL) on incubation with 15 mM calcium supplemented citrated human plasma. Following 
SDS PAGE,  semi-quantitative estimation of the relative amount of the main FSAP protein bands found  were 
determined by densitometry and represented in histograms. 
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Given these findings, we decided to probe the kinetics of coagulation in a concentration 
dependent manner. Figure 51A demonstrates a biphasic curve of coagulation activation by 
zwitterionic, neutral, and anionic particles where at the lower concentrations to 25 ug/mL 
activated coagulation, however at 25 ug/mL they became slightly less activating, and as the 
concentration increased above 50 ug/mL, the trend leveled off. Similarly, silica nanoparticles 
shown in Figure 51B, steadily activated coagulation as the concentration increased. 
Conversely, cationic Au-NPs showed a biphasic curve where at concentrations below 100 
ug/mL, the particles enhanced coagulation whereas above 100 ug/mL the nanoparticles 
became inhibitory. Thus, despite the proposed activation role of FSAP in the coagulation 
cascade and according to some studies in the C cascade, FSAP-gold NPs complexes inhibited 
the clotting time of human isolated plasma and did not generate C3a after a short (max 15 
min) incubation time. 
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Figure 50: SDS-PAGE analysis of the pattern of FSAP proteins adsorbed on cationic Au-NPs. (A) Cationic Au-NPs (200 g/mL) 
were incubated for the indicated amount of time at 37 °C in 70% HP, washed and analyzed by SDS-PAGE (12%). Equal sample 
volumes were loaded onto an SDS-PAGE and stained by silver nitrate. (B) Samples were compared to conditions without 
particles and represented our control groups.   
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Conclusions: 
In line with previous thinking, the surface charge of the particle is important for dictating the 
ultimate function of the particle. We have shown specific protein binding favoring one charge 
over another based solely on surface charge. Anionic appears to favor Apo H whereas 
cationic particles bind Apo A and FSAP. In addition, further probing the effect of FSAP and 
particle-protein binding, we have found FSAP and activated fragments of FSAP are in fact 
bound to the surface of the cationic particles when incubated in human plasma supplemented 
with calcium. The levels of FSAP increases with particle concentration as well as plasma 
incubation time. However, although FSAP is an activator of coagulation factor VII, FSAP-
gold NPs complexes inhibited the clotting time of human isolated plasma. Because we looked 
at plasma supplemented with calcium, parameters which mimic those in the human body, we 
can understand more accurately the way in which particles activate the immune system when 
administered into the body. Similarly to ORMOSIL outcomes, gold nanoparticles must be 
tested in conditions which most closely represent those seen clinically or the particles could 
potentially have severely adverse reactions in patients.  
A B 
Figure 51: Coagulation kinetics of clot formation in citrated human plasma with 15 mM CaCl2. Curves tracking changes in 
the clot formation via changes in optical density of A) Anionic, neutral, and zwitterionic Au-NPs and B) Cationic Au-NPs 
and SiO2-NPs in relation so control samples (black line). 
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Chapter 3: Methods 
1. Nanoparticles synthesis and characterization 
Solvents were purified by standard methods. All commercially available reagents and 
substrates were used as received. Silica nanoparticles are synthesized by base catalyzed 
polymerization of silicon alkoxides in an ethanol/water solution (the Stober protocol). 
PEGylated ORMOSIL nanoparticles are prepared by ammonia-catalyzed co-polymerization 
of vinyltriethoxysilane (VTES) following a modification of the Prasad procedure in an 
aqueous solution of co-micelles of a non-ionic surfactant and n-butanol. O-(2-aminoethyl)-
O’-methylpolyethylene glycol (MPEG2000-amine, 150 mg, 0.075 mmol, 1 equiv) is 
dissolved in 1.5 mL of dry dichloromethane. Then 42 mg of K2CO3 (0.300 mmol, 4 equiv) 
and 98 μl of 2-(4-chlorosulfonylphenyl) ethyltrimethoxysilane (50% solution in 
dichloromethane, 0.15 mmol, 2 equiv) are added. Stirring occurs for 3 hr at 40 °C, in a 
Schlenk tube under N2 atmosphere. Following filtration and evaporation, the residue is 
dissolved in 1 mL of ethanol. 14 mL of cold tert-butyl methyl ether and centrifuged at 4 °C 
precipitates the product. Following repetition 3 times of purification, the precipitate is dried 
under vacuum (85%). PMOXA and PEtOXA coated ORMOSIL nanoparticles are prepared 
by N-(2-aminoethyl)-poly(2-methyloxazoline) (PMOXA3800-amine, 363 mg, 0.097 mmol, 1 
equiv) and equivalent for PEtOXA is dissolved in 1.5 mL of dry dichloromethane. Then 54 
mg of K2CO3 (0.388 mmol, 4 equiv) and 126 μl of 2-(4-chlorosulfonylphenyl) 
ethyltrimethoxysilane (50% solution in dichloromethane, 0.194 mmol, 2 equiv) are added. 
Stirring occurs for 3 hr at 40 °C, in a Schlenk tube under N2 atmosphere. Following filtration 
and evaporation, the residue is dissolved in 1 mL of ethanol. 14 mL of cold tert-butyl methyl 
ether and centrifuged at 4 °C precipitates the product. Following repetition 3 times of 
purification, the precipitate is dried under vacuum (80%). Ultrafiltration was used to filter 
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uncoated particles using a 50 mL Amicon Ultra 15 centrifugal filter, using a cellulose 
membrane with a cut-off of 100,000 Da. For purification of coated particles, centrifugation 
(12000 rpm, 10 min, 3 times) in 15 mL centrifuge tubes was used. Dynamic Light Scattering 
(DLS) and UV-Visible spectra and kinetic traces were used to confirm the formation of the 
nanoparticles, hydrodynamic particle size, and zeta potential on a Malvern Zetasizer Nano-S 
equipped with a HeNe laser (633 nm) and a Peltier thermostatic system for DLS, and with a 
Cary 50 spectrophotometer equipped with thermostated multiple cell holders for UV-vis. 
Measurements were performed at 25 °C in water or PBS buffer at pH 7.0. Transmission 
Electron Microscopy (TEM) was recorded on a Jeol 300PX instrument where a drop of 
sample was allowed to evaporate in a sample grid. NMR spectra were recorded using a 
Bruker AV III 500 spectrometer operating at 500 MHz for 1H, 125.8 MHz for 13C. Chemical 
shifts are reported relative to internal Me4Si. MALDI spectra were recorded with an AB 
SCIEX MALDI TOF/TOF, and α-Cyano-4-hydroxycinnamic acid (CHCA) was used as the 
matrix. Thermogravimetric analysis (TGA) was used to measure the stoichiometry to 
calculate the percent mass of the substance in the sample as well as the polymer footprint by 
running 100 μl of the nanoparticle solution, using a Q5000 IR model TA instrument from 30 
to 1000 °C under a continuous air flow.  
Rhodamine labeling of particles occurred following previous protocols.142 Covalent bonding 
of the fluorophore to silica occurred via the functionalization of the rhodamines with a 
triethoxysilane group. Synthesis occurred by dissolving the following in 4.16 mL of mQ 
water, in a thermostated reaction vessel at 30 °C: 833 μl of Brij35P (30 mM, pH 2), 150 μl of 
n-butanol, rhodamine B-Si (10 mM in DMSO) and the appropriate amount of vinyl-
triethoxysilane (VTES). For 30 min, stirring occurred and then 10 μl of aqueous ammonium 
hydroxide (15% solution) was added. Another stirring occurred for 2 hr at 30 °C, where the 
particles were pelleted and collected by centrifugation and washed with 3 x 5 mL of milliQ 
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water (12000 rpm, 10 min, 3 times). Conversely, uncoated particles were transferred to a 50 
mL Amicon Ultra 15 centrifugal filter, followed by the addition of 10 mL of mQ water and 
centrifuged until reaching a final volume of 5 mL (2900 rpm, 10 min, 3 times). Final 
solutions are filtered using a 0.45 μm membrane filter and stored at 4 °C. Rhodamine 
concentrations were in the 0.1-0.3% w/w range determined from absorbance  = 567 nm 
(after scattering contribution subtraction) using the molar extinction coefficient () of 9.5×104 
cm-1M-1.  
2. Isolation and culture of cells. 
2.1 Human Peripheral blood mononuclear cells (PBMC) 
PBMC were isolated from buffy coats, obtained anonymously from healthy donors (Padova, 
Italy), by centrifugation over a Ficoll-Hypaque (Amersham Biosciences, UK) step gradient 
followed by a Percoll (Amersham Biosciences, UK) gradient and suspended in RPMI-1640 
(Invitrogen, CA, USA) supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen, CA, USA). For human PMNs purification, after centrifugation of buffy coats 
through Ficoll-Hypaque gradient, red blood cells contained in the bottom fraction were 
eliminated by dextran sedimentation, followed by hypotonic lysis and washing with PBS. 
The percentage of contaminating cells were <5%. Unless otherwise specified, monocytes and 
PMNs were kept at 37 °C in a humidified atmosphere containing 5% (v/v) CO2 in RPMI-
1640 supplemented with antibiotic and 10% FCS (Euroclone, Italy, endotoxin <0.3 EU/mL). 
To differentiate macrophages, human monocytes were incubated for 7 days with 100 ng/mL 
of macrophage colony-stimulating factor (M-CSF, Peprotech, UK) in RPMI 1640 
(Invitrogen, CA, USA) supplemented with 20% (v/v) fetal calf serum, FCS, (Euroclone, 
Italy, endotoxin < 0.3 EU/mL), and antibiotics (100 U/mL penicillin, and 100 μg/mL 
streptomycin). 
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2.2 Pig monocyte and macrophage cell isolation 
Primary pig monocytes and macrophages were prepared following an established protocol.143 
Venous blood was taken from healthy pigs and immediately anticoagulated with 3.8% tri-
sodium citrate (9:1 of blood: citrate) for a total of ~500 mL total blood collection. The Buffy 
coat was extracted by layering aliquoted blood onto PBS in 50 mL flacon tubes and 
centrifuged for 15 min at 1,200 g without brake. Buffy Coat was further diluted and layered 
(25 mL) over aliquots 15 mL lymphoprep while inclining the falcon tube as to not mix the 
blood. Centrifuge for 25 min at 1,200 x g with no brake and remove the mononuclear cell 
layer into a fresh 50 mL centrifuge tube. Add PBS and centrifuge 10 min at 600 x g with 
brake on in order to remove any remaining Ficoll and resuspend the pellet in PBS or RPMI. 
Centrifuge at 400 x g with brake on. Resuspend the pellet RPMI, count the cells in a 
haemocytometer where 1 to 2.10e6 PBMC can be obtained per mL of pig whole blood.  
To differentiate macrophages, pig monocytes were prepared as with human monocytes where 
they were incubated for 7 days with 100 ng/mL of macrophage colony-stimulating factor (M-
CSF, Peprotech, UK) in RPMI 1640 (Invitrogen, CA, USA) supplemented with 20% (v/v) 
fetal calf serum, FCS, (Euroclone, Italy, endotoxin < 0.3 EU/mL), and antibiotics (100 U/mL 
penicillin, and 100 μg/mL streptomycin).  
2.3 Mouse macrophage cell isolation 
Primary mouse macrophages were prepared and isolated from mice bone marrow. Mice were 
sacrificed and following dissection, the pelvic and femoral bones were collected and all the 
remaining tissue on the bones were removed. The ends of the bones were cut off, and bone 
marrow was expelled via washing with Iscove’s modified Dulbecco’s medium (IMDM, 
Thermo Fisher Scientific, MA, USA). Red blood cells were then lysed with ammonium-
chloride-potassium lysis buffer (5 min, RT), leukocytes were recovered, and mononuclear 
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phagocytic precursor cells were propagated for 7 days with 10 ng/mL M-CSF (Miltenyi, 
Germany) in RPMI1640 with 10% FBS medium. One-half of the medium was replaced with 
fresh medium after 4 days. Adherent cells were detached by trypsin (0.5%) digestion.  
The RAW 264.7 is a macrophage-like cell line derived from tumors induced in male BALB/c 
mice by the Abelson murine leukemia virus. Growth medium was warmed for 15 to 20 min 
in a 37° C water bath and the vial of RAW cells were thoroughly immersed in water bath 
until only partially frozen fraction remained. Cells were extracted with a pipette and into a 75 
cm2 flask. Cells were maintained at 37 °C, in a humidified atmosphere, with 5% CO2. After 
the cells have adhered, approximately 6 hours, aspirate the old medium and add 15 mL of 
fresh medium. When the cells are 80% confluent, they were passed into a new vessel with 
fresh medium.  
 
3. Serum preparation 
3.1 Human  
Venous blood was taken from healthy human volunteers (Padova, Italy) and collected into 
BD Vacutainer clot activator tube (Becton Dickinson, NJ, USA). Experiments with human 
sera were performed under local guidelines. Clotting was performed at room temperature, 
where blood samples were then centrifuged at 1,250g for 5 min to obtain sera. Collected sera 
were aliquoted, frozen in liquid nitrogen, and stored at -80 °C. Before use, all serum was 
thawed at 37 °C for 30 min.  
3.2 Mouse  
Whole blood from 12 adult, healthy male and female BALB/c mice were collected via 
severing the jugular vein following anesthetization. Clotting and retraction was allowed to 
take place spontaneously at room temperature (around 20 °C) following procedures outlined 
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in Lachmann.129 The initial centrifugation was carried out at 3000 g for 5 min at room 
temperature and the serum extracted. A second, high speed, centrifugation was performed to 
remove all red and white cell fragments at 20,000 g for 2 min. The serum was removed from 
this second centrifugation, aliquoted and frozen with liquid nitrogen, and stored at -80 °C for 
future use. Before use, all serum was thawed at 37 °C for 30 min. 
 
3.3 Porcine 
Venous blood was taken from healthy pigs where clotting and retraction was allowed to take 
place spontaneously at room temperature (around 20 °C) following procedures outlined in 
Lachmann.129 After clotting at room temperature, blood samples were centrifuged at 1,250g 
for 5 min to obtain sera. Collected sera were aliquoted, frozen in liquid nitrogen, and stored at 
-80 °C. Before use, all serum was thawed at 37 °C for 30 min.  
 
4. Confocal Microscopy  
Confocal microscopy filters out-of-focus light creating images which have higher contrast, 
clarity, and detection sensitivity. This is achieved as the specimen is optically sectioned with 
a shallow depth of field (0.5–1.5 μm), allowing information to be collected from a well-
defined plane. One or more points of laser light is sharply focused in all three directions: x, 
y, and z, and then passes through a pinhole in front of the camera to remove out-of-focus 
light. In order to detect nanoparticles with fluorescence techniques, ~100 nm diameter 
nanoparticles were conjugated with rhodamine dye (red, λexc 570 nm and λem 590 nm). 
During synthesis, the nanoparticles allow for covalent grafting of the dye to the silica, 
hindering the possibility of dye leaking from the nanoparticles. 
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Intracellular distribution of fluorescent NPs was assessed by confocal microscopy where 
human macrophages (2x106) were seeded on glass slides and washed with PBS (Invitrogen, 
CA, USA). 70% (v/v) human serum (HS), pig serum (PS), or mouse serum (MS), were 
incubated with 800 g/mL (unless otherwise stated) uncoated, PEGylated, PMOXA-coated, 
or PEtOXA-coated NPs first in the absence of cells for 20 min at 37 °C and then incubated 
with cells after a 10-fold dilution in protein-free culture medium for 3 h at 37 °C. The media 
was removed following incubation, and cells were washed with PBS, and incubated for 30 
min with 75 nM LysoTracker Green DND-26 (Invitrogen, CA, USA) for endolysosomal 
staining and then directly analyzed by confocal microscopy (Leica SP2, Germany). ImageJ 
software were used to analyze images. For control experiments NP were incubated in PBS.  
 
5. Flow Cytometry 
70% (v/v) human serum (HS), pig serum (PS), or mouse serum (MS), were incubated with 
800 g/mL (unless otherwise stated) uncoated, PEGylated, PMOXA-coated, or PEtOXA-
coated NPs first in the absence of cells for 20 min at 37 °C and then incubated with cells after 
a 10-fold dilution in protein-free culture medium for 3 h at 37 °C.  Cells were than washed 
with PBS, resuspended in FACS buffer (1% FBS in PBS), and analyzed by cytofluorimetry 
(FACSCantoII, Becton Dickinson, NJ, USA). Data were analyzed by FACSDiva software 
(Becton Dickinson, NJ, USA) and expressed as MFI (mean fluorescence intensity) values, 
normalized based on intrinsic quantum yield of different NPs types and batches. Certain 
experiments were performed with 10 mM EGTA/2 mM MgCl2 or 10 mM EDTA or with 25 
mM-100 mM of D-mannose, N-acetylglucosamine (inhibitors of lectin complement pathway) 
or D-galactose (as control). Dilution occurred as above in culture medium.  
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6. Proteomics: 
6.1 Shotgun 
Sera were thawed by incubation under stirring at 37 °C for 30 min. 75% (v/v) serum was 
further incubated with 800 ug/mL (or as stated) NPs under stirring at 37 °C for 20 min. The 
NP-serum mixture was washed via centrifugation and resuspension three times with 1 mL of 
ice-cold PBS pH 7.4, or PBS supplemented with 10mM EDTA2+ or 10mM EGTA2+ /2.5mM 
MgCl2 or with D-mannose, N-acetylglucosamine (inhibitors of lectin complement pathway) 
or D-galactose (as control), and centrifuged for 30 min, 21,000 g at 4 °C. Determination of 
the amount of protein was done according to the standard Bradford Assay (Biorad, CA, USA) 
with Bovine serum albumin (BSA) as a standard. Following incubation and centrifugation, 
NP-protein pellets were resuspended in 8 M urea/50 mM NH4HCO3 (Sigma, MO, USA). 5 
mM TCEP (Sigma, MO, USA) was added to reduce disulfide bonds for 30 min, and alkylated 
with 40 mM iodacetamide (Fluka, Mexico) at room temperature in the dark. The content of 
urea was brought to 6 M with 50 mM NH4HCO3, and 1 to 100% (w/w) of LysC (Promega 
Co., WI, USA) was added to each sample for 6 hr at 37 °C. Following experiment (20 min 
incubation with NPs at 37℃, centrifuge 3x at 13,000 at 4℃) resuspend final pellet in 40 ul of 
8 M Urea in 50 mM NH4HCO3 (Sigma, MO, USA). 5 mM TCEP was added to reduce 
disulfide bonds for incubate for 30 min at RT, and alkylated with 40 mM iodacetamide 
(Fluka, Mexico) for 45 min at RT in the dark. The content of urea was brought to 6 M with 
50 mM NH4HCO3, and 1:100% (w/w) of LysC (Promega Co., WI, USA) was added to each 
sample for 6 h at 37 °C. The content of urea was brought to 1.2 M by dilution with 50 mM 
NH4HCO3.1:50% (w/w) of sequencing grade modified trypsin (Promega Co., WI, USA) was 
added to samples where digestion was carried out at 37 °C overnight. Samples were 
centrifuged at 18,000g for 30 min at 4℃ to recover supernatant. Samples were then dried 
under vacuum and suspended in 24 μL of 3% (v/v) acetonitrile/0.1% (v/v) formic acid. Next, 
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2 μL of each samples were analyzed by LC-MS/MS on a LTQ-Orbitrap XL mass 
spectrometer (ThermoFisher Scientific) coupled online to a nano-HPLC Ultimate 3000 
(Dionex –ThermoFisher Scientific) as described earlier.144 Peptides were loaded onto a pico-
frit column (New Objective, NJ, USA) packed in-house with C18 material (Aeris Peptide 3.6 
mmXBC18; Phenomenex, CA, USA) using a flow rate of 8 μL/min, and separated at a flow 
rate of 250 nL/min with a linear gradient of acetonitrile/0.1% (v/v) formic acid from 3% to 
40% in 45 min. Ion source capillary temperature was 200 °C and spray voltage was set to 3% 
to 40% in 45 min. Ion source capillary temperature was 200 °C and spray voltage was set to 
1.2-1.3 kV. The instrument operated in a data-dependent mode with a full scan at 60,000 
resolution on the Orbitrap followed by MS/MS fragmentation in the linear trap of the four 
most intense ions.  
 
6.2 In gel digestion and Mass-spec 
Following initial experiments described above, and SDS PAGE gels (Section 7), the bands, 
stained with Coomassie, were excised from the gel and washed with 50% v/v acetonitrile 
(ACN) in 0.1 M NH4HCO3 and vacuum-dried. The proteins were reduced for 30 min at 56 °C 
with 10 mM DTT in 0.1 M NH4HCO3. The DTT solution was replaced with 55 mM 
iodacetamide in 0.1 M NH4HCO3 for 20 min at 25 °C in the dark. 50% ACN in 0.1 M 
NH4HCO3 was used to wash the dried gel pieces and then they were swollen in 15 μL of 
digestion buffer containing 25 mM NH4HCO3 and 12.5 ng/μL trypsin (Promega Co., WI, 
USA) and incubated overnight at 37 °C. Following the protocol described by Kin et al, 
tryptic peptides were extracted and analyzed by LC-MS/MS on a 6520 Q-TOF mass 
spectrometer (Agilent Technologies, CA, USA) coupled to a chip-based chromatographic 
interface. MALDI spectra were recorded with an AB SCIEX MALDI TOF/TOF, and α-
Cyano-4-hydroxycinnamic acid (CHCA) was used as the matrix. MS/MS spectra were 
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searched against the SwissProt database, with the Mammalia taxonomy filter (June 2014 
version, Taxonomy Mammalia, 66370 peptide entries). Enzyme specificity was set to 
trypsin/P with 2 missed cleavages, using a mass tolerance window of 20 ppm for parent mass 
and 0.6 Da for fragment ions. Carbamidomethylation of cysteine was set as fixed 
modification and methionine oxidation as variable modification. Proteins were considered 
positive hits if at least 2 peptides per protein were identified with high confidence (p < 0.05).  
 
7. SDS-PAGE (PolyAcrylamide Gel Electrophoresis) and Western Blots 
Sera were thawed by incubation under stirring at 37 °C for 30 min. 70% (v/v) serum was 
further incubated with NPs under stirring at 37 °C for 20 min. The NP-serum mixture was 
washed via centrifugation and resuspension three times with 1 mL of ice-cold PBS pH 7.4, or 
PBS supplemented with 10 mM EDTA2+ or 10 mM EGTA2+ /2.5 mM MgCl2 or with D-
mannose, N-acetylglucosamine (inhibitors of lectin complement pathway) or D-galactose (as 
control), and centrifuged for 30 min, 21,000 g at 4 °C. Pellets were dissolved in 25 μL of 
loading sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% w/v SDS, 25% v/v glycerol, 0.01% 
w/v bromophenol blue, with or without β-mercaptoethanol). After heating at 95 °C for 5 min 
equal volumes (12 μL) of samples were subjected to SDS-PAGE in 12% acrylamide gels. 
Mock samples were always performed with serum protein in the absence of NPs exactly the 
same way the previous samples were prepared, to estimate nonspecific protein background. 
Proteins were stained with silver nitrate or with colloidal Coomassie G-250 in case of mass 
spectrometry analysis.  
 
As for Gold NPs, anionic, cationic, neutral, or zwitterionic Au-NPs at indicated 
concentrations were incubated for 10 min at 37 °C in 70% citrated human plasma 
supplemented with 15 mM CaCl2. 
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7.1 Colloidal Coomassie G-250 Staining  
Gels were fixed for 18 hr in 50% methanol 2% H3PO4, rinsed 3 times for 30 min with water, 
and incubated for 1 hr in a solution containing 34% methanol, 2% H3PO4 and 17% 
(NH4)2SO4. Staining was performed for 3 days in 34% methanol, 2% H3PO4, 17% (NH4)2SO4 
and 0.066% Coomassie G-250, and it was followed by de-staining in water for additional 3 
days.  
 
7.2 Silver Staining  
Gels were fixed for 30 min in 50% methanol 10% acetic acid, incubated for 15 min in 5% 
methanol 1% acetic acid, washed 3 times with water and exposed for 90 seconds to 
thiosulfate solution (200 μg/mL Na2S2O3 pentahydrate). After extensive washing with water, 
gels were incubated in the dark for 30’ with 2 g/l AgNO3, rinsed and developed for 5’-15’ 
with a solution containing 60 mg/mL Na2CO3, 4 μg/mL Na2S2O3 pentahydrate and 0.01875% 
formaldehyde. Reaction was stopped with 6% acetic acid.  
 
7.3 Densitometry 
Following SDS-PAGE (PolyAcrylamide Gel Electrophoresis) and Western Blot procedure as 
described in section 7, band intensities of NP associated proteins were estimated using Image 
J software after subtraction of the lane background from the calculations. 
The area under the peak of identified peptides for each composition of the NPs corona is 
calculated and estimates the amount of protein by averaging the area.  
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7.4 Western Blot 
In order to control complement activity, 25 μL of HS were treated with 6.25 μL of Zymosan 
(25 mg/mL, Sigma, MO, USA, prepared as described by manufacturer’s instructions) for 30 
min at 37 °C to be used as a positive control. 25 mM EDTA was used to stop the reaction. 
Following experimental incubation as described above, 1.6 μL of each sample were mixed 
with 38.4 μL of water and 6.7 μL of loading buffer without β-mercaptoethanol, and 15 μL of 
sample was loaded onto a 12% gel. Proteins were transferred on a PVDF membrane (Biorad, 
CA, USA) (100 V, 200 mA, 1 h). After membranes blocking for 1 hr at RT with 5% nonfat 
dry milk in TBS 0.1% Tween, primary antibodies were diluted in 1% nonfat dry milk in TBS 
and were added to the membranes overnight at 4 °C. Membranes were washed three times 
with TBS 0.1% Tween, incubated 1 hr with secondary antibodies, washed 4 times and 
developed using enhanced chemiluminescence by Huvitec (Eppendorf, Germany). 
 
8. Coagulation kinetics 
HP was incubated for 15 min at 37 ℃ to thaw. 80% HP +15 mM CaCl2 was added to 96 well 
flat bottom plate. Particles at varying concentrations depending on experiment was added to 
the wells and mixed rapidly both manually and in the spectrophotometer for 5 seconds prior 
to readings. Lag time from calcium addition to HP until first reading was 3min. Optical 
Density was measured at 405 nm for 1 hr with readings every 1 min at 37 ℃.  
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Chapter 4: Perspectives 
The area of biomedicine and nanotechnology is quite vast and encompasses a wide variety of 
research. My thesis work specifically pertains to the field of nanomedicine where NPs are 
utilized as drug delivery vehicles for the purpose of targeted drug delivery. Our data directly 
effects the preclinical trials of NPs including testing models and design of the NP itself. 
According to our research, current testing methods of NPs for drug delivery have many 
shortcomings, the most important being the way in which the NP interacts with interspecies 
complement proteins. As I have mentioned in chapter 1, it is crucial to improve specific drug-
delivery methods in order for the NP systems to transfer into clinical effectiveness. Most 
drugs in biotechnology are limited by their poor solubility, high toxicity, high dosage 
requirements, aggregation, poor solubility, nonspecific delivery, in vivo degradation, and 
short circulating half-lives. However, drugs coupled with nanoparticles increase the drugs’ 
theranostic abilities. Polymer coatings increase the NP-drug complex’s bioavailability as well 
as decreases immune response and clearance. Our data pertains to this area by specifically 
studying certain polymer coatings and suggesting alternatives to current standards. Most 
significantly is the failure of Poly(2-oxazolines) to inhibit complement activation in humans 
and pigs as well as their ability to inhibit in mice. These results should affect the way in 
which we study NPs in the lab before bringing them to clinical trials with patients.  
I have effectively demonstrated that coating ORMOSIL nanoparticles with PMOXA and 
PEtOXA polymers, which provides “stealthing” effects in murine conditions, effectively 
activates the complement system in human and pig environments. However, there were some 
limitations in experimental design which should be addressed. Firstly, although we suggested 
the potential role of ficolins in NP capture, further experiments are required to fully 
investigate the mechanism of ficolin in particle binding and capture. Effective protocols to 
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study the effect of sugars with cells should be designed in order to probe the effect of higher 
sugar concentrations on competition with ficolin with particle phagocytosis. For example, 
particles can be incubated with sugars to form the corona with ficolin binding competition. 
Therefore, cells do not need to be supplemented with sugars as the inhibition of ficolin will 
have already occurred in the initial incubation. Thus, high concentrations of sugars can be 
used without affecting cell viability.  
Secondly, all experiments utilized pooled pig and mouse sera from multiple donors. 
However, we demonstrated previously in this lab NPs in human serum are captured 
differently depending on the blood donor from which the serum came from. Therefore, it 
would be quite interesting to study the variability in phagocytosis of specific porcine donors. 
The size of mice and the amount of blood that can be extracted from one mouse does not 
make it possible to look at an individual’s complement response.  
Thirdly, I have demonstrated ORMOSIL NPs behave similarly in pig serum as they do with 
human serum. This indicates complement proteins are either the same in both species or they 
interact with the NPs in a similar manner or mechanism. Further experiments with pig 
macrophages would be useful in supporting the previous findings discussed in this thesis 
including additional confocal microscopy and additional flow cytometry.  
Fourthly, in order to probe the compatibility of the nanomaterial with the human immune 
system preclinically, it is highly beneficial to do so with human materials, instead of 
depending on non-human species such as murine models. Given Poly(2-oxazoline) (POZ) has 
been proposed as an alternative polymer for PEG as they are easier to synthesize and can 
incorporate varying monomers to tailor the nanoparticle for specific applications, future 
perspectives should focus on further modifications of POZs in order to evade recognition by 
components of the human innate immune system. Poly(2-isopropyl-2-oxazoline) (PPrOXA) 
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has been proposed as another polymer with side-chains of different variants of propyl which 
like PMOXA and PEtOXA are water-soluble or thermoresponsive polymers, however 
PPrOXA is semi-crystalline instead of amorphous. This difference could possibly change the 
way in which PPrOXA interacts with complement proteins and thus clearance by the immune 
system.  
Furthermore, the shape of the surface is known to activate complement in different ways, for 
example spheres and short filomicelles are more rapidly taken up by cells than are longer 
filaments examined under fluid flow conditions because longer filaments are extended by the 
flow.76 This indicates the internalization of nonspherical particles occurs via different 
mechanisms of endocytosis. Although such particles have already been tested in labs, they 
have not been tested using the serum of varying species nor cross-tested them with different 
polymers. It would be interesting to test nonspherical particles in the conditions we tested our 
spherical NPs and see if any particles would become more stealth. 
Finally, my thesis focused on in vitro interactions between the NPs and serum proteins, 
however, in order to utilized NPs in the biomedical field, in vivo studies are particularly 
important. Since the most common model to study NPs is the mouse, it would be interesting 
to test the stealth abilities of the four ORMOSIL NPs in vivo in mice. Yet, more interestingly 
would be to test the NPs in a porcine model as it replicated the trends seen in humans in vitro. 
The most obvious difference between the mouse and humans is size where mice are about 
2,500 times smaller than humans. Size is correlated with metabolic rates and the variations 
between mice and humans can manifest in anatomic, physiologic, and biochemical 
differences. Furthermore, different composition and properties of cellular components results 
in different strategies in immune responses. Thus, looking at the way in which the NPs 
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behave and interact with porcine cells would better characterize the NPs for future use in 
clinical trials in humans.  
Although I have already proposed the pig as a great alternative to mice, purely out of my own 
personal curiosity, I would be highly interested in looking into particle behavior in rabbit and 
monkey models. Although I do not have access to them for any in vivo studies, sera could be 
purchased to conduct in vitro experiments, replicating what I’ve done with mice and pigs.    
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Figure 52: UV-VIS Spectral Analysis of 100 ug/L  Uncoated, PEGylated, PMOXA-coated, and PEtOXA- coated 
ORMOSIL NPs in Water. Rhodamine concentration was determined from absorbance = 567 nm (after 
scattering contribution subtraction) using the molar extinction coefficient () of 9.5×144
 
cm-1
 
M-1.  
 
Figure 53: A) 1H-NMR (500 MHz) subspectrum of a) PMOXA-amine in D2O, b) PMOXA-coated NPs in D2O /H2O 1:9, (H20 signal was 
suppressed), c) Diffusion filtered spectrum of b. B) 1H-NMR (500 MHz) subspectrum of a) PEG-OMe in D2O, b) PEGylated NPs in D2O / 
H20 1:9, (H20 signal was suppressed), c) Diffusion filtered spectrum of b. (* indicates the residual solvents.) 
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